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Uveal  Melanoma
Uveal melanoma (UM) is the most frequent primary intraocular malignant tumor 
in adults and represents ∼85% of ocular melanomas (OM) and ∼5% of all 
melanomas (Singh et al, 2011).  The mean age at the diagnosis is 60 year and its 
incidence in the past 30 years remained stable, with 5 new cases per million every 
year (Singh et al, 2011). The incidence rate in Europe ranges between less than 
two and more than eight per million population (Virgili et al, 2007).
To date, no environmental risk factor has been established, but a correlation 
between UM and different patient characteristics have been investigated. 
The gender has been a debated and controversy topic. Bishop (Bishop et al,
2014) found a significantly lower incidence of UM in women than in men, 
evidence observed also in other work (McLaughlin et al, 2005). Other studies 
didn’t demonstrate statistically significant differences in survival rate (Zloto et al, 
2013; Nichols et al, 2016). A correlation between UM and ethnicity has been 
suggested from epidemiological studies: a major incidence rate of UM was 
observed in white Caucasian populations compared to Chinese, Korean, and 
Japanese populations (Nichols et al, 2016). Iris color, a phenotype correlated 
with ethnicity and geographical origin, is another characteristic evaluated in 
several studies. In a meta-analysis, Weis (Weis et al, 2006) showed a 
statistically significant relationship between light eye color and higher risk of 
UM.
UM is a cancer arising from melanocytes localized in the uveal tract, a pigment 
vascular layer situated in the eye between sclera and retina (Figure 1). 
Figure 1. Structure of the eye with components of the uvea (iris, ciliary body and choroid)
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Melanoblast cells, derived from neural crest, are the precursors of uveal 
melanocytes. Approximately 85-90% of UM involve choroid, 7% ciliary body and 
2% the iris (Chang et al, 1998). 
Cytological classification is an important prognostic factor. Callender, in 1931 
(Callender et al, 1931), first classified UM in six groups, with different prognosis 
according to the cell type: spindle type A, spindle type B, fascicular, epithelioid, 
mixed and necrotic. More recently, in a large retrospective study, McLean 
modified this classification and defined three cell types and relative melanomas, 
with different prognosis: spindle, epithelioid and mixed cells (McLean et al, 
1983). Other clinical prognostic factors in UM include age, tumor size, extra 
ocular extension, tumor stage according to AJCC classification, mitotic activity, 
tumor infiltrating macrophages and lymphocytes, and specific chromosomal 
aberrations and gene expression profile (GEP). In Table 1 are summarized the 
clinical and histologic factors that have prognostic significance.
Despite the advances in eye-preserving therapies and/or early enucleation, the 
half of UM cases develops distant metastases, mostly in the liver (Diener-West 
et al, 2005). Other target sites of metastases are lung, bone, skin, lymph node 
and, with a rare frequency, central nervous system, kidney, spleen, colon, and 
pancreas. The uveal tract is highly vascularized, thus the hematogenous spread 
is the mechanism for metastatic dissemination, but the reason for the hepatic 
tropism is still not clear. The only confirmed evidence is that in liver of patients 
with UM, foci of non-proliferative and not vascularized micro metastasis have 
been identified. 
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Diagnostic Methods in Uveal Melanoma 
The diagnosis of UM is based on clinical examination through  ophthalmoscopy 
exam. Ancillary tests, such as color funds photography, fundus fluorescein 
angiography (FFA), ultrasonography (USG), indocyanine green angiography 
(ICGA), optical coherence topography (OCT) and fundus auto-fluorescence 
(FAF) are also used to help and to confirm the diagnosis. It was estimated that 
in 28-37% of UM cases there is a delay in UM diagnosis, due to the lack of 
detection during the first examination, especially in patients with a blind eye or 
with a dense cataract (Tarlan et al, 2016; Chattopadhyay et al, 2016). Many 
patients present distortion or loss of vision without pain,  flashing, or flickering of 
light caused by retinal detachment. On the other hand, some patients are 
asymptomatic and the tumor is identified on routine ophthalmologic visit.
Clinical, histological and pathological features of uveal melanoma
• Size of tumor
The macroscopic pathological characteristics of UM depend on size and tumor 
localization. The Collaborative Ocular Melanoma Study Group (COMS report n
°4,1997) has classified in small, medium and large the UM based on the tumor 
thickness: small tumors if major size is thicker than 10 mm, medium tumors if 
major size is 11-15 mm, and large tumors if major size exceeds 15mm. The 
classical appearance of UM is a brown, dome-shaped mass, but also may 
appear as mushroom- shaped or diffuse type. Considering the pigmentation, 
about 55% of tumors are pigmented, 15% are not pigmented, and 30% contains 
both pigmented and non-pigmented areas. It has been estimated that the risk of 
metastasis increases of 5% with each 1 mm increase tumor thickness.
Usually, small UM presents flat or dome-shaped type because sclera prevents 
the extra-scleral growth. According to its location, UM may occlude the choroid 
capillaries, and, with its enlargement, breaks Brunch’s membrane and forms its 
pathognomonic mushroom shape (Ophthalmic Pathology, an Atlas-Textbook; 
McLean et al, 1983). Invasive tumors might also affect the lens. Scleral 
infiltration is estimated in 30% of UM (Figure 2). The American Joint Committee 
on Cancer (AJCC) (Edge et al, 2010) classified the tumor size in T categories 
(T1-T4), the lymph-node involvement in N categories (NX, N0, N1), and the 
presence of metastases in M categories (MX, M0, M1a, M1b, M1c). For 
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posterior UM, AJCC divided each T category in subgroups reflecting ciliary body 
involvement and extra-scleral extension: subgroups a, b, c, d, and e. Several 
studies (Simpson ER, et al 2015; Shields et al 2013) have shown the 
usefulness of this tumor classification to predict prognosis with an estimated 
survival rate of 100% for patients with T1 tumors, 90% for patients with T2 
tumors, 50% with T3, T3a or T4 tumors. 
The rate of UM progression was estimated as 15% for T1 tumors, 25% for T2 
tumors, 50% for T3 tumors and 63% for T4 tumors (Edge et al, 2010).
• Cytology and histopathology 
Among the histologic prognostic factors, UM cell type is an important feature 
correlated to bad prognosis. Callender first classified UM histologically in 1931 
in six groups with different prognosis according to the cell type: spindle type A, 
spindle type B, fascicular, epithelioid, mixed and necrotic (Callender et al, 
1931). This original classification was later modified in 1983 by Mclean (McLean 
et al, 1983). Two main cell types were described: spindle and epithelioid cells. 
Spindle cells show a cohesive pattern, plasma membrane not very evident, low 
cytoplasm with a fibrillary or granular appearance. In addition Callender 
(Callender et al, 1931) identified two subgroups of spindle cells based on nuclei 
morphology. The spindle cells subgroup A show elongated nuclei, nucleoli not 
evident and homogeneous chromatin. Instead, the spindle cells subgroup B 
shows round nuclei, less homogeneous chromatin and visible eosinophilic 
nucleoli. 
Compared with spindle cells, the epithelioid cells are larger and more 
pleomorphic, showing a clear plasma membrane, extracellular space, large and 
round/oval nuclei, plentiful cytoplasm. In these cells, nuclear membrane is 
irregular, with introflexions and extroflexions. The chromatin is not 
Figure 2.  Posterior Uvea
photoreceptor
Bruch’s membrane
Vascular network pattern of choroid
retinal pigment epithelium
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homogeneous and often it is localized to the periphery of the nucleus. Large 
and eosinophilic nucleoli are often present. Epithelioid cells show a high mitotic 
rate, greater than mitotic rate observed in spindle cells. The mitotic/proliferative 
index is important due to its correlation with a worst prognosis. 
UM with epithelioid cell type are strongly associated with high metastasis and 
high mortality rates, whereas UM with spindle cells type are usually associated 
to a good prognosis. A limitation of Callender’s classification is the too simplified 
classification. 
Indeed, in UM, a spectrum between the spindle and epithelioid cell type exists 
and many tumors show a mixed cellular population. In addition, this 
classification is not very reproducible and standardized. Callender (Callender et 
al,1931) did not defined the percentage of epithelioid cells to define a UM as a 
mixed. COMS, through the analysis of 1527 UM samples, defined as epithelioid 
the tumors with a minimum percentage of 50% epithelioid cells. According to 
this classification, about 86% UM were with mixed cells and only 5% and 9% 
belonged to epithelioid-type and spindle-type, respectively (Edge et al, 2010).
• Infiltrating cells
Another prognostic feature in UM is the presence of infiltrating cells. McLean 
first suggested the importance of immune response in cancer progression 
(McLean et al, 1983). Later, de la Cruz (de la Cruz et al, 1990) studied the 
prognostic significance of infiltrating cells in UM: conversely to other cancer 
types, the researcher observed a correlation between infiltrating cells in lesion 
and reduced patient survival (de la Cruz et al, 1990; Vit et al,1983; Folberg et al, 
1993). 
• Tumor vascularization
Tumors require a blood supply to sustain their growth. Taking into account that 
cancer microcirculation plays a central role in the hematogenous dissemination 
of cancer cells, great attention has been directed on tumor angiogenesis, that 
tumors recruit both from the existing circulation and new angiogenesis (Folkman 
et al,1995). 
In 2000, Folberg (Folberg et al, 2000) described in UM nine different patterns of 
vascularization: back-to-back closed loops, arcs (incompletely closed loops), 
arcs with branching, networks (networks were defined arbitrarily as at least 
three back-to-back closed PAS-positive loops), straight channels, straight 
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channels that cross-link, parallel, normal. PAS-positive loops and networks were 
also detected in hepatic metastases and in all secondary metastatic sites.
Folberg observed a higher survival rate if network, parallel and loops patterns 
were not present (Folberg et al, 2000). The histological detection of closed PAS-
positive loops was associated with the presence of other histological features 
predictive of metastases: the presence of epithelioid melanoma cells by the 
modified Callender classification and mitotic figures.
  
  
Table 1. Clinical and histologic factors with prognostic significance
Clinical factors Histologic factors 
Patient age Epithelioid cell type
Tumor thickness High mitotic rate
Ciliary body involvement Closed-loop vascular periodic acid-shift staining
Extraocular extension Mean diameter of 10 largest nucleoli
Diffuse growth pattern degree of pigmentation
Optic nerve involvement inflammation
Large tumor basal diameter vascular invasion 
Ring melanoma Tumore necrosis
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Primary UM Treatment
The anatomical evidence of a tumor contained in the scleral shell and the 
absence of lymph vessels in the eye globe, justified for many years enucleation 
as the only therapeutic option. Nevertheless, McLean (McLean et al, 1995) 
reported a mortality peak during the first two years after enucleation, maybe due 
to tumor cells dissemination during the surgery. In the last 30 years, many 
conservative approaches have been developed, and now UM patients can be 
treated preserving anatomical and (often) functional integrity of affected eye.  
Among the available eye-conserving therapies, there are photocoagulation, 
transpupillary thermotherapy and radiotherapy (Chattopadhyay et al, 2016).
• Photocoagulation is a method used in the past to treat small choroidal 
melanoma; today, tumors smaller than 3mm are treated with transpupillary 
thermotherapy (TTT). 
• Transpupillary thermotherapy (TTT) or Laser therapy is a diode laser- 
based method used to treat melanomas smaller than 4 mm. 
• Radiotherapy is the most common eye-conserving approach used by ocular 
oncologist. There are more possibilities for radiotherapy, including the 
application of radioactive plaques (brachytherapy), the external beam therapy 
(hadrontherapy or stereotactic radiotherapy), the gamma-knife. The 
brachytherapy is the most diffused radiotherapy approach and permits a high 
irradiation of the tumor without damaging the other tissues. It is performed by 
attaching the radioactive plaque to the tumor base surface (Figure 3). This 
plaque can emit gamma-ray by different radioactive source (125Iodine or 
106Ruthenium). The plaque remains in this position until the whole radiation 
dose is emitted, in general 4-7 days for a total dose of 100 Gy. This method is 
used to treat UM < 9 mm thickness  in case of iodine, and < 5mm thickness 
in case of Ruthenium as radioactive source. The hadrontherapy is the 
irradiation of a tumor with charged particles and permits the irradiation at a 
desired depth. This method is used to treat tumors until a 16 mm diameter 
and 8 mm of thickness. This type of radiotherapy is used to treat tumors up to 
14 mm with a basal diameter up to 28 mm. The gamma knife therapy 
requires a complex equipment and adverse effects have been reported, i.e. 
radiation retinopathies and neo-vascular glaucomas (Tarlan et al, 2016). 
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Compared with the other eye-conserving primary treatments, proton beam is 
associated with the lowest overall risk of local tumor recurrence in UM. 
Nowadays, the enucleation is reserved for cases with the worst visual 
prognosis, such as patients with large uveal melanoma, with choroidal 
melanoma surrounding optic nerve or presenting hemorrhage. Local resection 
is an alternative treatment choice for patients with choroidal melanoma, which 
spares the eye and allows a detailed histopathological and cytogenetic analysis 
(Tarlan et al, 2016). 
Metastatic disease and Adjuvant therapies 
Despite successful local treatment, 25% and 34% of UM patients develop 
metastases within 5 and 10 years, respectively (Diener-West M, et al 2005). 
Liver is the first site of metastasis of UM (93%), followed by lungs (24%), and 
bones (16%) (Diener-West M, et al 2005). After metastastatic progression, 
survival time depends on metastasis type and localization, and, until now, there 
are no approved adjuvant therapies for UM. Several adjutant trials have been 
conducted in attempt to prevent metastatic disease in UM, but none of these 
demonstrated an increase of overall survival or benefit (Chattopadhyay et al, 
2016).
Figure 3. Episcleral Plaque brachitherapy
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• Liver-directed therapy
Since the liver is the first site of metastasis in UM, local treatments such as 
surgical resection, hepatic arterial infusion, hepatic artery embolization, and 
radio frequency ablation have been used. 
Surgical resection of liver metastasis could increase patient’s survival, but it is 
limited to single metastasis (Mariani et al, 2009).             
A trial with 22 patients to test the hepatic arterial infusion of fotemustine showed 
an improving in progression free survival but it did not reach statistical 
significance (Ophtalmic Oncology Task Force, 2016). Isolated hepatic perfusion 
is another therapeutic option to treat metastatic, UM but it is an invasive 
operative procedure. More commonly used is chemoembolization, a treatment 
which combines hepatic artery embolization and infusion of chemotherapeutic 
agents, but also this therapeutic strategy did not showed significant benefits.
• Targeted therapy and Immunotherapy
Targeted therapies based on activated mitogen-activated protein kinase 
(MAPK) pathway by mutated Gnaq and Gna11 have been tested in several 
clinical trials but to date they did not provide meaningful responses in metastatic 
UM (Chattopadhyay et al,2016). Selumetinib, a MEK inhibitor, initially has 
shown promising clinical outcomes (Carvajal et al, 2014) but phase II trials did 
not confirmed the results.  
Similarly to MAP kinase-targeted therapies, immune checkpoint blockade 
therapy through monoclonal antibodies directed to immunomodulatory 
receptors or ligands are objects of studies, but they show only limited activity in 
metastatic UM. Ipiluminab, a human antibody against CTLA-4, showed in a 
phase III study an increase in overall survival in melanoma patients, but until 
now only few data are available. Currently,the combination between ipiluminab 
and Nivolumab, a monoclonal human antibody against PD-1, is object of study 
(Chattopadhyay et al, 2016).
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Cytogenetic of uveal melanoma
It is known that aneuploidy and chromosomal abnormalities were observed in 
many types of cancer. Since the detection of PH chromosome (Rowley et al, 
1973), many specific cytogenetic changes have been identified and described 
in a variety of malignancies, and, overall, an high degree of aneuploidy and 
chromosomal aberrations were found in solid tumor, with a complex change in 
karyotype (Papadopoulos et al, 2002). 
UM is different because it exhibits a relatively low degree of aneuploidy 
compared to skin melanoma and other cancers and it shows specific recurrent 
cytogenetic alterations involving the short arm of chromosome 1, and 
chromosomes 3, 6 and 8. The evidence of a low degree of chromosomal 
abnormalities, led to believe that these recurrent cytogenetic changes are more 
important to tumor progression rather than random events (Papadopoulos et al, 
2002). By using standard karyotyping, fluorescence in situ hybridization, and 
comparative genomic hybridization techniques, non-random chromosomal 
aberrations occurring on chromosomes 3, 6 and 8 were detected (Prescher et 
al, 1992; McNamara et al, 1997; Bastian et al, 1998; Tschentscher et al, 2000; 
Hughes et al, 2005; Cross et al, 2006). More recently, many other alternative 
analysis methods were used to identify chromosomal alterations, such as 
microsatellite analysis (MSA), multiplex ligation-dependent probe amplification 
(MLPA), genome-wide single- nucleotide polymorphism array (Prescher et al, 
1996; Parella et al, 2003; Hausler et al,2005; Damato et al, 2007; Damato et al, 
2012) (Table 2). In these studies, it was reported that the risk of metastatic 
disease can be predicted by the presence of monosomy 3 and 8q gain.
Chromosome 3 monosomy is the most frequent cytogenetic aberration:  in most 
cases one entire copy of chromosome 3 is lost, but partial deletions are 
possible. It was reported that preferential deletions include 3p25-25 and 
3p11-14 chromosome bands and 3q arm (Chattopadhyay et al, 2016; Parella et 
al, 2003). Several studies have been performed with the purpose to identify 
tumor suppressor genes, whose inactivation due to partial deletion or 
chromosome 3 monosomy could correlate with a higher metastatic risk (Scholes 
et al, 2003; Killic et al, 2005). A relationship was found when Harbour et al 
(Harbour et al, 2012) reported in UM cases the presence of somatic mutations 
on BRCA1 Associated Protein 1 (BAP1) gene.
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In a small percentage of UM (5-8%), chromosome 3 isodisomy is present: it 
occurs when a cell loses one of the chromosome 3 and there is a duplication of 
the remaining copy. The association of this chromosomal alteration and 
metastatic risk was demonstrated (Onken et al, 2007). 
Loss of 8p occurs in about 25% of UM and gain of 8q occurs in almost 40% of 
UM. Chromosome 8q gain statistically associated to metastasis and it is also 
shown to be an independent predictor of survival (Sisley et al, 1997; Harbour et 
al, 2012). As for monosomy 3, gain of 8q correlates with ciliary body 
involvement (Sisley et al, 2000). Monosomy 3 and 8q gain  often occur together 
(Aalto et al, 2001). 
Chromosome 8q contains many potential oncogenes such as ASAP1, NBN, 
DDEF1, that are over-expressed in UM with poor prognosis (Ehlers et al, 2008). 
In addition, the 8q23-24 region, containing the oncogene MYC, it has been 
described (Parella et al, 2001) as amplified in about 30% of UM. In 8p, a 
potential tumor supressor gene, LZTS1, was reported (Onken et al, 2008a).
Other studies showed that often 8q gain occurs together with 8p loss, 
suggesting an isochromosome formation (Prescher et al, 1996).
Chromosome 1p alterations frequently occur in neural crest derived tumors, and 
are associated to advanced cancer or metastatic disease. In a small case series 
(29 subjects), Aalto (Aalto et al, 2001) reported a correlation between 1p loss 
and UM-related patient survival. Results from large UM patients’ cohorts did not 
confirm 1p loss as an independent prognostic factor. These studies suggested 
instead that monosomy chromosome 3 together with 1p loss may correlate with 
poor prognosis (Kilik et al, 2005; Trolet et al, 2009; Cassoux et al, 2014). 
Chromosome 6 anomalies (6p gain and/or 6q loss) are observed in about 25% 
of UM cases. Both 6p gain and 6q loss may occur in the same tumor, 
suggesting the formation of isochromosome 6p (Aalto et al, 2001; Harbour et al, 
2012). 
Since 6p gain was associated to good prognosis and low risk of metastasis, 
several authors supposed a protective effect of this chromosomal abnormality 
against metastatic progression (Prescher et al,1996; Damato et al, 2009). This 
aberration tends to occur in absence of monosomy 3, indicating a mutually 
exclusive pattern with this predictor of metastasis. 
Loss of 6q, present in about 30% of UM, was associated with a poor prognosis 
(Elhers et al, 2008).
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Table 2. Most commonly used techniques for genetic typing of UM
Techniques Molecular basis Quantitative 
dosage 
analysis
Degree of 
automation
Cost Remarks
Karyotipe Large gain, loss or 
alteration of 
chromosome
+ + + Low-resolution copy number variation, it 
cannot use with FFPE samples
FISH Gain or loss of small 
number of chromosome 
segments labelled with 
specific probes
+ + + + Low-resolution copy number variation, it 
can use with FFPE samples
CGH Gain or loss of large 
number of chromosome 
segments labelled with 
specific probes
+ + + + + + + C-CGH: low resolution;A-CGH high 
resolution copy number variation. Both 
can use with FFPE samples
MSA Loss of heterozygosity 
of a small number of 
highly polymorphic DNA 
segments
+ + + + + Low-resolution copy number variation 
or LOH, it can use with FFPE samples
SNP Loss of heterozygosity 
of a moderately 
polymorphic DNA 
segments
+ + + + + + High-resolution copy number variation 
or LOH, it can use with FFPE samples
MLPA Gain or loss of multiple 
chromosome segments 
+ + + + + + + + High-resolution copy number variation. 
50 targets in one reaction. It can use 
with FFPE samples
UM-GEP 
(PCR 
based)
Simultaneous 
measurement of mRNA 
expression of multiple 
genes
Not 
applicable
+ + + + + + + Gene expression. Fresh samples 
preferred 
Abbreviations: CGH, comparative genomic hybridisation; MSA, microsatellite analysis; MLPA 
multiplex ligation- dependent probe amplification; FFPE, formalin-fixed paraffin embedded 
material; FISH, fluorescence in situ hybridization; LOH, loss of heterozygosity; SNP, single-
nucleotide polymorphism; UM-GEP, uveal melanoma gene expression profiling (Coupland et 
al,2012).
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Gene Expression Profile
Data of gene expression profiles in UM samples were reported in different 
studies (Tschentscher et al, 2003; Onken et al, 2005; Onken et al, 2006;  Onken 
et al, 2006; van Gils et al, 2008).
In 2012, a prospective multicenter study assessed the prognostic accuracy of a 
15-gene gene expression profile assay for UM (Tschentscher et al, 2003; Onken 
et al, 2004; Van Gils et al, 2008; Onken et al, 2006). Based on gene expression 
profile (GEP) analysis, these authors showed that UM are clustered into two 
classes strongly correlated with metastatic risk: class 1 UM have a low risk of 
metastasis and class 2 UM have a high risk of metastasis. 
Genes mainly implicated in this classification were involved in cell 
communication, development, cell growth, cell motility, cell death and immune 
response (Onken et al, 2005; Onken et al, 2008). Using bioinformatic analyses, 
genes that were up-regulated and down-regulated in class 1 versus class 2 UM 
were compared. Other studies showed that the genes expressed in class 1 UM 
were similar to those in normal uveal melanocytes and cells committed to the 
neural crest lineage, whereas the genes expressed in class 2 UM were similar 
to those in primitive stem-like cells
Class 1 tumors were UM characterized by chromosome 3 disomy, chromosome 
6p gain and a low risk of metastasis. 
In a later study (Harbour et al, 2010) , it has been reported that a depletion of 
Bap1 protein in UM class 1 culture cells induces a change to epithelial-like 
phenotype and also a change in a GEP similar to class 2. This evidence 
suggested the role of Bap1 in maintaining the melanocyte phenotype and in 
malignant progression.
Among class 1 UM, PRAME mRNA expression was identified as the most 
significant independent biomarker of metastasis risk (Field et al, 2016). PRAME 
mRNA expression was reported in association with larger tumor diameter, 
SF3B1 mutations and chromosome copy number changes such as gain of 1q, 
6p, 8q, 9q, loss of 6q and 11q. 
PRAME expression is a marker of poor prognosis in many cancers and recently 
was found as a biomarker for differentiating benign nevi from melanoma 
(Epping et al, 2006; Clarke et al, 2015). PRAME may promote tumor 
progression by inhibiting differentiation, growth arrest, and apoptosis induced by 
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Figure 4. Molecular hypothesis of tumor progression in uveal melanoma and role of 
PRAME mRNA increased expression (Field et al,2016).
Figure 5. Flow diagram that show how prognostic and predictive testing in 
uveal melanoma can guide patient care.
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retinoic acid signaling (Epping et al, 2006). More specifically, an increased 
PRAME mRNA expression in class 1 UM is associated with transcriptional up-
regulation of key genes (many contained in chromosome 1q an 6p) involved in 
chromosome maintenance and stability (Figure 4).
In class 2 UM has been observed a down-regulation of genes involved in 
melanocytes differentiation, in lineage specification in neural crest cells, genes 
regulator of Wnt signaling (i.e. EDNRB and CTNNB1), and genes encoding in 
melanin biosynthesis (i.e. DCT, SILV, and TYR). Conversely, genes involved in 
epithelial adhesion (i.e. CDH1), in basal membrane synthesis (i.e. TPBG, 
LAMC1, and COL18A1), and basal membrane interaction (MAFC1, and 
SPARC) have been observed up-regulated (Onken et al, 2006). 
More recently, it has been suggested that this dichotomous model may be too 
simple and the concept of UM clonal heterogeneity was introduced (Harbour et 
al, 2012). Indeed, Damato et al (Damato et al, 2010) identified in a large UM 
series a wide difference in the prevalence of chromosomal abnormalities, 
suggesting that some alterations may occur earlier than other. Therefore, more 
clones of malignant melanocytes harboring different chromosomal aberrations 
could evolve and co-exist within a single UM and one/some of these clones 
could have the potential to override the others. 
The predictive information provided from gene expression profiling are 
accessible by direct sampling of primary or metastatic tumor tissue or also from 
DNA of circulating tumor cells. Thus, mutational profiling may provide valuable 
predictive informations to define the better therapy for each patients and may 
guide patient care (Figure 5) (Inamdar et al, 2010).
 19
Mutational Profiling
The mitogen-activated protein kinase (MAPK) pathway is commonly altered in 
many human cancers (Inamdar et al, 2010). In particular, MAPK pathway plays 
an important role in the development of cutaneous melanoma (CM) through 
mutations in oncogenes such as RAS and B-RAF or in tumor suppressor genes 
such as PTEN and CDKN2A. In UM, alterations in MAPK pathway have been 
reported in GNAQ and GNA11, but mutations in RAS, B-RAF, PTEN or 
CDKN2A genes were rare (Figure 6) (Janssen et al, 2008; Maat et al, 2008). 
These findings suggested that other molecular events are involved in UM 
pathogenesis. 
Recent data (Martin et al, 2013; Harbour et al, 2013) showed that UM has 
relatively few recurring mutations, indicating a low genetic complexity and a low 
genomic instability than other cancers. Several driver mutations supporting UM 
initiation, progression and metastasis development have been identified from 
sequencing of primary tumor samples and confirmed by several studies (Amaro 
et al, 2017). UM driver mutations have been described in the following genes: 
GNAQ, GNA11, PLCB4 and CYSLTR2, and metastasis driver mutations in 
BAP1, SF3B1, and  EIF1AX. 
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Figure 6. MAPK signaling pathway
MAP2K1 and MAP2K2 are also known as MEK1 and MEK2, and MAPK1 and 
MAPK3 are also known as ERK2 and ERK1, respectively. AKT1, protein kinase B. 
ERK, extracellular-signal-regulated kinase. FLT3, fms-related tyrosine kinase 3. 
GEFT= RAC/CDC42 exchange factor. GPCR=G protein-coupled receptor. LIMK= 
LIM domain kinase. MAPK= mitogen-activated protein kinase. MEK= MAPK/ERK 
k inase. MKP1=MAPK phosphatase 1. MLC= myosin l ight cha in . 
mTOR=mechanistic target of rapamycin. PAK= p21 protein (CDC42/RAC)-
activated kinase. PDGF= platelet-derived growth factor. PI3K= phosphoinositide 3 
kinase. PTEN=phosphatase and tensin homologue. RAC=RAS-related C3 
botulinum toxin substrate. RAF= rapidly accelerated fibrosarcoma. RAS= rat 
sarcoma. RHO= RAS homologue. ROCK= Rho-associated, coiled-coil containing 
protein kinase. RTK= receptor tyrosine kinase. VEGF= vascular endothelial growth 
factor (Romano et al, 2011).
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Guanine Nucleotide-binding Protein subunit α-Q (GNAQ)  and Guanine 
Nucleotide-binding Protein subunit α-11 (GNA11)
GNAQ and GNA11 are two genes localized on 9q21.2 and on 19p13.3, 
respectively, and both contain 7 exons. Both genes encode for Gα subunits of 
heterotrimeric Gq protein that activates the G protein signaling cascade via 
inositol-3-phosfphate, dyalglicerol and cyclic AMP leading to the stimulation of 
MAP kinases, protein kinase B (Akt) and protein kinase C (PKC).  Gnaq protein 
is a 42142 Da protein and Gna11 is 42123 Da protein. Both proteins contain 
359 aminoacids. Heterotrimeric G proteins are membrane bound GTPases that 
are linked to 7-TM receptors. Each G protein contains an α-, β- and γ-subunit 
and it is bound to GDP in the 'off' state. Ligand binding causes a receptor 
conformational change, detaching the G protein and switching it 'on'. Normal 
activation of Gq leads to a GTPase activity intrinsic to Gα subunits (Figure 7).
The mutations in these two genes are mutually exclusive and they are 
considered the major driver mutations in UM, indeed they are found in about 
80% of UM samples (Onken et al, 2008).
Mutations in GNAQ and GNA11 are found in all stages of UM and benign nevi, 
and this evidence suggests that GNAQ and GNA11 mutations are an early 
events in UM tumorigenesis but they are not sufficient for tumor progression (Xu 
et al, 2014). In UM, mutations in GNAQ and GNA11 genes the mutations are 
missense mutations at two hotspots, Q209  and R183 (Figure 8).
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a) In the GDP-bound state, Gα is inactive and bound to Gβγ near the plasma
membrane. 
b) Upon ligand binding, a conformational change catalyzes GDP exchange for GTP, which alters 
the conformation of switch I, II, and III regions in red and dissociates Gα from Gβγ.
c) Active Gα and Gβγ signal downstream to multiple effectors.
d) The intrinsic GTPase activity of Gα is accelerated by regulator of G protein signaling (RGS) 
proteins, which catalyze the hydrolysis of GTP to GDP by the Q209 residue of GNAQ/GNA11.
An adjacent R183 residue assists in hydrolysis without RGS binding. This returns the trimer to its 
membrane-bound, inactive state. GPCR, G-proteincoupled receptor; PLC, phospholipase C.
 (Shoushtari et al,2014).
a) b)
c) d)
Figure 7. Schematic of canonical GPCR and heterotrimeric G-protein signaling.
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There are at least five known variants at residue Q209, but GNAQQ209L   and 
GNAQQ209P are the most frequent. Both aminoacidic substitutions disable 
GTPase activity and lead to constitutive activation of MAP kinase pathway. 
Recently it has been shown that mutations in GNAQ/GNA11 genes activate the 
transcription factor complex YAP/TAZ in a pathway independent to HIPPO, a 
regulator of organ size involved in many tumors (Yu et al, 2014; Feng et al, 
2014; Feng et al, 2014) (Figure 9). GPCR is involved in cell proliferation and 
stimulate the activity of transcripional co-activator YAP, a component of Hippo 
signaling pathway. YAP/TAZ factors are active in proliferating cells, and the cell 
confluence triggers the activation of LATS1/LATS2 kinase, Hippo pathway 
inhibitors. O'Hayre (O'Hayre et al, 2014) indicated that mutations in gene 
encoding Gαq activate YAP by a pathway initiated upon actin polymerzation 
rather than by the inhibition Hyppo pathway.
Switch Regions
N CHelical domain GTPase domain
R183 Q209
Figure 8.  Schematic representation of Gnaq and Gna11 protein.
GNAQ and GNA11 genes encode for closely related Gq-α subunits that consist of helical and 
catalytic GTPase domains.
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Figure 9. Schematic representation of Hippo-dependent and Hippo-independent 
pathways resulting in YAP activation by the GNAQ and GNA11 oncogene in uveal 
melanoma (Feng et al, 2014). 
 25
BRCA1- associated protein 1 (BAP1)
BAP1 gene maps on chromosome 3p21.1, consists of 17 exons and codifies for 
a 90 kDA protein (729 amino acids), a nuclear deubiquitinating enzyme (DUB).
Bap1 protein is composed of a N-terminal ubiquitin carboxyl hydrolase domain 
(UHC), a host cell factor 1 (HCF1), binding domain (HBM) in the middle portion, 
and a C-terminal domain (CTD) with a coiled- coil motif for interaction with 
ASXL1/2. Two nuclear localization signals (NLS) and other binding regions are 
localized in C-terminal (Figure 10).
• Bap1 functions
Bap1 deubiquitinase activity is involved in key cellular pathways, including cell 
cycle control, cellular differentiation, transcription regulation and DNA damage 
repair (Figure 11).
- Bap1 regulates through de-ubiquitination of a lysine, the transcription 
regulator factor HCF1 activity. Through HCF1, Bap1 modulates chromatin 
architecture by recruiting histone-modifying complexes, and also by activation 
of transcription factors members of E2F family. Through E2F factors, Bap1 
controls G1/S transition. In case of Bap1 protein loss, an accumulation of 
HCF1 occurs, promoting transition from G1 to S cell-cycle phase (Figure 11) 
(Murali et al, 2013).
 
BAP1 include 721 amino acids: ubiquitin carboxyl hydrolase domain (UCH) 1-250, BARD1 
binding region 182-365,  HBM-HCF1 binding domain 365-385,  FoxK1/K2 binding region 
477-526, BRCA1 binding region 596-721,c-terminal domain (CDT)-ASXL1/2 binding 
domain 635-693, Ying Yang (YY1) binding region 642-686, nuclear location signals (NLS) 
656-661 and 717-722. 
Figure 10. Schematic representation of BRCA1 -associated protein 1 (BAP1). 
CTD
BRCA1BARD1
CN UCH HBM
NLS NLS
FoxK1/K2 YY1
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Figure 11. Schematic representation of BAP1 functions 
(Bhattacharya et al,2015). 
Left: role of BAP1 in transcription factor regulation. HCF1 is a major binding partner of BAP1 by 
mass spectrum analysis. HCF interacts with specific transcription factors, including OCT1, E2F1, 
Kox20, Sp1 and GA-binding protein. HCF1 also is associated to many chromatin methyltransferases, 
chromatin acetyltransferase and deacetylases. 
Middle: role of BAP1 in chromatin modifications. The trimethylation of lysine 27 of histone H3 is 
mediated by the histone methyltransferase EZH1/2, component of polycomb repressive complex 2 
(PRC2).
Right: Possible role of BAP1 in DNA repair . BAP1 bind BRCA1 and BARD1,which have important 
roles in double strand DNA repair process.
Figure 12.  Model of BAP1 as a co-regulator of E2F-mediated activation of S phase genes 
transcription (Pan et al, 2015). 
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- Bap1 protein forms a ternary complex with HCF1 and transcription factor Ying 
Yang (YY1), which controls cellular proliferation. This complex is recruited to 
activate Cytochrome C Oxidase Subunit 7C (COX7C), a component 
ofmitochondrial respiratory chain. YY1 can works both as inhibitor or as 
activator of COX7C promoter, depending on the presence/absence of  bound 
toHCF1-BAP1 complex (Daou et al, 2015). 
- Bap1 is part of a ternary protein complex interacting with HCF1 and forkhead 
transcription factors FoxK1/K2. This complex controls cell proliferation and 
cell cycle. In case of Bap1 loss, it follows an up-regulation of FoxK2 target 
genes. 
- Through the interaction with ASXL1/2, Bap1 forms the polycomb group 
repressive deubiquitinase complex (PR-DUB) (Pan et al, 2015). This 
important complex has effect on transcriptional regulators of stem cell 
pluripotency, embryonic development, self-renewal and cell differentiation. 
The polycomb-repressive complex works through histones hubiquitination 
and it follows gene silencing. In case of BAP1 loss, an up-regulation of 
polycomb target genes occur (Pan et al, 2015). More specifically, mutations 
targeting BAP1-ASXL1/2 interaction, led to loss of deubiquitination activity 
with an increased histone H2A ubiquitination, deregulation of cell cycle 
progression and cellular senescence (Pan et al, 2015) (Figure 17).
- Bap1 is involved in DNA damage signaling and repair through interaction with 
several proteins such as the BRCA1/BARD1 heterodimer: BAP1 binds and 
deubiquitinates BARD1 protein and consequently modulates the E3 ligase 
activity of  the same complex  (Murali et al, 2013; Daou et al, 2015) (Figure 
17). 
BAP1 is a tumor suppressor gene, and mutations in both alleles are necessary 
to inactivate its functions, according to “two hits” Knudson model. BAP1 
mutations occur almost exclusively in tumors with monosomy 3 (corresponding 
to class 2 UM) and they are strongly associated with metastasizing UM. BAP1 
mutations rarely occur in UM with disomy 3 (corresponding to class 1 UM), 
which typically shows mutation in SF3B1 and/or EIF1AX (Harbour et al, 2010). 
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BAP1 gene mutations are found in many tumors, such as small cell and non-
small cell lung cancers, renal cell carcinoma, breast carcinoma and 
mesothelioma (Peña-Llopis et al, 2012; Ladanyi et al, 2012; Carbone et al, 
2013; Murali et al, 2013). Harbour et al 2010 first described inactivating somatic 
mutations in BAP1 gene in 26 out of 31 (84%) metastasizing UM tumors, 
suggesting a connection between BAP1 inactivation and UM metastasis, 
hypothesis reinforced by multiple independent studies (Harbour et al, 2010; 
Luchini et al, 2016). For BAP1 mutations, all the different mutation types have 
been reported: deletions, insertions and base substitutions leading to nonsense, 
frame-shift, missense or synonymous mutations. It is possible to suppose that 
the different consequences on protein functionality depend on the mutation type 
and the region involved. For example, frameshift mutations may lead to 
abnormal mRNAs, subjected to nonsense-mediated decay, protein aggregation 
(Lykke-Andersen et al, 2015) or truncated proteins with the loss of c-terminal 
nuclear localization signals (NLS). Instead, missense mutations may lead to 
inactivation of UCH domain but maintaining protein expression and its nuclear 
localization. Bap1 has a role in uveal melanocytes as regulator of differentiation, 
and if Bap1 loss occurs, the cell exhibits stem-like phenotype (O’Shea et al, 
2017). However, the role of BAP1 mutations and their oncogenic potential is not 
fully understood.
Peña-Llopis and colleagues (Peña-Llopis et al, 2012) created a Bap1 protein 
model on the basis of the related family members Uch-L3 and Uch37, to 
evaluate the impact of BAP1 missense mutations in a structural context. Among 
the missense mutations studied, V43G and L112P were predicted to destabilize 
the protein.
More recently, Bhattacharaya (Bhattacharaya et al, 2015) investigated cellular 
localization, enzymatic activity and structural changes for four missense 
mutations (I47F, F81V, A95D, G178V) in Bap1 catalytic domain, to examine the 
mechanism behind protein structure destabilization. In particular, they observed 
in vitro a BAP1 loss enzymatic activity, decreased protein stability and 
consequent beta amyloid aggregation. These mutations destabilize BAP1 
secondary structure, inducing the hydrophobic core exposure and protein 
aggregation (Figure 18). In addition, Bhattacharaya observed that BAP1 
mutations lead to an up-regulation of heat-shock protein response, specifically 
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Hsp70 and Hsp90, yet known over-expressed in prostate cancer (Figure 13) 
(Bhattacharaya et al, 2015).
Until recently, it was thought that nuclear localization was required for all BAP1 
functions. Recent experiments, however, showed a novel BAP1 cytoplasmic 
activity: wt BAP1 localizes at the endoplasmic reticulum, and has a role in 
promoting apoptosis via Ca2+ mitochondrial changes. Moreover, it was shown 
that cells from individuals carrying heterozygous germline BAP1 mutations have 
a distinctive metabolic signature, consisting in impairment of mitochondrial 
respiration and increase of aerobic glycolysis leading to Warburg effect (Bononi 
et al, 2017). Warburg effect protects tumor cells from hypoxia, gives precursor 
for biosynthesis of many biologic molecules including acid nucleic, promote 
tumor cells growth through lactate release, and increases the resistance to 
chemotherapy-induced apoptosis (Cairns et al, 2011; Hsu et al, 2008; Bononi et 
al, 2017). Metastatic potential and prognosis in UM lacking BAP1 functions 
could be influenced also by these mechanisms.
Figure 13. Schematic model representing the effects of BAP1 functional loss.
BAP1 wild-type is represented as yellow, BAP1 mutant is 
represented in red. Mutant BAP1 forms oligomers which induce 
fibril formation. The consequence aggregation inhibits nuclear 
localization of BAP1 and PR-DUB complex formation 
(Bhattacharaya et al,2015).
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Splicing factor 3B subunit 1  (SF3B1)
SF3B1 gene is localized on 2q33.1 chromosome band, contains 25 exons, and 
codify for a 42142 Da protein.
Sf3b1 is the subunit 1 of the splicing factor 3b, part of splicesoma, a protein 
complex that processes pre-mRNA into mature mRNA. Together with splicing 
factor 3a and a 12S RNA unit, forms the U2 small nuclear ribonucleic proteins 
complex (U2 snRNP). The splicing factor 3b/3a complex binds the pre-mRNA 
upstream of the intron's branch site in a sequence-independent manner and 
may anchor the U2 snRNP to the pre-mRNA. Splicing factor 3b is also a 
component of the minor U12-type spliceosome (Figure 14).
Figure 14. Stepwise assembly of the early splicesome highlighting the known splicing 
factors that bind to the substrate. In red circle is highlighted Sf3b1 (Fredericks et al, 2015). 
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The two thirds carboxy-terminal have 22 non-identical, tandem HEAT repeats 
that form rod-like, helical structures (Figure 15). Alternative splicing results in 
several different isoforms. 
Mutations in SF3B1 were found in about 20% of UM (Alsafadi et al, 2016). 
SF3B1 is essential in pre-mRNA splicing and it is hypothesized to be involved in 
cancer through alternative splicing of target genes, which may play a role in 
tumorigenesis (Golas et al, 2003; Furney et al, 2013). Alsafadi et al (Alsafadi et 
al, 2016) supposed that mutations in HEAT domains may induce a 
conformational change of complex U2 and, consequently, an alteration in 
selectivity for normal splice site. As a result, this conformational change could 
activate cryptic splices sites (Figure 16).
SF3B1 mutations most frequently lead to arginine-625 residue and less 
frequently to lysine-666 residue substitution (Figure 15). 
SF3B1 mutations are almost mutually exclusive with BAP1 mutations and 
define a subclass of UM characterized by disomy 3. Initially it has been 
suggested a protective role of SF3B1 mutations in UM, but some authors 
proposed an association with the appearance of late metastasis (Tschentscher 
et al, 2003; Yavuzyigitoglu et al, 2016). 
Figure 15. Schematic representation of SF3B1 protein.
Sf3b1 protein consists of a U2AF2 interaction motif (U), SF3B1 interaction motif (S) and 22 
non redundant HEAT domains (HD) . The most common mutation occurs on HD5 at R625.
R625 K666
HD6HD5
HEAT domain
N CU S
 32
Figure 16. A model for alternative splicing dysregulation induced by SF3B1 hotspot 
mutations (Alasafadi et al,2016).
The 3′ss contains a segment, which is rich in pyrimidines (Y), a well-conserved 
AG dinucleotide and a branchpoint (BP) sequence recognized by the U2 
snRNP. The U2 snRNP complex binds to the intron through base-pairing 
interactions between the BP sequence and the U2 snRNA, and through 
interactions between intron sequences, SF3B1 and p14. The HEAT repeats of 
SF3B1 form helical structures that occlude the surface of RNA recognition 
motif of p14. U2 snRNP containing SF3B1WT recognizes the canonical U2AF-
dependant BP. The hotspot mutations of SF3B1 targeting the HEAT repeats 
occur on the inner surface of the structure and might induce a conformational 
change in the U2 snRNP complex altering its selectivity for BPs. U2 snRNP 
containing SF3B1MUT has more stringent requirement for BP sequences and 
less for U2AF-dependent sequences, leading to the binding of alternative 
branchpoints (BP') with high potential of base-pairing with U2 snRNP. AG, 
canonical 3′ss; AG', alternative 3′ss; x, average number of pyrimidines; Y, 
pyrimidine
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Eukaryotic translation initiation factor 1A, X-chromosomal (EIF1AX)
EIF1AX gene is localized in Xp22.12 and encodes for a 164 protein kDA protein 
(Figure 17). Eif1ax protein is required for binding the 43S complex (40S subunit, 
eIF2/GTP/Met-tRNAi and eIF3) to the 5' end of capped RNA (Figure 18). With a 
translation initiation factor activity, it stimulates the transfer of methionyl initiator 
tRNA (Met-tRNA) to the small ribosomal subunit during translation and it allows 
the formation of a stable mRNA-ribosome complex.
Mutations in EIF1AX were mainly observed in UM samples with disomy 3 and 
BAP1 wild type, and they were associated to a low risk of metastatic disease 
(Ewens et al, 2014). 
Identified EIF1AX mutations are missense mutations or deletion and they are 
heterozygous or hemizygous (in males) mainly occurring in the exon 1 and 2, 
the amino-terminal portion of the encoded protein. However, in UM, only mutant 
mRNA transcripts were expressed, suggesting that the wild-type copy of 
EIF1AX is epigenetically inactivated and, in this case, EIF1AX may act like a 
recessive gene (Harbour et al, 2014) (Figure 19).
Figure 17. Schematic representation of EIF1AX protein.
Eif1ax protein consists of a N-terminal tail, oligonucleotide binding (OB) fold and C-terminal tail. The 
mutation to date reported led to to substitutions or loss of one or two amino acid near the amino 
terminus. 
CN-terminal tail C-terminal tailOB FOLDN
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Figure 19. Schematic presentation of cellular functions of proteins commonly mutated uveal 
melanoma (Harbour et al, 2014).
Figure 18. Summary of functional domains in eIF1A and its interactions.  
The figure shows N-terminal domain, oligonucleotide-binding domain and C-terminal 
domain which bind other transcription factors (eIF2,eIF3), 40S ribosome, ternary 
complex (TC) respectively  (Olsen et al, 2003). 
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Novel identified mutations
Phospholipase C beta 4 (PLCB4)
Through Next Generation Sequencing of UM samples, Johansson et al 
(Johansson et al, 2016) found in UM samples a recurrent mutation in PLCB4 
gene: c.1888G>T p.D630Y (NM_000933). This finding was later confirmed by 
Moore  et al (Moore et al, 2016). 
PLCB4 gene maps in 20p12.3-p12.2, and encodes a protein that catalyzes the 
reaction from phosphatidylinositol 4,5-bisphosphate to inositol 1,4,5-
trisphosphate and diacylglycerol.  
Four Plcb4 isoforms have been found. Plcb4 protein contains three domain: PI-
PLC X-box, between the amino acids 313-463, PI-PLC Y-box, between the 
amino acids 565-681, and C2, between the amino acids 688-786. Plcb4 protein 
is part of GPCr signaling pathway, and it is involved in many molecular and 
biological functions: calcium binding, phosphatidylinositol phospholipase C 
activity, phospholipase C activity, signal transducer activity. In the retina, Plcb4 
plays an important role in intracellular transduction of many extracellular 
signals.
In UM, both Johansson et al (Johansson et al, 2016) and Moore et al (Moore et 
al, 2016) identified PLCB4 mutations only in GNAQ and GNA11 wild-type 
samples, and this finding suggested that PLCB4 mutation are gain-of-function 
mutations leading to activation of the same pathway activated by GNAQ/GNA11 
mutations.  As a consequence of these findings, the authors suggested an 
oncogenic role of PLCB4 mutations in UM with GNAQ and GNA11 wild-type 
(Johansson et al, 2016; Moore et al, 2016). 
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Cysteinyl leukotriene receptor 2 (CYSLTR2)
CYSLTR2 gene maps on 13q14.2, and consists of four exons with all introns 
located in the 5' UTR region of the gene. Moore et al (Moore et al, 2016) 
analyzed WGS and WES data from 136 UM form multiple cohorts. Using a 
mutation analysis algorithm to detect hotspot mutations in oncogenes, they 
identified a hotspot mutation in CYSLTR2 gene. This mutation was observed 
only in samples lacking mutations in GNAQ, GNA11 or PLCB4, suggesting that 
they activate the same pathway (Moore et al, 2016).
Mutation L129Q (Moore et al, 2016) is a missense mutation in transmembrane 
helix 3 (between 124-144 aminoacids) which associates extracellular ligands, 
intracellular G-alpha subunit, and the other transmembrane helices. L129Q 
CysLTR2 is constitutively activated, as evidenced by increased calcium 
mobilization and insensitivity to CysLTR2 agonist leukotriene D4. The missense 
mutation L129Q has melanocyte lineage-specific effects. In vivo experiments 
also showed that subcutaneously engrafted melan-a cells expressing mutant 
L129Q CysLTR2 were able to form tumor more rapidly than wild-type cells, 
suggesting that this novel mutation enhances melanoma tumorigenesis in vivo. 
Taken together, these findings may indicate an oncogenic role of CysLTR2 in 
UM through activation of Gα-q signaling.
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Multistep carcinogenesis
Hanahan and Weinberg (Hanahan and Weinberg, 2000; Hanahan and 
Weinberg, 2011) defined the cancer as un uncontrolled, clonal proliferation of 
cells, which progressively acquire most or all of the 8 “hallmarks" of neoplasia. 
These hallmarks, which are considered prerequisites necessary for survival, 
proliferation capacity and invasion of neoplastic cells, are acquired by a 
multistep process that leads to insensitivity to anti-growth signals, avoiding 
apoptosis, limitless replicative potential, angiogenesis, sustaining  proliferative 
signaling, reprogramming of energy metabolism, evading immune distruction, 
tissue invasion and metastasis (Hanahan and Weinberg, 2000; Hanahan and 
Weinberg, 2011).
Also in UM it is hypothesized that various genetic and epigenetic alterations 
occur in the development pathway from melanoblasts to UM cells.
UM is a cancer arising from melanocytes localized in the uveal tract. The 
precursors of the uveal melanocytes are the melanoblast cells, derived from 
neural crest. Until now, it is not clear whether the melanoma-initiating cells or 
cancer stem-like cells arise from melanocytes precursor of from melanocytes 
de-differentiated.
Almost all uveal nevi and UM show mutations in GNAQ or GNA11, suggesting 
their role in promoting melanocyte proliferation and survival. As already 
explained activating mutations in PLCB4 and CYSLTR2 genes could have the 
same role in UM with GNAQ and GNA11 wild type (Moore et al, 2016; Hanahan 
et al, 2000). Mutations in GNAQ, GNA11 or PLCB4 and CYSLTR2 are 
necessary for melanocyte cell proliferation but they are not sufficient for 
malignant transformation to UM. Other mutations and chromosomal aberrations 
are needed for the progression from uveal nevi to UM (Bauer et al, 2009; van 
Raamsdonk et al, 2009). 
It has been proposed that uveal nevi could progress through one of the two 
exclusive pathways, characterized by distinct genetic signatures and different 
metastatic risk. UM with monosomy 3, BAP1 gene mutations, and additional 1p 
loss and/or 8q gain show a high metastatic risk (class 2 tumor). UM with 6p gain 
and EIF1AX gene mutations show a low metastatic risk (class 1) (Figure 20). 
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A metastatic intermediate risk is observed either in class 1 and class 2 UM: 
class 1 UM harboring SF3B1 mutations and/or increased PRAME mRNA 
expression show a risk of late metastasis development, and class 2 UM 
harboring 6p gain show an intermediate risk of progression (Harbour et al,
2010). 
Figure 20. Schematic representation of molecular events that occur during progression from 
uveal melanocyte to metastatic melanoma (Amaro et al, 2017).
The figure shows an hypothesis of multistep UM tumorigenesis based on the current state of 
knowledge of  molecular alterations. UM develops from melanoblasts or melanocytes through 
mutations in GNAQ ,GNA11 genes or in CYSLTR2, PLCB4 genes. Monosomy chromosome 3, 
BAP1 mutation and 8q gain are associated to high metastatic risk but the presence of 6p gain may 
attenuate the metastatic risk. UM harboring SF3B1 mutation shows intermediate risk.
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BAP1 germline mutation and BAP1- TPDS
Germline BAP1 mutations were reported in less than 1% of UM patients in the 
UK (Soura et al, 2016; Aoude et al, 2013), in association with a novel hereditary 
cancer syndrome, described as BAP1 tumor predisposition syndrome (BAP1-
TPDS, #614327 OMIM) or as Cutaneous/Ocular Melanomas, Mealanocytic 
proliferations and other internal neoplasm. Heterozygous germline BAP1 
mutations were instead described in about 20%-30% of subjects with a family 
history of UM (Popova et al, 2013; Gupta et al, 2015; Turumen et al, 2016). 
This tumor predisposition syndrome related to BAP1 is inherited as autosomal 
dominant character: in carriers harboring heterozygous germline BAP1 
mutations, the somatic inactivation of the remaining allele is enough for the 
development of a malignant phenotype. Indeed, carriers of germline BAP1 
mutations have a high-risk of developing of a spectrum of primary tumor  types 
at younger age, including benign melanocytic tumors as well as UM, cutaneous 
melanoma, malignant mesothelioma, lung adenocarcinoma, meningioma, and 
renal cell carcinoma (Abdel-Rahman et al, 2011; Testa et al, 2011; Popova et al, 
2013; Soura et al, 2016; Rai et al, 2016) (Figure 21 ). 
Other suspected but unconfirmed tumors included in this novel tumors 
predisposition syndrome are also cholangiocarcinoma, non-small cell lung 
adenocarcinoma (NSCLC), meningioma, and neuroendocrine carcinoma (Testa 
et al, 2011; Popova et al, 2013; Rai et al, 2017). 
Association between BAP1 germline mutations and development of breast and 
ovarian cancers has been suspected, but contradictory results are reported 
in the literature (Coupier et al, 2005; Guénard et al, 2009). 
BAP1 tumor predisposition syndrome was phenotypically characterized by 
Wiesner (Wiesner et al, 2011). The author described specific pink skin lesions, 
classified as atypical Spitz tumors (ASTs), in two unrelated families harboring 
BAP1 germline mutations and with a concomitant loss of wild type allele in 
these skin lesions (Figure 22). The ASTs are a heterogeneous group of 
melanocytic tumors with both histological features of benign Spitz nevi, 
characterized by large melanocytes with high mitotic activity and uncommon 
BRAF mutations, and malignant melanoma. Wiesner et al and Njauw et al 
(Wiesner et al, 2011; Njauw et al, 2012) described these novel lesions  as 
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nevus-like lesions, round, dome-shaped and ranging in color from orange to 
red, large epithelioid BAP1 immunohistochemistry negative cells, virtually no 
mitotic activity, frequent BRAFV600 mutations in melanocytes cells (Wiesner et 
al, 2011; Njauw et al, 2012). 
Due to the differences with benign Spitz nevi, Carbone et al proposed the name 
BAP1-mutated atypical intradermal tumors (MBAITs) to classify these novel 
lesions (Carbone et al, 2012).
Also malignant mesothelioma in patients without occupational exposure to 
asbestos, UM, ovarian cancer, breast cancer, renal cell carcinoma, squamous 
cell carcinoma, basal cell carcinoma, and pancreatic cancer have been 
diagnosed in different family members (Wiesner et al, 2011; Abdel-Rahman et 
al, 2011). Recently, Kadariya et al (Kadariya et al, 2017) performed in vivo 
studies to determine if heterozygous germline truncating mutation BAP1 in mice 
predisposes to tumor formation. 
Figure 21. BAP1 tumor syndrome phenotype (Soura et al, 2016). 
Patients with the BAP1 tumor 
syndrome are at risk for 
cutaneous melanoma, 
MBAITs, ocular melanoma, 
mesothelioma, lung cancer 
and renal cell cancer.
Figure 22: MBAITs (Soura et al, 2016). 
Typical melanocytic BAP1-mutated atypical intradermal 
tumors (MBAITs). These lesions are generally round, dome-
shaped and orange to red color. 
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They observed that inactivating BAP1 mutations in mouse models induced an 
increase incidence of ovarian cancer, lung adenocarcinoma, mammary gland 
carcinoma, spindle cells tumor of skin, and MMs. It has to note that cancer 
spectrum observed in mice differs from of human tumors, indeed UM, CM, and 
RCC were not described in mice.
UM is the most frequent cancer diagnosed in patients with BAP1-TPDS (31%), 
and it is the cancer with the earliest age of diagnosis (Rai et al, 2016). 
Malignant mesothelioma and cutaneous melanoma are the second and the third 
most frequent cancers identified in BAP1-TPDS (Rai et al, 2016; Wiesner et al, 
2011). 
Current knowledge suggests that the presence of germline BAP1 mutations in 
patients with CM, UM, and RCC are associated with more aggressive cancers. 
Moreover, Abdel Rahman et al (Abdel-Rahman et al, 2011) reported UM with 
larger diameters, major involvement of ciliar body and increased risk of 
metastasis in patients carrying BAP1 germline mutation.
In contrast, patients with germline BAP1 mutations developing malignant 
mesothelioma (MM) showed a significantly longer survival rate than the other 
patients with BAP1-TPDS developing the other type of cancers (Rai et al, 
2017). 
Based on literature data, the penetrance of BAP1-TPDS appears high, but it 
must be considered that the number of families reported is limited, and also the 
natural history and the frequencies of BAP1-associated tumors are incomplete. 
In a recent review (Rai et al, 2017), 57 families and 174 individuals with BAP1-
TPDS were described: 148 out 174 (85%) carriers of a heterozygous germline 
BAP1 pathogenic mutation developed a cancer. Moreover, the authors 
estimated that BAP1 mutations are present in about 22% of families with familial 
UM, compared to 2-4% of sporadic UM.
In the clinical context, germline BAP1 mutations can be used as a diagnostic 
tool to identify mutation carriers and patients with BAP1 tumor predisposition 
syndrome, but significant uncertainty in terms of appropriate cancer surveillance 
has been highlighted: lifetime risk of developing cancer is not well known, as 
well as it is not clear if surveillance could lead to detect cancer early enough to 
improve the outcome of patients (Pilarski et al, 2014; Carbone et al, 2015). Until 
now, there are no cancer screening guidelines for BAP1 germline carriers (Rai 
et al, 2016). 
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An important challenge in cancer surveillance is to provide non-invasive tests, 
and also the detections of symptoms as soon as possible (more difficult for 
RCC and MM). Pilarski  (Pilarski et al, 2014) proposed a cancer screening plan 
with full-body skin examination, eye examination, abdominal ultrasound 
examination and abdominal MRI to identify possible primary tumors early (ATS, 
CM, UM, MMe, RCC). 
In addition, if a germline BAP1 mutation is identified, it could be important to 
extend the genetic status analysis to the other family members in order to 
identify possible other carriers. Because BAP1-TPDS is inherited in an 
autosomal dominant manner, genetic counseling to inform the BAP1 germline 
mutation carriers about the nature, the inheritance, and the implications of this 
tumor predisposition syndrome could be appropriate.
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Aim of the research project
Almost half of the patients with UM develop distant metastases. The poor 
outcome of UM patients with metastatic disease derives from the absence of 
proven effective adjuvant therapies. Predictive information on the clinical 
outcome of UM patients could provide the basis to determine an individualized, 
targeted therapeutic strategy for each UM patient. To reach this goal, it is 
important to have an accurate prediction system to assess the individual 
patient’s metastatic risk. To address this issue, in this study we evaluated 
genetic features of a UM series, and analyzed their associations with metastatic 
progression.
At first, we carried out a multiplex ligation-dependent probe amplification 
(MLPA) to identify chromosomal imbalances involving chromosomes 1p, 3, 6, 
and 8. To confirm chromosome 3 status, we used microsatellite analysis (MSA), 
that could identify samples with isodisomy 3, not identifiable with MLPA 
analysis. 
Because of their importance in UM tumorigenesis, we performed mutational 
analysis of GNAQ, GNA11, PLCB4, CYSLTR2, BAP1, EIF1AX, and SF3B1.
In particular, the well-established prognostic indicator BAP1 was investigated: 
we sequenced all the 17 BAP1 exons, and, to better understand the relationship 
between BAP1 mutational status and its functional activity, we carried out BAP1 
immunohistochemistry (IHC). The contemporary use of the two methodologies 
to study BAP1 has given us the opportunity to compare the validity of BAP1 IHC 
compared to Sanger sequencing. In addition, we used RNAscope® in situ 
hybridization, to verify the presence/absence of BAP1 mRNA transcripts in 
selected UM samples.
Univariate associations between studied parameters and metastatic disease 
were performed, and associations between mutations and distant progression 
free survival (DPFS) were studied. In addition, to evaluate if germline BAP1 
mutations occur in our UM and their potential contribution in UM developing, we 
performed BAP1 mutational analysis in DNA extracted from blood of 27 UM 
patients.
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Materials and Methods
Patients and specimens 
A total of 63 tissue samples were obtained from primary uveal melanoma after 
enucleation surgery at E.O. Galliera Hospital during the time period from 2012 
to 2016. The clinical data collected were: patient age at time of enucleation, 
sex, pathological TNM stages, histological cell type, time from enucleation to 
occurrence of metastasis (months), and the follow-up (months). Written 
informed consent was obtained for all patients.
Tissue sampling and histopathological analysis
Tumor sampling was performed immediately after enucleation by trans-scleral 
fine-needle aspiration biopsy (FNAB) or by trans-scleral incisional biopsy. After 
marking the tumor boundary using trans-pupillary transillumination, FNAB was 
performed with a 25-gauge needle attached to a 10-ml syringe using manual 
aspiration with a biopsy gun. Trans-scleral incisional biopsy was performed 
creating a partial lamellar scleral flap, then incising the inner scleral lamella and 
sampling the tumor with the Essen biopsy forceps (Dutch Ophthalmic Research 
Center, Zuidland, The Netherlands). In any case UM biopsies were then placed 
in RNAlaterTM (Ambion, Monza, Italy) and the eyes were formalin fixed and 
paraffin embedded (FFPE). For histopathologic examination, 2 µm-thick FFPE 
sections were stained with the conventional hematoxylin and eosin stain. Cell 
type was assigned according to the modified Callendar classification system 
(Callender et al,1931). 
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DNA extraction
DNA was extracted from fresh UM samples (biopsies) conserved in RNA later 
(Ambion, Monza, Italy) or from archival formalin-fixed, paraffin embedded 
(FFPE) block using respectively QIAamp DNA MINI Kit (Qiagen,Hilden, 
Germany) and QIAamp DNA FFPE MINI kit (Qiagen, Hilden, Germany). DNA 
from blood samples  was extracted with QIAsymphony SP instrument (QIA), a 
fully integrated system that can automate perform DNA purification from a wide 
range of samples with minimum input volume of  200 µl.
- DNA from biopsy was isolated in accordance with manufacturer’s instructions: 
the sample was resuspended in 180 µl of ATL buffer (lysis buffer) and 20µl of 
Proteinase K and it was heated to 56°C until the complete lysis of tissue. 
200µl Buffer AL was added to the lysate and it was incubated at 70°C for 10 
minutes. The lysate, with 200µl of ethanol 100%, was placed in a spin column 
and centrifuged. Two steps  with wash buffer were followed and  lastly the 
DNA was eluted with Buffer AE.
- DNA form FFPE sample was isolated in accordance with manufacturer’s 
instructions: two 10 um-thick section was cut from paraffin block and 
subjected to de-paraffinization using xylene. After centrifugation, the pellet 
was resuspended in a mixture containing 180µl lysis buffer and 20µl of 
Proteinase K and heated to 56°C until the complete lysis of tissue. An 
incubation at 90°C for 10 minutes followed.  The next steps are similar to the 
DNA  extraction from fresh samples. 
• DNA Quantification and Quality Assessment
DNA concentration and purify were estimated measuring the absorbance at 280 
and 260 nm with NanoDrop ND-1000 spectrophotometer (NanoDrop, 
Minneapolis, MN).  
If DNA quality resulted not optimal, we used Amicon Ultra-0.5 mL Centrifugal 
Filters to clean up the DNA before its use (Merck-Millipore).
Indeed, the ratio of absorbance at 260 and 280 nm is used to assess the purity 
of DNA. A 260/280 ratio of ∼1.8 is generally accepted as “pure” DNA. 
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The 260/230 ratio is a secondary measure of DNA purity. A ratio in the range of 
1.8-2.2 values is accepted as “pure” DNA. Ratio considerably lower may 
indicate presence of co-purified contaminants. 
Multiplex Ligation-dependent Probe Amplification or MLPA
MLPA is a method developed by MRC-Holland based on the semi-quantitative 
polymerase chain reaction principle. MLPA technique can be applied for 
detecting copy number changes in genomic DNA and, in particular, it is possible 
to detect DNA copy number changes in up to 40 sequences in a single reaction. 
MLPA advantages are the possibility to use a few DNA amount with good 
results, short execution time (24-48h) and no special equipment is required 
except for a thermal cycler and a capillary electrophoresis sequencer. In 
addition, it is possible to analyze in a unique reaction many target sites. 
MLPA probes consist of two oligonucleotides, each containing a specific PCR 
primer sequence (PCR primer sequence X and PCR primer sequence Y) and a 
sequence complementary to the target, known as the hybridization sequence. 
The two probes hybridize adjacent to each other (23.1). If the probes correctly 
hybridize to the target sequence they are ligated by a ligase enzyme (Figure 
23.2). The PCR primers exponentially amplify the ligated probes (Figure 23.3). 
One of the primers is labeled with a fluorescent dye to visualize the 
amplification product. 
• MLPA procedure
SALSA® MLPA® probemix P027-C1 and P417-B2 BAP1 (MRC-Holland) were 
used in association with MLPA reagents kit to identify chromosomal imbalances 
in UM samples (P027-C1) and deletions/duplications of one or more sequences 
in the BAP1 gene (P417-B2 BAP1).
SALSA® MLPA® probemix P027-C1 Uveal Melanoma probe mix contains 38 
probes: 7 probes on chromosome 1p, 15 probes on chromosome 3p and 4 
probes on chromosome 3q, 4 probes on chromosome 6p and 2 probes on 
chromosome 6q, 4 probes on chromosome 8p and  2 probes on chromosome 
8q. In addition SALSA P027-C1 contains 12 reference probes detecting 
sequences that could be stable in UM  (chromosomes 2, 4, 10, 11, 12, 13, 14, 
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15, and 18). Table 3 and Figure 23 show the salsa MLPA probes of probemix 
P027-C1 and their cytogenetic localization. 
SALSA® MLPA® probemix P417-B2 BAP1 contains one probe for each exon of 
BAP1 gene. In addition, 10 flanking probes for BAP1 gene and 15 reference 
probes are included in this probemix to facilitate the determination of the extent 
of a copy number change. Reference probes are included to detect autosomal 
chromosomal locations which are relatively stable both in melanocytic tumours. 
Table 4 and Figure  24 show P417-B2 BAP1 probes and their cytogenetic 
localization.
Figure 23. Schematic representation of MLPA procedure.
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We performed the MLPA procedure as follows: 
- Denaturation: 100 ng of DNA sample were diluted with TE to 5 µl and it was 
heated at 98°C for 5-30 min in a thermal cycler (Veriti 96 well, Applied 
Biosyjstem) and then cooled at 25°C;
- Hybridization: 3 µl of Hybr-probe mix (1.5 µl salsa probe and 1.5 µl MLPA 
buffer) was added to the sample, heated for 1 min at 95°C, and then 
incubated at 60°C for a minimum of 16 h and maximum of 20 h;
- Ligation: it was performed by diluting sample to 40 µl with Lig-mix containing 
25 µl water, 3 µl ligase-65 BufferA and 3 µl ligase-Buffer B. The sample was 
incubated at 54°C for 15 min, and then heated to 98°C for 5 min to allow 
ligase enzyme inactivation.
- Amplification: the amplification of ligation products was performed using a pair 
of universal primers complementary to PCR primer sequence X and PCR 
primer sequence Y. The sample was diluted with 10 µl of Pol-mix (0.5 µl salsa 
PCR primers, 7,.5 µl salsa polymerase and 0.5 µl water) and the MLPA 
reaction took place in the thermal cycler with the following conditions: x35 
( 95°C 30’’, 60°C 30’’, 72°C 1’), x1 (72°C 30’) .
After amplification 0.85µl of PCR products were mixed with injection mixture 
containing 18 µl of highly deionized HI-DI formamide (Applied Biosystem, ABI, 
Foster City, CA) and 0.4 µl internal line size standard ROX-500 (GeneScan-500 
ROXSize Standard, ABI). The PCR products, suchly diluted, were separated by 
electrophoresis on ABI Prism 3130xl Genetic Analyzer and analyzed by 
Coffalyser.net
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Table 3. SALSA® MLPA® probemix P027-C1 arranged according to chromosomal 
position
Length (nt) SALSA MLPA probe Gene (exon) Chromosomal 
position
196 04888-L04272 MFN2 1p36.22
274 « 04148-L03503 NBL1 1p36.13
355 02267-L01425 PTAFR 1p35.3
220 13671-L17892 GJB3 1p34.3
418 03964-L03351 MUTYH 1p34.1
241 ± 03601-L19174 RPE65 1p31.2
136 02867-L02334 NOTCH2 1p12
207 14147-L17987 CHL1 3p26.3
283 ‡ 15895-L18089 BRK1 3p25.3
391 13322-L14735 VHL, ex 2 3p25.3
445 15899-L18091 VHL, ex 3 3p25.3
259 06900-L06480 PPARG 3p25.2
474 ± 06118-L05573 XPC 3p25.1
190 15896-L17989 MIR128-2 3p22.3
139 15288-L20037 MLH1 3p22.2
454 16407-L18832 CTNNB1 3p22.1
364 15897-L18094 RBM5 3p21.31
483 16644-L19176 BAP1, ex 9 3p21.1
226 16643-L20039 BAP1, ex 4 3p21.1
178 ± 02292-L02212 FHIT, ex 5 3p14.2
337 02290-L01781 FHIT, ex 4 3p14.2
409 04603-L03256 ROBO1 3p12.3
328 ± 05297-L04685 PROS1 3q11.1
247 05708-L19175 CASR 3q21.1
201 00487-L00069 MME 3q25.2
344 ± 03271-L02708 OPA1 3q29
382 10252-L11363 ECI2 6p25.2
463 10253-L18092 DCDC2 6p22.3
427 00585-L18090 CDKN1A 6p21.2
160 « ± 02611-L02082 RUNX2 6p21.1
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266 04745-L19276 CTGF 6q23.2
233 02798-L20038 IGF2R 6q25.3
310 02552-L19178 LZTS1 8p21.3
318 ± 04239-L03575 NRG1 8p12
184 ± 16641-L19172 RP1 8q12.1
165 15894-L16789 MYC, ex 1 8q24.21
154 00580-L00145 MYC, ex 3 8q24.21
299 16241-L18499 ASAP1 8q24.21
Table 3. SALSA® MLPA® probemix P027-C1 arranged according to chromosomal 
position
Length (nt) SALSA MLPA probe Gene (exon) Chromosomal 
position
Table 4 SALSA® MLPA® probemix P417-B2 BAP1 arranged according to chromosomal 
location
Length 
(nt)
SALSA MLPA probe Gene/exon location/ ligation site
telomeric
385 16176-L21699 MLH1 3p22.2
364 15897-L18094 RBM5 3p21.31
184 12125-L21391 RASSF1 3p21.31
214 03206-L13082 ZMYND10 3p21.31
BAP1 at 3p21.1
STOP codon 2415-2417 (Exon 17)
332 17414-L21123 Exon 17 2580-2581
281 21244-L29701 Exon 16 2214-2215
190 17404-L21113 Exon 15 2139-2140
263 17409-L21118 Exon 14 2111-2112
244 17407-L21116 Exon 13 1814-1815
308 17413-L21122 Exon 12 1388-1389
179 17403-L21112 Exon 11 1342-1343
285 17411-L21120 Exon 10 1057-1058
268 17398-L19176 Exon 9 923-924
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299 17412-L21397 Exon 8 879-880
149 17400-L21109 Exon 7 710-711
257 17408-L21394 Exon 6 610-611
208 17405-L21114 Exon 5 483-484
227 16643-L19177 Exon 4 441-442
173 17402-L21111 Exon 3 321-322
159 17401-L21110 Exon 2 285-284
232 17406-L21392 Exon 1 238-237
START codon 228-231 (Exon1)
221 07223-L21127 HESX1 3p14.3
317 04710-L01787 FHIT 3p14.2
346 10794-L11434 MITF 3p13
274 06439-L05965 ROBO1 3p12.3
202 05292-L21125 PROS1 3q11.1
378 14836-L21403 CPOX 3q12.1
telomeric
Table 4 SALSA® MLPA® probemix P417-B2 BAP1 arranged according to chromosomal 
location
Length 
(nt)
SALSA MLPA probe Gene/exon location/ ligation site
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Microsatellite analysis
Microsarellite analysis (MSA) utilizes short, highly polymorphic repeated 
sequences within the chromosome. The number of repetitions aimed at a 
specific microsatellite often varies between the maternal and paternal allele. 
We performed this technique to identify samples with isodisomy of chromosome 
3, not identifiable with only MLPA analysis. Through microsatellite analysis we 
determined allelic imbalance (AI), loss of heterizigosity (LOH) or retention of 
heterozygosity (ROH) at specific loci by comparing the intensity of amplification 
products between the UM sample and the corresponding normal control. 
MSA on chromosome 3 required many tests in order to choose the best 
microsatellite panel. We used 12 polymorphic microsatellite repeats on 
chromosome 3 divided according to the lengths and the labels (VIC, FAM or 
NED) in three microsatellite panels for DNA extracted from fresh samples, two 
panels for DNA extracted from FFPE samples, and amplified in multiplex PCR. 
Table 5 and Table 6 show the list of microsatellite repeats, their chromosomal 
localization, size and micro satellite primers. Figure 25 shows both localization 
of MLPA probes and microsatellite loci on chromosome 3.
• Microsatellite procedure
Microsatellite analysis was performed using 25 ng of genomic DNA extracted 
from tumor an blood sample in a 25 µl reaction mix: 10x Platinum® PCR 
Supermix, 1.5 mM MgCl₂, 200 µM M dNTPs, 0.4 µM  each primer pair and 2U 
Taq Platinum (Invitrogen– Life Technologies Corporation, Italy). 
After an initial cycle of denaturation at 95°C for 12 min, amplification was 
obtained by 10 x (15s, 94°C; 15s 56°C; 30s 72°C), 20 x (15s 89°C; 15s 56°C;
30s 72°C); 30m 72°C. PCR products were quantified and analyzed using the 
ABI 3130XL (Applied Biosystems-Life Technologies Corporation, Milan, Italy) 
and Genemapper™ software (Applied Biosystems, Foster City, CA, USA) 
respectively. A comparison of the peak area of DNA from UM biopsy specimens 
and normal DNA from matched blood samples allowed the determination of 
allele ratio in tumour.
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Table 5. Microsatellite panels for fresh samples
Panel Locus Map Size Forward primer Reverse primer
Panel 
1 
D3S1292 (VIC) 3q21-q22 142-166   TGGCTTCATCAC
CAGACC
CAGATTCAAGAGG
CACTCCA
D3S1265 (VIC) 3q29 212-236 GAAGCAGGAGAA
TCACGGA
CGTTCTGTGTGTT
GCTAGTATGT
 D3S3681 (NED) 3p12.3 210-246 GTGAGAACCATT
TGGGGCAG
GGCGAGCTATCTG
TCAGGG
 D3S1271 (NED) 3q12.3 146-158 TGATTGGAGGTG
GTAGAGG
AGCTATCATGTAGA
AAAGCAGC
Panel 
2
D3S1304 (VIC) 3p26 253-269 TTCGCTCTTTGAT
AGGC
ATTTCATTTGTAATT
TACTAGCAG
D3S3521 (FAM) 3p21.3 227-287 CAGTAAGTCCAT
GCCAGGG
GCAGCAGTTACCT
TGGAGTG
D3S3686 (FAM) 3q26.3 108-134 AGGGTATTTCATT
CCCATTG
CCAGGTTACGCCA
AGTG
D3S1558 (FAM) 3p13.32 152-166 GGGTGCTATCATT
TTAACC
CCTTAATGTGCTCA
TGGAAG
 D3S3668 (NED) 3q25 235-257 CTTTTGGGAATTA
AAAACTTCAGG
GTCAGTAAAACATG
GAAATATGAGC
D3S1597 (NED) 3p25.3 162-180 AGTACAAATACAC
ACAAATGTCTC
GCAAATCGTTCATT
GCT
Panel 
3
 D3S3697 (VIC)  3p14.1 190-225 TAGCCCCCTGCT
GTCA
CTGGCCCAGGTTG
GAA
D3S3630 (FAM) 3p26 172-188 AAGGGATAAGCT
GCAAATCA
ACCAAATACAATTC
ATGAGACCTGA
Table 6. Microsatellite panels for FFPE samples
Panel Locus Map Size Forward primer Reverse primer
Panel 
A
D3S3697  (VIC)  3p14.1 190-225 TAGCCCCCTGCT
GTCA
CTGGCCCAGGTTG
GAA
D3S3686 (FAM) 3q26.3 108-134 AGGGTATTTCATT
CCCATTG
CCAGGTTACGCCA
AGTG
D3S1558 (FAM) 3p13.32 152-166 GGGTGCTATCATT
TTAACC
CCTTAATGTGCTCA
TGGAAG
D3S1597 (NED) 3p25.3 162-180 AGTACAAATACAC
ACAAATGTCTC
GCAAATCGTTCATT
GCT
Panel 
D
D3S1292 VIC 3q21-q22 142-166 TGGCTTCATCAC
CAGACC
CAGATTCAAGAGG
CACTCCA
D3S3697  VIC  3p14.1 190-225 TAGCCCCCTGCT
GTCA
CTGGCCCAGGTTG
GAA
D3S3630 FAM 3p26 172-188 AAGGGATAAGCT
GCAAATCA
ACCAAATACAATTC
ATGAGACCTGA
D3S1271 NED 3q12.3 146-158 TGATTGGAGGTG
GTAGAGG
AGCTATCATGTAGA
AAAGCAGC
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D3S630   3p26; D3S1304 3p26
D3S1597 3p25-p22
D3S3521 3p21.3
D3S3697 3p14.1
D3S3681 3p12.3
D3S1271 3q12.3
D3S1558 3q13.32
D3S1292 3q21-q22
D3S3668 3q25
D3S3686 3q26.3
Chromosome 3 Microsatellite loci
XPC 3p25.1
CTNNB1 3p22.1
CHL1  3p26.3
PPARG 3p25.2
MIR128-2 3p22.3 MLH1 3p22.2
RBM5 3p21.31 BAP1 ex 9; BAP1 ex 4   3p21.1
FHIT ex 5; FHIT ex 4  3p14.2
ROBO1   3p12.3
PROS1  3q11.1
CASR  3q21.1
MME  3q25.2
OPA1  3q29
BRK1; VHL ex 2; VHL ex3  3p25.3
MLPA  probes
Figure 24. Localization of MLPA probes and micro satellite loci on chromosome 3
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Immunohistochemical staining
The immunohistochemistry assay was performed at the Pathology Unit, E.O. 
Galliera. A representative block containing the largest amount of viable tumour 
was selected from each case, from which unstained 2 µm sections were 
prepared and submitted for assessment of BAP1 expression by 
immunohistochemistry (IHC)
Immunohistochemistry was performed with an automated IHC staining system 
(Ventana BenchMark ULTRA, Ventana Medical Systems) according to the 
manufacturer’s instructions and using red chromogen. After deparaffinization of 
paraffin-embedded  blocks, heat–induced antigen retrieval was performed and 
the section were incubated with a mouse monoclonal antibody raised against 
amino acids 430-729 of human BAP1 (C-4 clone sc-28383, 1:50 dilution, Santa 
Cruz Biotechnology, inc. USA). This was followed by incubation with 
haematoxylin II. Endothelial cells vascular of UM were used as positive controls 
for BAP1 expression. 
Immunohistochemistry scoring: staining BAP1 expression was scored as diffuse 
(nuclear staining present in >90% of tumor cells) or absent (nuclear staining 
present in <10% of tumor cells).
Sodium bisulfite modification and Pyrosequencing Assay 
Genomic DNA (500 ng) extracted from UM frozen or FFPE tissues was 
chemically modified with the Epitect Bisulfite kit (Qiagen, Milan, Italy) following 
the manufacturer instructions. The PCR and sequencing primers for BAP1 were 
designed with the Pyrosequencing Assay Design Software (Biotage, Uppsala, 
SW)) to recognize some CpG sites in the CpG island in the TSS defined as 
Area 1 (Ibragimova et al, 2013). The PCR primers sequences were: BAP1 
Forward: 5’-Bio-GAGGGAGGGTTTGGATATG-3’; BAP1 Reverese: 5’-
ATCCCCTCCTCACCTAAA-3’. The sequence of the sequencing primer was: 
BAP1 Sequencing primer: 5’-CCCCTCCTCACCTAAA-3’. The PCR reactions 
were performed using IMMOLASE™ DNA Polymerase (Bioline, Aurogene, 
Rome) according to according to the manufacturer instructions (95°C for 10 min 
followed by a three steps PCR (annealing temperature 62°C) for 45 cicles. The 
setup of the primers design was checked utilizing commercial bisulfite modified 
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DNA derived by chemically methylated and un-methylated  samples (EpiTect 
PCR Control DNA Set, Qiagen, Milan). The resulting amplicons were subjected 
to pyrosequencing analysis with a SPQ 96MA instrument (Qiagen). The 
sequencing reactions were performed with the Pyro Gold reagent kit SPQ 
96MA, according to the manufacturer instructions. The  analysis  was 
conducted with the Pyro Q-CpG software (version 1.0.9)
Mutational analysis 
Polimerase Chain Reaction (PCR)
PCRs was generally carried out using 25 ng of genomic DNA on 25 µl reaction 
mix containing 10x Platinum PCR supermix, 1.5 mM MgCl2, 1.25 mM dNTPs, 
10mM primers and 0,5U Taq Platinum (Invitrogen-Life Technologies 
Corporation, Monza, Italy) on a Verity 96 well thermal cycler. Thermal cycling 
conditions were: x1 (95°C 5 min), x35 (95°C 30s 58°C 30s 72°C 30s) x1 (72°C 
7min). All PCR primers were designed with the  universal M13 sequence at 5’- 
end: universal forward primer 5’-GTTGTAAAACGACGGCCAGT-3’ and M13 
reverse primer 5’-GTGTGAAATTGTTATCCGCT-3’. 
A challenge was encountered in PCR primers design. We designed additional 
primers specific for amplification from FFPE samples because the extraction 
procedure usually leads to DNA  fragmentation. We tested every primers pairs 
on control DNA extracted from blood and FFPE tissue control sample with 
different  annealing temperature and magnesium concentration to choose the 
best PCR conditions. For some genes we increased the initial denaturation time 
and/or we added additive such as DMSO to reduce the secondary structure’s 
development. 
• GNAQ and GNA11 PCR
GNAQ and GNA11 mutations occur at the two known hotspots:  exon 5 c.626 
A>T Q209L or A>C Q209P, and exon 4 c.548 G>A R183Q. We designed two 
couples of PCR primers for exon 4 and exon 5 (GNAQ isoform NM_ 002072.3, 
GNA11 isoform NM_002067.2) (Table 7). 
PCRs was carried out with 25 ng of genomic DNA on 25 µl reaction mix 
containing 10x Platinum PCR supermix,1.5 mM MgCl2, 1.25 mM dNTPs, 10mM 
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primers and 0,5U Taq Platinum (Invitrogen-Life Technologies Corporation, 
Monza, Italy) on a Verity 96 well thermal cycler. Thermal cycling conditions 
were: x1 (95°C 5 min), x35 (95°C 30s 58°C 30s 72°C 30s) x1 (72°C 7min). The 
PCR reaction mix also contained DMSO to reduce secondary structures 
development.
• BAP1 PCR
A set of 16 couples of primers to perform the amplification in DNA extracted 
from fresh samples were used. A problem occurring with DNA extraction form 
FFPE samples is its possibly fragmentation due to the same extraction 
procedure,  thus we designed additional FFPE primers  to cover the length of 
longer exons. All primers used for fresh and FFPPE samples and the size of 
amplicons  are summarized in Table 8. 
PCRs was generally carried out with 25 ng of genomic DNA on 25 µl reaction 
mix containing 10x Platinum PCR supermix, 1.5 mM MgCl2, 1.25 mM dNTPs, 
10 mM primers and 0.5U Taq Platinum (Invitrogen-Life Technologies 
Corporation, Monza, Italy) on a Verity 96 well thermal cycler. Thermal cycling 
conditions were: x1 (95°C 5 min), x35 (95°C 30s 58°C 30s 72°C 30s) x1 (72°C 
7min) for all out the exon 2 which it works at 60°C  of annealing temperature.
Table 7.  GNAQ and GNA11 primers
Gene/Exon Name Primer sequence (5’!3’) Amplicon 
Size
GNAQ, exon 4 GNAQ 4F GTGTCACTGACATTCTCATTGTG 231 Bp
GNAQ 4R GAGTTTACCAAATGTACTCAAGGC
GNAQ, exon 5 GNAQ 5F AATTGACTTGGATGATCATCGTC 233 Bp
GNAQ 5R TTGATCATATTCACTAAGCGCTAC
GNA11, exon 4 GNA11 4F AGCCGGCCTGAGCAC 212 Bp
GNA11 4R CAAATGAGCCTCTCAGTGCC
GNA11, exon 5 GNA11 5F CAGGTGGCTGAGTCCTGG 173 Bp
GNA11 5R TTGGCAGGTGGGGAAG
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Table 8. BAP1 PCR primers
Exon Name Primer sequence (5’!3’) Amplicon Size
1
BAP1 1F GAGGGCCTGGACATGGC
145 Bp
BAP1 1R GTCAGGCAGGCGCGTC
2
BAP1 2F ACGCGCCTGCCTGAC
138 Bp
BAP1 2R TTGAGTGAGGGCGCAGG
3
BAP1 3F GGGCTGTCCTTCCCTACTG
160 Bp
BAP1 3R CCTGTTCTCTGGGACCTTCC
4
BAP1 4F TGGCTGATCTGGCTCTGC
213 Bp
BAP1 4R CATGGCAGCATCCCACC
5
BAP1 5F TGACTGACCTGCTCTGGATC
200 Bp
BAP1 5R AGTGGCCCTCAGGGTCAG
6
BAP1 6F_FFPE TTTGCCTTCCACCCATAGT
169 Bp
BAP1 6R_FFPE CTCCCACCCCACATCAG
7
BAP1 7F_FFPE TTTGGGCCCTGACTCT
208 Bp
BAP1 7R_FFPE AGAGACACCCAACAGGC
6-7
BAP1 6.7F TCCACCCATAGTCCTACCTGAG
260 Bp
BAP1 6.7R GCTCCCTAGGAGGTAGGCAG
8
BAP1 8F CCTGGCCTGCCCAAAC
194 Bp
BAP1 8R TCCCAAAGTAGGTACAGCTCCAG
9
BAP1 9F CTCAACCTGATGGCGGG
234 Bp
BAP1 9R AATGCAGGGAGGGTTGG
10
BAP1 10F_FFPE CTTTCTCCTCTGAGCCCTGG
256 Bp
BAP1 10R_FFPE AGACATTAGCGGGTGGCTC
BAP1 10F AAGGTAGAAGCCCGGGTCTAC
275 Bp
BAP1 10R TGTTTAGGCCTCCCATGTCAG
11
BAP1 11.1F_FFPE GGAGGTCCTGCCTGTGTTC
186 Bp
BAP1 11.1R_FFPE CTAGAAAGGCCGGCAGC
BAP1 11.2F_FFPE GGTGAAGCCTCCAGGCAG
142 Bp
BAP1 11.2R_FFPE GCAGCCTCTCAAGAGAATCAAGT
BAP1 11F GGAAGTGCTGGTTCACAGG
388 Bp
BAP1 11R AGCTTGACCCAGCCATG
BAP1 12F_FFPE CAGCACTTGTTTGTAACTGCC
207 Bp
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12
BAP1 12R_FFPE ACCTAGAACCTGGTAGCCTTAGA
207 Bp
BAP1 12F TAGGCTCAGCCTGGGCC
253 Bp
BAP1 12R GAGATATTCAGGATGGGATCCG
13
BAP1 13.1F_FFPE TGGTCACCTGGCCCG
163 Bp
BAP1 13.1R_FFPE AAGACGTTGATGGTGTTGGG
BAP1 13.2F_FFPE GCCAGGGGCATTGAGC
222 Bp 
BAP1 13.2R_FFPE GGGTGAGGGGTGCGAG
BAP1 13.3F_FFPE ATTCCTCTGTCCATCAAGACTAGC
177 Bp
BAP1 13.3R_FFPE ATAGGCGAGCGCAGTGG
BAP1 13.3bisF_FFPE CCCCAGCAATGAGAGTACAGAC
159 Bp
BAP1 13.3bisR_FFPE AACACGCAGCAGGCTGTC
BAP1 13.4F_FFPE CTCCCACATCTCCAAGGTG
197 Bp
BAP1 13.4R_FFPE GGGTGCACCAAGTGGC
BAP1 13aF TACTGCTGGGTATGGTCACCT
335 Bp
BAP1 13aR CACCTTGGAGATGTGGGAG
BAP1 13bF AGCAATGAGAGTACAGACACGG
345 Bp
BAP1 13bR GGACACTTTGTGGTCACTTGG
14
BAP1 14.1F_FFPE CACTCTGATGATTTTCTTGTGACC
135 Bp
BAP1 14.1R_FFPE CTGCTGTCCGTGGCTTC
BAP1 14.2F_FFPE ATCAGACCAATCCAAGGCAG
191 Bp
BAP1 14.1F_FFPE AGCTCAGGCCTTACCCTCTG
BAP1 14F CCAAGTGACCACAAAGTGTCC
300 Bp
BAP1 14R AAGAACTTGGCACCTGGGC
15
BAP1 15F_FFPE GTGGGGCTTTGTTGCTG
198 Bp
BAP1 15R_FFPE GGGAGAGGCCAGATGAGG
16
BAP1 16F-FFPE AGATTGGCTCCAGTGCTCTC
168 Bp
BAP1 16R-FFPE AAGGACACGGCCCTCAG
15-16
BAP1 15.16F TAGCTGCCTATTGCTCGTGG
406 Bp
BAP1 15.16R GAAGGACACGGCCCTCAG
17 BAP1 17F_FFPE GCCAGCACCTGCTCAAG 233 Bp
BAP1 17R_FFPE ACACGGCAAGAGTGGGC 233 Bp
Table 8. BAP1 PCR primers
Name Primer sequence (5’!3’) Amplicon SizeExon 
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• EIF1AX PCR
EIF1AX mutations occur on exon 1 and 2. To perform the amplification in DNA 
extracted from fresh samples, we designed two couples of PCR primers for 
exon 1 and exon 2  (isoform NM_001412.3). We also designed additional FFPE 
primers to perform the amplification in DNA extracted from FFPE samples. The 
primers used and the sizes of amplicons  are summarized  in Table 9.
Exon 2 PCR was carried out with 25 ng of genomic DNA on 25 µl reaction mix 
containing 10x Platinum PCR supermix, 2 mM MgCl2, 1.25 mM dNTPs, 10mM 
primers and 0,5U Taq Platinum (Invitrogen-Life Technologies Corporation, 
Monza, Italy) on a Verity 96 well thermal cycler. Thermal cycling conditions 
were: x1 (95°C 5 min), x35 (95°C 30s 54°C 30s 72°C 30s) x1 (72°C 7min). 
Exon 1 PCR conditions were slightly modified with a reaction mix containing 1.5 
mM MgCl2 and with 54°C of annealing temperature. For both the exons, the 
PCR reaction mix contained DMSO to reduce secondary structures 
development.
17 BAP1 17F CCTCAGCTCCTGGCCTG
311 Bp
BAP1 17R AGGGAAGGACCCTGGTGA
Table 8. BAP1 PCR primers
Name Primer sequence (5’!3’) Amplicon SizeExon 
Table 9. EIF1AX primers
Gene/Exon Name Primer sequence (5’!3’) Amplicon 
Size
EIF1AX, exon 1
EIF1AX 1F_FFPE CGCTACCCGGAAAGAAGTC
146 Bp
EIF1AX 1R_FFPE CTGGGTGACCTGCAATCTAC
EIF1AX 1F GAAAAGCGACGCAAAGAGTC
320 Bp
EIF1AX 1R CTGGGTGACCTGCAATCTAC
EIF1AX, exon 2
EIF1AX 2F_FFPE TTACAGATAATTAATGTCATTTAC
CTCC 225 Bp
EIF1AX 2R_FFPE ATGGGCAAGACGCTGTC
EIF1AX 2F GGGTAGGGAGGTGATAATGTG
406 Bp
EIF1AX 2R CTGTAATCGTGCCACCACAC
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• SF3B1 PCR
The mutation hotspots in SF3B1 occur on exon 15 (R625 and K666), primers 
used and the sizes of amplicons are summarized in Table 10.      
PCR was carried out using 25 ng of genomic DNA on 25 µl reaction mix 
containing 10x Platinum PCR supermix, 1.5 mM MgCl2, 1.25 mM dNTPs, 10mM 
primers and 0,5U Taq Platinum (Invitrogen-Life Technologies Corporation, 
Monza, Italy) on a Verity 96 well thermal cycler. Thermal cycling conditions 
were: x1 (95°C 5 min), x35 (95°C 30s 60°C 30s)x1 (72°C 7min). The PCR 
reaction mix also contained DMSO to reduce secondary structures 
development.
   
• PLCB4 PCR
The mutation hotspot in PLCB4 occurs on exon 20 (pD630Y) (isoform 
NM_00933). We designed one couple of primers to amplify only this exon 
(Table 11). 
PCR was carried out with 25 ng of genomic DNA on 25 µl reaction mix 
containing 10x Platinum PCR supermix, 1.5 mM MgCl2, 1.25 mM dNTPs, 
10mM primers and 0,5U Taq Platinum (Invitrogen-Life Technologies 
Corporation, Monza, Italy) on a Verity 96 well thermal cycler. Thermal cycling 
conditions were: x1 (95°C 5 min), x35 (95°C 30s 58°C 30s 72°C 30s) x1 (72°C 
7min). The PCR reaction mix contained DMSO to reduce secondary structures 
development.
Table 10. SF3B1 primers
Gene/Exon Name Primer sequence (5’!3’) Amplicon Size
SF3B1 exon 15
SF3B1 15F TGATTATGGAAAGAAATG
GTTGAAG
191 Bp
SF3B1 15Rint CATGTTCAATGATTTCAA
CTAAACTTC
SF3B1 exon 15
SF3B1 15intF TCCGTAACACAACAGCTA
GAGC
217 Bp
SF3B1 15Ru CAACTTACCATGTTCAAT
GATTTCAAC
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• CYSLTR2 PCR
The mutation hotspot in CYSLTR2 occurs on exon 6 (p.L129Q) (isoform 
NM_020377.3) (Table 12). PCRs was carried  out using 25 ng of genomic DNA 
on 25 µl reaction mix containing 10x Platinum PCR supermix, 1.5 mM MgCl2, 
1.25 mM dNTPs, 10mM primers and 0,5U Taq Platinum (Invitrogen-Life 
Technologies Corporation, Monza, Italy) on a Verity 96 well thermal cycler. 
Thermal cycling conditions were: x1 (95°C 5 min), x35 (95°C 30s 58°C 30s 
72°C 30s) x1 (72°C 7min). The PCR reaction mix also contained DMSO to 
reduce secondary structures development.
• PTK2B PCR
In this gene no mutation hotspots were identified. We analyzed the gene region 
codifying the chinasic domain (exons 19, 20, 21, 22,23 24,25,26 and 36) and 
the Focal Adhesion Targeting region (FAT) (isoform NM_173174.2).
We designed thirteen pairs of primers to amplify the twelve exons (due to the 
length, the exon 36 was divided in two amplicons). All PCR primers are 
summarized in Table 13.
PCR was carried out with 25 ng of genomic DNA on 25 µl reaction mix 
containing 10x Platinum PCR supermix, 1.5 mM MgCl2, 1.25 mM dNTPs, 
10mM primers and 0,5U Taq Platinum (Invitrogen-Life Technologies 
Corporation, Monza, Italy) on a Verity 96 well thermal cycler. To perform the 
Table 11. PLCB4 primers 
Gene/Exon Name Primer sequence (5’!3’) Amplicon Size
PLCB4 exon 20
PLCB4  F CAAACGGCAAATGAGTC
GC
185 Bp
PLCB4 R CAACTGATGGGAAGTGC
TGG
Table 12. CYSLTR2 primers
Gene/Exon Name Primer sequence (5’!3’) Amplicon Size
CYSLTR2 exon 6
CYSLTR2  F GATATTTGGAGACCTGGCCT
GCA 199 Bp
CYSLTR2 R TGAGGAAGCCATGATAAGG
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reaction for amplicons 20, 21, 27, 34, 36.1, thermal cycling conditions were: x1 
(95°C 5 min), x35 (95°C 30s  58°C 30s 72°C 30s) x1 (72°C 7min), for amplicons 
19, 22, 23, 24, 25, 26, 35 were  x1 (95°C 5 min), x35 (95°C 30s  60°C 30s 72°C 
30s) x1 (72°C 7min) and  for amplicons 36.2 were  x1 (95°C 5 min), x35 (95°C 
30s  62°C 30s 72°C 30s) x1 (72°C 7min). The PCR reaction mix also contained 
DMSO to reduce secondary structures development.
Table 13. PTK2B primers
Gene/Exon Name Primer sequence (5’!3’) Amplicon 
Size
PTK2B exon 19
exon 19 F GCATCTTGTCCACGGCTG
210 Bp
exon  19 R GTCTAGCACGAAGGGAGGAT 
PTK2B exon 20
exon 20 F TAGAGCCTGCAGACACTCAG
212 Bpexon 20 R GGAAGAGGAGTGTAAGGGA
AGA 
PTK2B exon 21
exon 21 F GGGTCCTGAACACACTCTTG
175 Bp
exon 21 R CCCTCTCTTCCCAGGCTG 
PTK2B exon 22
exon 22 F GCTCCACCTGTCCCTCTT 
197 Bp
exon 22 R CTGTGCTCTGAATGCCCC
PTK2B exon 23
exon 23 F GTCCCCTGGCTCCATACTG
196 Bp
exon 23 R CCACTCCCTCCACCCCTA
PTK2B exon 24
exon 24 F TTCCATCTGTCTGTCCATCTC
T
264 Bp
exon 24 R ACTGTAGACTTCCTTCTTCTG
GA
PTK2B exon 25
exon 25 F CAGGCTAAGGGTCTTCAGAAA
G 210 Bp
exon 25 R CACCTTTTCATGCCCTCCC
PTK2B exon 26
exon 26 F CCTGACGCTCCCTTACACC
250 Bp
exon 26 R ACAGCCCACACTCCATGC
PTK2B exon 27
exon 27 F GCGTCTCACTTTGACCTAGTT
T 208 Bp
exon 27 R TGGCTTTGCTTTGACTCACA
PTK2B exon 34
exon 34 F AAGAATCATTCCGTGCCCC 
265 Bp
exon 34 R CAGTCCCCTTTCCTTCCAG
PTK2B exon 35
exon 35 F GCCATCCTGCCCCTTTCTC
137 Bp
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PTK2B exon 35 exon 35R CTATGGTGCTGTCTGGAATGG
G
137 Bp
PTK2B exon 36
exon 36.1 F GGCCTCTCAACCTGTCCTG
170 Bp
exon 36.2 R GGGTGTGTGAAGCCGTCA
exon 36.2 F CAGAACGCCGTGACCTCC 179 Bp
exon 36.2 R GGAAGACGCAGGCAGGTG
Table 13. PTK2B primers
Name Primer sequence (5’!3’) Amplicon 
Size
Gene/Exon 
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Sequencing  reaction
The PCR fragments were sequenced with direct Sanger sequencing and it was 
performed in 10 µl reaction mix containing BigDye® Terminator with dNTPs and 
a small amount of all four dideoxynucleotides labeled with fluorophores, 5X 
sequencing Buffer (BigDye™ Terminator v1.1 Cycle Sequencing Kit ABI 
PRISM®, Applied Biosyjstem) 10mM  universal M13 primers on a Verity 96 well 
thermal cycler. Thermal cycling conditions were: 1X(95°C 1min) 20X ( 95°C 
30sec, 60°C 3min) 1X( 10°C 10min). In some difficult cases we used an higher 
denaturation temperature ( 96°C instead 95°). Sequencing data were analyzed 
with ABI PRISM® SeqScape® Software. SeqScape® is a software for 
sequencing and  genetic analysis who help for variant identification and permits 
basecalling, sequence assembly, alignment and comparison for comparative 
sequencing analysis, simultaneous viewing of multiple sequences and 
electropherogram.
RNAscope® In Situ Hybridization Assay 
The RNAscope® Assays (Advanced Cell Diagnostic ACD) is a gene expression 
analysis by RNA In  Situ Hybridization. In situ hybridization (ISH) is a powerful 
research tool that can provide mechanism of gene expression changes in a 
specific cell population. Initially, probes containing radio labeled nucleotides 
were used to detect mRNA transcripts. However, the recents techniques use 
alternative methods of detection, such as probes labeled with digoxigenina, 
biotin, enzymes or fluorophores. Among some of the more recent ISH methods 
there is RNAscope®, a novel in situ mRNA analysis technology available also 
for FFPE Tissues. The ability to detect single mRNA transcripts using standard 
microscopy techniques is the biggest advantage of this method. This method is 
based on  probes designed to be highly specific to the target and all steps are 
standardized with a reproducible protocol. We used  the RNAscope protocol 
pretreatment specific for FFPE samples and  the RNAscope®  2.5HD Reagent 
Kit-RED. In addition to BAP1 specific probe,  we used probe PPIB as positive 
control probe and  dapB as negative control probe. After the assay, we 
visualized the stained tissue sections under a standard bright field microscope 
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and we evaluated  target probe signal. A positive signal is a pink punctate dots 
in cells. RNAscope®  2.5HD Reagent Kit-RED contains FAST RED dye, it is a 
chromogenic staining and permits high contrast. 
• RNAscope® In Situ Hybridization Assay Workflow
Deparaffinization was performed in according to the RNA scope pretreatment 
protocol specific for FFPE tissue samples: 2x(10min) in histoclear and after 2x 
(4min) in ethanol 100%. After deparaffinization, the assay can be divided in four 
general steps summarized in figure 25:
- STEP 1- Permeabilization: the slides are before baked 1h at 60°C, after 
deparaffinized. It follows three pretreatment with the RNA-scope 
Pretreatment Kit to unmask target RNA and permeabilize cells. The 
pretreatment kit contains  hydrogen peroxide to block the activity of 
endogenous peroxidase enzyme, target retrieval reagent and protease 
reagent to allow a better access to RNA target. With the IMMEDGETM 
Hydrophobic  barrier pen we designed a square around each section.
- STEP 2- Hybridization: RNAscope Probes pool hybridize to our RNA target of 
interested. The hybridization probe step is performed baking the slides 2h at 
40°C. The probes has a particular double Z design and ~20 double Z  are 
specifically designed for detecting  the RNA target. Every probe pool contains 
a tag that permit the visualization under the microscope. In order to 
substantially improve the signal-to-noise ratio, this assay employs this 
specific probe design that permit a tandem hybridization to the target 
sequence (Figure 26). Each probes consists in  three elements (Figure 27): a 
spacer sequence that links the two components of the probe, the upper 
region of the Z is a 14-base tail sequence, the two tails from a double Z probe 
pair forms a 18-25 base binding site for the pre-amplifier. Thus special double 
z probe design provides hybridization also against partial target RNA.
- STEP 3-Amplification:  this step consist of  six sequential hybridization of 
amplifiers and label probes  (from AMP1 to AMP6) with the purpose to 
amplify the probe hybridization signal. 
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All the amplification are performed in the HybEZ Humidity Control Tray. The 
amplifications are performed as follows: 
1. AMP1: 30 min at 40°C;
2. AMP2: 15 min at 40°C;
3. AMP3: 30 min at 40°C;
4. AMP4: 15 min at 40°C;
5. AMP5: 1h min at room temperature;
6. AMP6: 15 min at room temperature; 
After the amplifications, it follows the signal detection and the counterstain: the 
slides are incubated 10 min at room temperature  with a mix  containing  1:60 
Fast RED-B /Fast RED-A, rinsed with tap water and stained with 50% 
Hematoxylin staining solution for 2 min at room temperature. Lastly the slides 
were baked up to 45 min at 60°C and mounted with ECOmount with a previous 
quickly  step  in ethanol. 
- STEP 4- visualization and evaluation the sample: each dot signal represents 
a single test target RNA molecule and can be visualized with a microscope.
Step 1: tissue is fixed and permeabilized to allow for target probe access;
Step 2: target RNA-specific “double Z” probes are hybridized in pairs;
Step 3: multiple signal amplification molecules are hybridized. Each labeled probe is 
conjugated to a different fluorophore or enzyme;
Step 4: detection signal. 
Permeabilization Hybridization Amplification Visualisation/
evaluation
Figure 25. Schematic presentation of RNAscope assay workflow (Wang et al, 2012)
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 Figure 26. Probe tandem hybridization (Wang et al, 2012)
A pair of target double Z probes, each 
possessing a different type of tail sequences, 
hybridize contiguously to the target region. 
The two tail sequences are the hybridization 
site for the pre-amplifier. 
Figure 27. Schematic presentation of double Z probes (Wang et al, 2012)
the upper region of the Z is a 14-base tail 
sequence;
spacer sequence that links the two components of 
the probe; 
18 to 25 base binding sequence for the pre-
amplifier.
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RESULTS
Patients
Tissue samples were obtained from 63 primary UM after enucleation surgery at 
E.O. Galliera Hospital, Genoa, Italy, between December 2005 and June 2016. 
Written informed consent was obtained from all patients. 
Among the 63 patients, 40 (63%) were men and 23 (37%) were women, with a 
median age at the time of eye enucleation of 64 years (range 28-89 years) and 
median follow-up  time of 3 years (interquartile range, IQR: 2-6 years). Thirty-
five out of 63 (56 %) patients had developed UM metastases to the liver (mean 
time to metastasis 25.7 months; range 0–97 months), and 13 out 60 (21,7%) 
died for UM metastatic progression during the follow up period. UM 34 and 
UM46 died for other causes. The pathological TNM stages showed stage 4c in 
1case (1,8%), 4b in 6 cases (10,7%), 4a in 16 cases (28%), 4 in 5 cases (9%), 
3b in 1 case (1,8%), 3a in 18 cases (32%), 3 in 1 case (1,8%), 2c in 1 case 
(1,8%), 2a  in 6 cases (10,7%), 2 in 1 case(1,8%). The ciliary body was involved 
in 5/63 UM (8%) and the only choroid in 58/63 (92%) cases. The histological 
examination showed spindle cells in 1 case (1,6%), mixed cells in 13 cases 
(20,7%), epithelioid cells in 49 cases (77,7%). Extrinsecation was found in 9 out 
of 56 cases (16%) and for 6 cases the data is not available. 
All patients’ clinical data, UM histological cell type, pathological T stages, time to 
metastasis and follow up are summarized in Table 14.
 70
Table 14. Patients, tumor characteristics, and follow up 
Id
Age at 
Diagnosis 
(Y)
Sex T Cell Type MT
Time To 
MT 
(months)
Follow 
up 
(months
)
Dead
UM01 64 M T4A M yes 38 38 yes
UM02 62 M T2A F yes 30 30 no
UM03 69 M T4 M yes 24 24 yes
UM04 73 F T2A M yes 93 93 no
UM05 74 M T4C E yes 47 47  yes
UM06 71 F UN M no 0 148 no
UM07 80 M T4B E yes 29 29 yes
UM08 60 M T2C E yes 97 100 no
UM09 75 F T4A E yes 26 31 no
UM10 69 M T3A E no 0 13 no
UM11 62 M T4 E yes 6 6 no
UM12 78 F T4A E no 0 51 no
UM13 47 M T3B E yes 25 25 yes
UM14 57 F T4A E yes 14 14 UN
UM15 48 M T3A E no 0 33 no
UM16 77 M T4B E yes 3 3 yes
UM17 64 M T3A E yes 7 21 no
UM18 85 M UN E no 0 0 no
UM19 53 M T2A E yes 6 13 no
UM20 78 M T3A E no 0 3 no
UM21 74 M T4 E yes 27 27 yes
UM22 67 M T4B E yes 17 17 yes
UM23 47 M T2A E no 0 11 no
UM24 47 M T3 E no 0 41 no
UM25 40 M T4B E no 0 25 no
UM26 86 M T4A E yes 12 19 yes
UM27 74 M T3A M UN UN UN UN
 71
UM28 49 F T3A M yes 25 25 no
UM29 41 M T3A E no 0 28 no
UM30 81 M UN E yes 40 43 no
UM31 78 F T4A E no 0 28 no
UM32 63 F T4A E no 0 42 no
UM33 51 F T3A E yes 0 0 no
UM34 74 F T2A M yes 64 64 yes
UM35 28 F UN M UN UN UN no
UM36 66 M T3A M no 0 22 no
UM37 79 M T3A M yes 17 20 yes
UM38 71 M UN E yes 25 39 yes
UM39 66 F T3A E no 0 21 no
UM40 66 F T4 E yes 6 19 no
UM41 59 M T4A E no 25 25 no
UM42 83 F T3A E no 0 36 no
UM43 30 M T3A E no 0 23 no
UM44 75 F UN M yes 11 11 no
UM45 28 F T3A E yes 13 28 no
UM46 89 F T4B E no 0 23 yes 
UM47 47 M T2 E no 0 52 no
UM48 58 M T4A E yes 7 7 no
UM49 41 M T3A E yes 26 39 no
UM50 64 F T4A E yes 6 23 no
UM51 59 M T3A M no 0 8 no
UM52 35 F T3A E no 0 1 no
UM53 64 F T4A M no 0 22 no
UM54 71 F T4 E yes 22 22 no
Table 14. Patients, tumor characteristics, and follow up 
Id
Age at 
Diagnosis 
(Y)
Sex T Cell Type MT
Time To 
MT 
(months)
Follow 
up 
(months
)
Dead
 72
UM55 28 M T4A E no 0 22 no
UM56 68 F T4A E no 0 43 no
UM57 64 M T4A E no 0 35 no
UM58 78 M T4A E yes 0 0 UN
UM59 40 F T4A E yes 26 38 no
UM60 52 M T3A E yes 0 36 no
UM61 66 M T2A E no 0 73 no
UM62 51 M UN E yes 23 27 no
UM63 84 M T4B E yes 30 34 no
Table 14. Patients, tumor characteristics, and follow up 
Id
Age at 
Diagnosis 
(Y)
Sex T Cell Type MT
Time To 
MT 
(months)
Follow 
up 
(months
)
Dead
Abbreviations: M, male; F, female, T, tumor stage, E, epithelioid cell; S, spindle cell; M, mixed 
epithelioid and spindle cells; UN, unknown. 
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Chromosome imbalances results (MLPA and MSA) 
The presence of chromosomal imbalances involving chromosome 1p, 3, 6 and 
8 in our cohort of UM samples were evaluated by MLPA analysis. MLPA was 
successfully carried in 60/63 (95%) UM samples but failed in UM14, UM38 and 
UM62. The distribution of losses on chromosome 1p, 3, 6q, 8p and gains on 
chromosome 8q, 6p is shown in Figure 28. Forty out of 60 (67%) samples 
harbored monosomy 3, 5/60 (8%) a partial monosomy 3 (Figure 29), 13/60 
(22%) the loss of the short arm of chromosome 1 (1p-), 17/60 (28%) 6p gain, 
and 41/60 (70%) 8q gain. Partial 8q gain was found only in sample UM49, 
whereas a partial 6p gain was found in 6 samples. MLPA showed a concomitant 
loss of all probes on chromosome 6q and 8p with gain 6p and 8q suggesting an 
the formation of isochromosomes i(6p) and i(8q), respectively. In particular: a 
presumptive i(6p) was identified in 7 UM samples, of which 3 with monosomy 3 
and 4 with disomy 3; a presumptive i(8q) was identified in 12 UM samples all 
with monosomy 3 (Figure 28 and Figure 30). In two samples with monosomy 3 
(UM20 and UM41), MLPA showed both the presumptive isochromosome i(6p) 
and  i(8q). A third sample, UM 16, MLPA showed the formation of i(8q) with loss 
6q and partial 6p gain (Figure 28 and Figure 31). In UM17, in addition to 1p 
loss, 6p gain, 6q loss, 8q gain, MLPA showed the losses of control probes in 
EDAR 2p12.3, GNRHR 4q13.2, ATP7B 13q14.3, RNMT 18p11.21 (Figure 32). 
In 57 UM samples, the monosomic/disomic status of chromosome 3 was also 
confirmed by chromosome 3 MSA. In 4 UM samples (UM2, UM20, UM33, and 
UM34) with a normal chromosome 3 dosage by MLPA, loss of heterozygosity 
(LOH) of all informative MSA markers indicated isodisomy of chromosome 3. 
MSA failed in UM01, UM06, UM10, UM40, UM49, and UM54.  
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Figure 30. UM cases identified  with gains/losses on chromosome 8 according to MLPA 
data 
Square in full grey color indicates deleted exon
 77
 
 
1p 3p 3q 6p 6q 8q control probes
MLPA showed 1p loss, 6p gain, 6q loss, 8q gain and losses of control probes in 
EDAR 2p12.3, GNRHR 4q13.2, ATP7B 13q14.3, RNMT 18p11.21.
Figure 32. UM17 MLPA  results.
Figure 31. UM cases identified  with gains/losses on chromosome 6 according to MLPA 
data 
Square in full grey color indicates deleted exon
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Mutational analysis results
GNAQ and GNA11 mutational analysis 
GNAQ and GNA11 sequencing was successful in all 63 UM samples. 
Altogether, GNAQ and GNA11 mutations were detected in 55/63 samples 
(71,4%): GNAQ mutations were found in 20 out 63 samples (33%) and GNA11 
mutations in 25/63 samples (40%). In GNAQ, all mutations are missense 
mutations on the two known hotspots Q209 and R183. In Q209,13/20 UM 
samples (65%) had the mutations  c. 626 A>C p.Q209P whereas 6/20 UM 
samples (30%) had c.626A>T p.Q209L. In R183, 1/20 UM samples (5%) had 
c.547 C>T p.R183C. 
Also in GNA11 all the mutations are missense mutations on the two known 
hotspots Q209 and R183. In Q209 hotspot, 23/25 UM samples (92%) had c.
626A>T p.Q209L whereas 2/25 (8%) had c.547 C>T p.R183C. Among the 55 
GNAQ and GNA11 mutations, 26 (47%) were found in patients with metastatic 
disease.  All the sequencing analysis results are summarized in Table 16. 
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BAP1 mutational analysis 
BAP1 coding regions and splice sites sequencing was successful in 60/63 
(95%) of UM samples. In three samples, UM14, UM19 and UM49, the 
sequencing failed due to poor DNA quality and/or quantity. BAP1 mutations 
were found in 31/60 UM samples (52%) of which 27 were with monosomy 3, 3 
with isodisomy (UM33, UM34, UM20) and 1 (UM48) with partial monosomy 3 
(Figure 22 and 23). BAP1 mutations were found in 8/12 (67%) UM samples with 
presumptive i(8q) and in a 2 out 7 (29%) UM samples with presumptive i(6p) 
(Figure 22). In 6 UM samples with monosomy 3 (UM16, UM28, UM31, UM36, 
UM43 and UM48), Sanger sequencing identified BAP1 heterozygous mutations. 
Thirteen out of 31 (42%) UM had in-frame mutations, consisting in 10 missense 
mutations and 3 in-frame deletions. To predict the possible impact of the amino 
acid substitutions due to the different missense mutation on the structure and 
function of BAP1 protein, Polyphen-2 (genetics.bwh.harvard.edu/pph2/
index.shtml) and SIFT (sift.jcvi.org) were used. Out-of-frame mutations were 
present in 18 out of 31 (58%) UM: 13 samples had frameshift insertions/
deletions, 2 samples splice site mutations, 2 samples nonsense mutations, and 
1sample a read-through mutation. In 21/31 (67%) samples with BAP1 
mutations, were presents metastasis. In Table 16 are summarized BAP1 
sequencing results and chromosomal 3 status. Figure 34 shows the 
distributions of BAP1 mutations in monosomic UM cases. 
Table 16. Genetic Analysis of 63 UM studied
ID Chrom. 3 Status 
Gnaq 
protein
Gna11 
protein
exon/
intron
Mutation BAP1 seq Bap1 
protein
IHC 
UM01 pM3 wt Q209L wt wt wt wt pos
UM02 Iso3 wt Q209L wt wt wt wt neg
UM03 M3 wt Q209L E14 FS del c.
1817_1821del
A606Gfs*
35
neg
UM04 M3 wt wt E05 del in 
frame
c.265_300del N89_L100
del
neg
UM05 M3 wt wt E05 missense c.290T>C L97P neg
UM06 D3 wt wt E06 syn c.417G>A wt 
(K139K)
-
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UM07 M3 wt Q209L E17 missense c.2089T>C S697P neg
UM08 M3 wt wt E05 del in 
frame
c.287_307del L96_N102
del
neg
UM09 M3 wt Q209L nd nd nd nd neg
UM10 M3 wt wt wt wt wt wt neg
UM11 M3 wt wt E08 missense c.638G>C R213P neg
UM12 D3 wt wt wt wt wt wt pos
UM13 D3 Q209P wt wt wt wt wt pos
UM14 M3 wt wt nd nd nd nd negb
UM15 D3 wt Q209L wt wt wt wt pos
 
UM16
M3 Q209L wt E6 FS del c.425del ª N142Ifs*
45
neg 
UM17 D3 wt wt wt wt wt wt pos
UM18 M3 wt wt wt wt wt wt neg
UM19 M3 Q209P wt wt wt wt wt neg
UM20 Iso3 Q209P wt E11 FS del c.
1074-1081del
A359Rfs
*36
neg
UM21 M3 wt Q209L E4 missense c.188C>G S63C neg
UM22 M3 wt Q209L E04 missense c.233A>G N78S neg
UM23 M3 wt wt wt wt wt wt negb
UM24 D3 Q209P wt wt wt wt wt pos
UM25 D3 Q209L wt wt wt wt wt pos
UM26 M3 wt Q209L E04 FS del c.175_179del R59Kfs*
8
neg
UM27 D3 wt wt wt wt wt wt pos
UM28 M3 wt Q209L E07 missense c.466C>T ª Q156* neg
UM29 M3 wt R183C Ex5 missense c.335T>G L112R neg
UM30 M3 Q209P wt E05 del in 
frame
c.356_358del T119del neg
UM31 M3 wt Q209L E04 FS del c.145del ª L49Cfs*23 neg
UM32 M3 Q209P wt E03 FS del c.79del V27Cfs*
45
neg
Table 16. Genetic Analysis of 63 UM studied
ID Chrom. 3 Status 
Gnaq 
protein
Gna11 
protein
exon/
intron
Mutation BAP1 seq Bap1 
protein
IHC 
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UM33 Iso3 Q209L wt E04 FS del c.145del L49Cfs*2
3
neg
UM34 Iso3 Q209P wt E13 FS del c.
1499_1515de
l
G500Afs
*31
neg
UM35 M3 wt wt wt wt wt wt neg
UM36 M3 wt Q209L E08 missense        
syn
c.629T>A ª
c.627C>A ª
I210N                          
(V209V)
neg
UM37 M3 Q209L wt E05                                 
E13
Missense     
syn
c.283G>C       
c.1356C>T                           
A95P                                  
(L452L)
neg
UM38 pM3 Q209P wt                        
E09                             
E17
                 
syn        
syn
c.681C>T ª 
c.2163T>C ª
(R227R)                           
(S721S)
neg
UM39 M3 wt wt wt wt wt wt pos
UM40 pM3 wt Q209L wt wt wt wt negb   
UM41 M3 wt Q209L E05 FS ins c.
327_328insAG
P110Sfs*4 neg
UM42 pM3 R183Q wt wt wt wt wt pos
UM43 M3 wt wt I6 SA c.438-2A>G ª SA neg
UM44 M3 Q209P wt E17 RT c.2189G>T *730Lext
*205
neg
UM45 M3 Q209P wt E09 FS del c.760_763del T254Yfs*2 neg
UM46 M3 Q209P wt wt wt wt wt neg
UM47 D3 wt Q209L wt wt wt wt pos
UM48 pM3 wt wt E11 FS del c.967del ª A323Pfs*12 neg
b
UM49 M3 wt R183C nd nd nd nd pos
UM50 M3 wt Q209L _ _ wt wt neg
UM51 M3 Q209P wt E09 FS del c.681_697del F228Gfs
*9
neg
UM52 D3 wt Q209L wt wt wt wt pos
UM53 M3 Q209P wt E05 missense c.281A>G H94R pos
UM54 pM3 wt wt I5 var intr 
NM_0046
56.3 
c.
376-4_376-1
5del ª
wt neg
Table 16. Genetic Analysis of 63 UM studied
ID Chrom. 3 Status 
Gnaq 
protein
Gna11 
protein
exon/
intron
Mutation BAP1 seq Bap1 
protein
IHC 
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UM55 M3 wt Q209L I5 SA c.375+1G>A SA neg
UM56 D3 Q209L wt wt wt wt wt pos
UM57 D3 wt Q209L wt wt wt wt pos
UM58 M3 wt Q209L E07 FS del c.503del F168Sfs*
19
neg
UM59 M3 wt Q209L E01 NS c.7A>T K3* neg
UM60 D3 wt Q209L wt wt wt wt pos
UM61 D3 wt  Q209L wt wt wt wt pos
UM62 D3 wt wt wt wt wt wt pos
UM63 M3 Q209L wt E07 missense c.580G>A G194R neg
Table 16. Genetic Analysis of 63 UM studied
ID Chrom. 3 Status 
Gnaq 
protein
Gna11 
protein
exon/
intron
Mutation BAP1 seq Bap1 
protein
IHC 
Abbreviations: D, disomy; M, monosomy; pM, partial monosomy; Iso3, isodisomy 3; FS, 
frameshift; IF, in frame; NS, nonsense; RT, readthrough; syn, synonimous; E, exon; I, intron. 
Numbering of mutations on the genomic level refers to build GRCh37/hg19 (ensemble/
UCSC).
A) Structure of BAP1 gene in 17 exons, and relative mutations distribution (BAP1 - 
GRCh37(hg19); transcript NM_004656.3): missense and in/del in frame mutations are 
typed in italic, and frameshift mutations in bold. Splice indicates splice-site mutation. 
B) Functional domains and regions of interaction of the 729 aa BAP1 protein, consisting of 
an Ubiquitin Carboxyl-terminal Hydrolase (UCH, 1-240), a BARD1 binding domain 
(BARD1, 182-365); an HCF-1-binding domain (HBM, 363-386), a BRCA1  binding domain 
(BRCA1, 594-722), and two putative Nuclear Localization Signals  (NLS, 656-661 and 
717-722).
Figure 34. Distributions of BAP1 mutations in monosomic UM cases
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Thirty-one BAP1 mutations were found and 19/31 (61%) mutations were not 
already reported in any other cancer, thus we submitted these mutations in 
NCBI GeneBank. Mutations References and GeneBank accession number of 
submitted BAP1 mutations were summarized in Table 17. 
Table 17. Reported and unreported BAP1 mutation
ID BAP1 seq BAP1 protein
Reference/NCBI 
GeneBank accession 
nr.
UM03 c.1817_1821del A606Gfs*35 MF947150
UM04 c.265_300del N89_L100del MF802277
UM07 c.2089T>C S697P MF802270
UM11 c.638G>C R213P MF802269
UM16 c.425del N142lfs*45 MF802272
UM20 c.1074-1081del A359Rfs*36 MF947147
UM26 c.175_179del R59Kfs*8 MF802274
UM30 c.356_358del T119del MF802276
UM34 c.1499_1515del G500Afs*31 MF947149
UM36 c.629T>A c.627C>A I210N                          
(V209V)
MF802273                                                                                            
UM41 c.327_328insAG P110Sfs*4 MF947144
UM44 c.2189G>T *730Lext*205 MF802271
UM45 c.760_763del T254Yfs*2 MF947145
UM48 c.976del  A323Pfs*12 MF947148
UM51 c.681_697del F228Gfs*9 MF947146
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EIF1AX and SF3B1 mutational analysis 
EIF1AX sequencing was successful in 60/63 (95%) UM samples. Five out of 60 
(8%) UM had a missense mutation in EIF1AX gene (Figure 35a and 35b), in 
either exon 1 (UM32, UM52, UM60) or exon 2 (UM27, UM51). Two out of 5 
EIF1AX mutations were found in cases with monosomy 3, BAP1 mutation, and 
loss of BAP1 nuclear immunostaining. No UM with a mutation in EIF1AX gene 
contained presumptive i(6p) or i(8q). All the results of EIF1AX sequencing are 
summarized in Table 18. 
SF3B1 sequencing was successful in 61/63 (97%) samples. SF3B1 
heterozygous mutations were found in 6/61 (9,8%) samples at the known 
hotspot R625. In R625 hotspot, 3/6 UM samples (UM02,UM12,UM57) showed 
c.1873 C>T p.R625C mutation and 3/6 UM samples (UM15, UM24, UM42) 
showed c.1874 G>A p.R625H mutation (Figure 35b and 35c). Five SF3B1 
mutations occurred in non-metastatic UM with BAP1 wild type and positive 
BAP1 nuclear IHC, and 1/6 in metastatic UM with BAP1 wild type but with 
negative  BAP1 nuclear IHC. Three out five UM with a mutation in SF3B1 
harbored a presumptive i(6p) and 1/6 with loss 6q and partial gain 6p. No UM 
with mutation in SF3B1 harbored a presumptive i(8q).  All the results of SF3B1 
sequencing are summarized in Table 18. 
UM53 c.281A>G H94R MF802275)
UM55 c.375+1G>A SA MF947151
UM58 c.503del F168Sfs*19 MF802269
UM59 c.7A>T K3* MF588675
Table 17. Reported and unreported BAP1 mutation
ID BAP1 seq BAP1 protein
Reference/NCBI 
GeneBank accession 
nr.
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Figure 35. Sequencing analysis of EIF1AX and SF3B1 
a
a) UM32, EIF1AX exon 1 c.16 G>C p.G6R, heterozygous;
b) UM52, EIF1AX exon 2 c.17G>T p.G6V, homozygous;
c) UM57, SF3B1 exon 15 c. 1873 C>T p.R625C, heterozygous;
d) UM24, SF3B1 exon 15 c. 1874 G>A p.R625H, heterozygous.
b
dc
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PLCB4, CYSLTR2 and PTK2B mutational analysis
Sanger sequencing of PLCB4, CYSLTR2 and PTK2B genes was performed in 
13 UM samples, characterized by GNAQ and GNA11 wt. Due to poor DNA 
quality and/or quantity  PLCB4 sequencing failed in two UM samples (UM05 
and UM06), CYSLTR2 in 5 UM, and PTK2B in 7 UM.                                                                                                               
In sample UM17  we detected the mutation c.1888 G>T p.D630F in PLCB4 
gene. In UM05 and UM06 we identified the mutations c.2807G>A  p.R936Q, and 
c.1625G>T p.S542I in exon 35 and in exon 23 respectively, of PTK2B gene. No 
mutations were found in CYLSTR2 gene. All sequencing results are 
summarized in Table 18. 
Table 18. EIF1AX, SF3B1, PLCB4 and PTK2B  sequencing analysis results
ID Plcb4 protein Cysltr2 protein
Ptk2b protein Eif1ax 
protein
Sf3b1 protein
UM01 _ _ _ wt wt
UM02 _ _ _ wt R625C
UM03 _ _ _ wt wt
UM04 wt _ _ wt wt
UM05 _ wt R936Q wt wt
UM06 _ _ S542I wt wt
UM07 _ _ _ wt wt
UM08 wt wt wt wt wt
UM09 wt wt _ nd nd
UM10 wt wt _ wt wt
UM11 wt wt wt wt wt
UM12 wt wt wt wt R625C
UM13 wt wt wt wt wt
UM14 _ _ _ wt wt
UM15 wt wt _ wt R625H
 UM16 wt _ _ wt wt
UM17 D630F wt _ wt wt
UM18 wt wt _ wt wt
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UM19 _ _ _ wt wt
UM20 wt _ _ wt wt
UM21 wt wt _ wt wt
UM22 wt _ wt wt wt
UM23 _ _ _ wt wt
UM24 wt wt _ wt R625H
UM25 wt _ _ wt nd
UM26 wt wt wt wt wt
UM27 wt wt wt G15N wt
UM28 wt wt _ wt wt
UM29 _ _ _ nd wt
UM30 wt wt wt wt wt
UM31 wt wt _ wt wt
UM32 wt wt wt G6R wt
UM33 wt wt _ wt wt
UM34 wt wt _ wt wt
UM35 _ _ _ wt wt
UM36 wt wt _ wt wt
UM37 wt wt _ wt wt
UM38 _ _ _ wt wt
UM39 wt _ wt wt wt
UM40 wt wt wt wt wt
UM41 wt wt _ wt wt
UM42 wt wt _ wt R625H
UM43 wt wt wt wt wt
UM44 wt wt _ wt wt
UM45 wt _ _ wt wt
UM46 wt wt _ wt wt
Table 18. EIF1AX, SF3B1, PLCB4 and PTK2B  sequencing analysis results
ID Plcb4 protein Cysltr2 protein
Ptk2b protein Eif1ax 
protein
Sf3b1 protein
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UM47 _ _ wt wt wt
UM48 wt wt _ wt wt
UM49 wt _ _ wt wt
UM50 wt _ _ wt wt
UM51 wt wt _ G9N wt
UM52 wt wt wt G6V wt
UM53 wt wt wt wt wt
UM54 wt wt _ wt wt
UM55 wt wt wt wt wt
UM56 wt wt _ wt wt
UM57 wt wt _ wt R625C
UM58 wt _ _ wt wt
UM59 wt wt _ wt wt
UM60 _ _ _ K3E wt
UM61 wt wt _ wt wt
UM62 wt _ _ nd wt
UM63 wt wt _ wt wt
Table 18. EIF1AX, SF3B1, PLCB4 and PTK2B  sequencing analysis results
ID Plcb4 protein Cysltr2 protein
Ptk2b protein Eif1ax 
protein
Sf3b1 protein
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BAP1 germline mutational analysis
BAP1 coding regions and splice sites sequencing was successfully performed 
in 26 samples of patients with UM (Table 19). Altogether, we found BAP1 
germline mutations in 2/26 (8%) samples (UM37, UM41, and UM58). In 
addition, in UM 37, we identified the heterozygous substitution in exon 13 c.
1356C>T that led to the synonymous mutation L452L , and in UM27 blood 
sample, the intronic variant c.1729+8 T>C. In UM41, we identified the 
heterozygous insertion in exon 5 c.327_328insAG that led to frameshift 
mutation p.P110Sfs*4 (Table 19 and Figure 36). In exon 11 of UM58 we 
identified the heterozygous  substitution c.1012 C>T that led to missense 
mutation p.P338S. As already reported (Page 15), in UM58 we identified the 
mutation c.503del p F168Sfs*19 (Table 19 and Figure 36).
Table 19. Germline mutational analysis results of 27 UM studied
ID Chrom. 3 Status BAP1 in UM
Germline 
exon/intron
Germline BAP1 
seq
Germline 
Bap1 
protein
UM14
M3 wt wt wt wt
UM58
M3 c.503del       F168Sfs*19 E11 c. 1012 C>T P338S 
UM09
M3 wt wt wt wt
UM15
D3 wt wt wt wt
UM17
D3 wt wt wt wt
UM19
M3 wt wt wt wt
UM25
D3 wt wt wt wt
UM28
M3 wt wt wt wt
UM31
M3 c.145del p.L49Cfs*23 wt wt wt
UM33
M3 c.145del p.L49Cfs*23 wt wt wt
UM35
M3 wt wt wt wt
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UM37
M3
c.1356C>T 
p.L452L;                 
c.283G>C p.A95P 
wt c.1356C>T L452L
UM39
M3 wt wt wt wt
UM27
D3 c.1729+8T>Cª rs150945583 c.1729+8T>C ª 
rs1509455
83
UM43
M3 c.438-2A>G  wt wt wt
UM50
M3 wt wt wt wt
UM51
M3 c.681_697del F228Gfs*9 wt wt wt
UM52
D3 wt wt wt wt
UM56
D3 wt wt wt wt
UM29
M3 c.335T>G; p.L112R wt wt wt
UM36
M3 c.627C>A  p.V209Vc.629T>A p.I210N wt wt wt
UM23
M3 wt wt wt wt
UM18
M3 wt wt wt wt
UM20
M3 c.1074_1081del p.A359Rfs*36 wt wt wt
UM41
M3 c.327_328insAG p.P110Sfs*4 E5 c.327_328insAG 
a P110Sfs*4
UM45
M3 c.760_763del p.T254Yfs*2 wt wt wt
Table 19. Germline mutational analysis results of 27 UM studied
ID Chrom. 3 Status BAP1 in UM
Germline 
exon/intron
Germline BAP1 
seq
Germline 
Bap1 
protein
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A) UM58_S: exon 11, heterozygous mutation c.1012 C>T p.P338S in UM58 blood;
B) UM58: exon 11, UM58 tumor tissue, wild type;
C) UM58_S: exon 7,wild type;
D) UM58: exon 7, UM58 tumor tissue, homozygous mutation c.503del p.F168fs*19.
Figure 36. BAP1 mutational analysis  in UM58_S and UM58
B) UM58, exon 11A) UM58_S, exon 11
C) UM58_S, exon 7 D) UM58, exon 7
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BAP1 immunohistochemical assay results 
BAP1 IHC was successful in 62/63 UM samples. Nineteen out 62 (31%) 
samples showed a positive BAP1 nuclear immunostaining (Figure 37a and 37b, 
respectively) and 43/62 (69%) were IHC negative (Figure 37c). In positive UM 
samples, BAP1 staining did not show any intratumoral heterogeneity. Among 
the 43 UM with negative nuclear IHC, 4 UM samples (UM14, UM23, UM40, 
UM48) showed a cytoplasmic signal (Table 16) and 7 UM (UM16, UM28, UM31, 
UM36, UM38, UM43, UM48) showed immune-cell infiltration (Figure 37d). 
b   
c   
a
d   
a) BAP1 positive nuclear IHC signal in UM13, characterized by disomy 3 and BAP1 wt
 b) Lack of nuclear BAP1 IHC signal in UM32, with monosomy 3 and BAP1 c.79del 
mutation. 
c) Cytoplasmic BAP1 IHC signal in UM40, characterized by a partial monosomy 3 and 
BAP1 wt. 
d) IHC staining of UM16, a case with monosomy 3 and BAP1 c.425del mutation: tumor 
cells are BAP1 IHC negative, and infiltrating cells show BAP1 positive nuclear IHC signal 
(left panel); the electropherogram shows a heterozygous deletion (right panel). 
In all the cases with negative BAP1 IHC, BAP1nuclear IHC signal in endothelial cells 
represents the internal positive control.
Figure 37. BAP1 IHC in UM FFPE sections.
 93
Promoter methylation analysis  
BAP1 promoter methylation analysis was conducted in 3 out 11 UM samples 
with discrepancy between sequencing BAP1 and BAP1 IHC but no hyper-
methylation was detected (Figure 38).
Figure 38. BAP1 promoter methylation analysis
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RNAscope in situ hybridization 
We performed RNAscope® assay on UM samples with discrepancy between 
BAP1 sequencing and BAP1 IHC results: sample UM53 harboring the missense 
mutation H94R but with positive BAP1 nuclear immunostaining and samples 
UM35, UM50, UM46, UM18, UM10, UM40, and UM54, all resulting BAP1 wild-
type but with negative BAP1 nuclear immunostaining. 
We initially tested the RNAscope® assay by using HeLa FFPE control slides 
with negative control probe DapB and positive control probe PPIB, provided 
with the kit (Figure 39a and Figure 39b). Then we tested the assay conditions 
with UM FFPE sections: UM25 and UM32 were hybridized with positive control 
PPIB probe, negative control probe DapB, and BAP1 probe (Figure 39c, d and 
e). 
RNAscope® assay was successful in 7/12 UM samples with with discrepancy 
between BAP1 sequencing and BAP1 IHC. In 1/12 sample the melanin amount 
was too high to evaluate the result. In 4/12 samples no FFPE blocks were 
available.
In Table 20 are summarized the results. 
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Figure 39. RNAscope assay results on control slides 
a) HeLa control slide with DapB negative control probe; b) HeLa control slide with 
PPIB positive control probe; c) UM25 (BAP1 wild-type and positive nuclear BAP1 
IHC with PPIB positive control probe; d)UM25 (BAP1 wild-type and positive nuclear 
BAP1 IHC) performed with BAP1 probe; e) UM32 (missense mutation V27Cfs*45 
and negative BAP1 nuclear IHC) performed with BAP1 probe; f) UM35 (BAP1 wild-
type and positive nuclear BAP1 IHC) performed with BAP1 probe, plentiful presence 
of melanin.
All the microphotographs were taken at 40x magnification.
f) UM35 
d) UM25 c) UM25 
e) UM32 
a) HeLa b) HeLa 
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Table 20. RNAscope results
Sample Chr3 BAP1 sequencing
BAP1 
IHC
cytoplasmatic 
BAP1 signal
UM25 
(control 
sample)
D3 wt pos +++
UM53 M3 H94R pos ++
UM10 M3 wt neg ++
UM50 M3 wt neg ++
UM46 M3 wt neg +
UM40 pM3 wt neg -
UM18 M3 wt neg -
UM54 pM3 wt neg -
UM35 M3 wt neg
not evaluable for 
the presence of 
melanin
UM02 M3 wt neg nd
UM19 M3 wt neg nd
UM23 M3 wt neg nd
UM38 M3 wt neg nd
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MLPA P417- BAP1 results 
To detect deletions not recognizable with Sanger sequencing, we performed 
BAP1-MLPA analysis on samples with BAP1 wt and BAP1 negative IHC (UM54, 
UM46, UM38, UM19, UM10, UM35, UM23, UM50, UM40, UM02, and UM18). 
MLPA was successfully performed in 7/11 (70%) UM, and we identified deletion 
of 1 or more BAP1 exon in 4 out of 7 UM samples (Figure 33 and Table 15). 
UM50, UM23, UM02, and UM18 samples failed, due to the poor quality or 
quantity of DNA.
UM46
Figure 33. UM46 sample, harboring monosomy 3, showed the deletion 
of exon 5.
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Table 15. P417-BAP1 MLPA results
BAP1 exon
UM cases
UM19 UM54 UM46 UM38 UM40 UM35 UM10
Exon 17
Exon 16
Exon 15
Exon 14
Exon 13
Exon 12
Exon 11
Exon 10
Exon 9
Exon 8
Exon 7
Exon 6
Exon 5
Exon 4
Exon 3
Exon 2
Exon 1
Squares in full dark grey color indicate deleted exons with a ratio <0.5.
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Associations between mutations and distant progression free survival 
(DPFS)
Univariate associations between studied parameters and metastatic disease 
were performed using the Fisher’s exact test (Table 20). Significant associations 
with DPFS were found for monosomy 3 (p=0.008), gain of 8q (p=0.012), BAP1 
mutation (p=0.019), and loss of BAP1 protein expression (p=0.005). 
Conversely, gain of 6p was associated with the absence of liver metastases 
(p=0.019).
As regards time-to-event analysis, after a median follow-up time of 3 years 
(interquartile range, IQR: 2-6 years), median DPFS was 2.5 years (IQR: 1.8–7.7 
years). Kaplan-Meier DPFS curves and Hazard Ratios adjusted for age, sex 
and tumor stage, T (Cox regression) showed that the presence of monosomy 3 
was significantly associated to DPFS (HR=6.3, 95%CI: 1.5-27.2), as well as 8q 
gain (HR=3.6, 95%CI: 1.05-12.6), and BAP1 negative IHC (HR=4.3, 95%CI: 
1.4-12.8), while the presence of BAP1 mutation was not statistically significant 
(HR=1.6, 95%CI: 0.7-3.8) (Figure 42).
The presence of monosomy 3 and 8q gain together was associated to 
metastatic disease (log rank p=0.004) (Figure 43). Since no events were 
registered in the group without UM specific chromosome imbalances (n=7 
subjects), we could not estimate HRs by COX model. 
Table 20.   Association of clinical and molecular characteristics with metastasis onset.
No MT MT Tot. two-tailed P 
value
 Sex
M 17 23 40
P=0.79
F 11 12 23
 Position
choroid+ciliar 
body
1 4 5
P=0.36
choroid 28 30 58
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 Extrinsecation
no 26 21 47
P=0.28
yes 3 6 9
 Cell type
epithelioid 23 26 49
P=0.55mixed 
epithelioid/
fused
8 6 14
 GNAQ
wt 19 24 43
P>.99
mut 9 11 20
 GNA11
wt 18 20 38
P=0.61
mut 10 15 25
 BAP1 (Sanger 
seq)
wt 19 10 29
P=0.019
mut 10 21 31
 BAP1 IHC
pos 14 5 19
 P=0.005
neg 14 29 43
 SF3B1
wt 22 33 55
P=0.08
mut 5 1 6
 EIF1AX
wt 23 32 55
P=0.16
mut 4 1 5
 Chr3 status
D 12 4 16
P=0.008
M 16 30 46
Table 20.   Association of clinical and molecular characteristics with metastasis onset.
No MT MT Tot. two-tailed P 
value
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 1p
wt 22 25 48
P=.76
1p- 7 6 12
 6p
wt 17 27 46
P=0.019
6p+ 12 4 14
 6q
wt 21 21 42
P=0.57
6q- 7 11 18
 8q
wt 14 5 19
P=0.012
8q+ 15 27 41
Table 20.   Association of clinical and molecular characteristics with metastasis onset.
No MT MT Tot. two-tailed P 
value
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Figure 42. Kaplan-Meier DPFS curves and Hazard Ratios
Distant Progression Free Survival (DPFS) curves and Hazard Ratios adjusted for age, sex and 
tumor stage (T) (Cox regression) (HR*) for: 
a) chromosome 3 status (monosomy/disomy);
b) 8q status (disomic 8q/8q gain); 
c) BAP1 IHC nuclear signal (positive/negative);
d) BAP1 mutation by Sanger sequencing (wt/mutated).
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 Figure 43. Kaplan-Meier DPFS curves and Hazard Ratios for chromosome 3 status 
(monosomy/disomy) and 8q status (disomic 8q/8q gain).
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DISCUSSION
In this study, we evaluated clinical, pathologic, and genetic features of a cohort 
of UM and we analyzed their associations with metastatic progression. Based 
on MLPA results, mutational analysis and BAP1 IHC we wanted to assess if 
there was a prognostic factor combination able to identify all metastatic cases. 
In addition, we wanted to assess the specificity of BAP1 IHC for prognostic 
testing in comparison with the predictive value of the other genetic markers (i.e. 
monosomy 3, 8q gain, and BAP1 mutations). 
Familial UM, defined as two or more family members diagnosed with UM, is 
estimated at less of 1% of all UM cases. BAP1 is the only gene known to 
contribute significant risk of UM, thus we investigated the presence, and the 
frequency, of BAP1 germline mutations in our UM samples blood.
Chromosomal aberrations, sequencing, and BAP1 expression 
Chromosomal aberrations
Specific cytogenetic alterations are associated in UM to metastatic progression 
(Shields et al, 2017). According to previous results, monosomy 3 and 8q gain 
were found associated to metastatic UM, and 6p gain to UM with a good 
prognosis (Sisley et al, 1997; Patel et al, 2001; Damato et al, 2010; van den 
Bosch et al, 2012; Versluis et al, 2015; Bagger et al, 2017; Shields et al, 2017). 
Monosomy 3 together with 8q gain was found associated to metastatic disease, 
as already reported (Damato et al, 2010; Versluis et al, 2015). In our cases 
series, also monosomy 3 without 8q gain (n=9 subjects) was associated to 
metastases, in contrast with previous data derived from larger cohorts (Damato 
et al, 2010; Versluis M, et al, 2015). In addition to MLPA, MSA was used to 
identify cases with isodisomy 3, which carries the same prognostic significance 
as monosomy 3 but is not detected by MLPA, as well as by all the techniques 
that count the number of chromosomes, i.e. FISH and CGH (Onken et al, 
2007) . In our UM case series, isodisomy 3 was found in 6% of total UM cases 
(9% of UM with monosomy 3), a frequency comparable to that reported in the 
few reports wherein two different prognostic tests have been performed on the 
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same tumor samples to identify isodisomy 3 (White et al, 1997; Singh et al, 
2011).                                 
Besides the 46 UM with monosomy 3, we found 5 samples with partial 
monosomy 3, 4 of which were metastatic. UM harboring partial monosomy 3 
have already been reported by several authors, with discrepant evidences: 
Tschenysher et al (Tschentscher et al, 2001), and Abdel-Rahman et al (Abdel-
Rahman et al, 2011), observed metastatic disease exclusively in UM with 
monosomy 3, while Scholes et al (Scholes et al, 2003) reported metastatic UM 
harboring partial monosomy 3.  
A protective role of 6p gain towards metastatic progression has been supposed 
(Damato et al, 2010; Harbour et al, 2012). In agreement with these studies in 
our UM cohort 6p gain resulted associated to a good prognosis.    
In our UM series MLPA showed loss of 6q and 8p with concomitant gain of 6p 
and 8q, suggesting the formation of an isochromosome i(6p) and i(8q), as 
already reported (Bastian et al, 1998, Aalto et al, 2011, Shields et al, 2017). 
However, mechanism(s) causing isochromosome formation are not yet known 
(Aalto et al, 2011). Recently, Yavuzyigitoglu et al (Yavuzyigitoglu et al, 2017) 
analyzed a large cohort of UM (277 UM samples) and described 
isocrhromosomes 6p and 8q (74%) only in samples harboring BAP1 mutations. 
For this reason the authors hypothesized that UM with specific mutations in 
BAP1,SF3B1 or EIF1AX mutations, are characterized by different mechanisms 
causing different types of chromosomal abnormalities. In contrast to 
Yavuzyigitoglu's data, we identified 3/5 i(6p) in UM harboring SF3B1 mutations, 
that are associated with late metastasis. This finding would suggest that there is 
a similar mechanism at the basis of  chromosomal abnormalities in UM mutated 
in BAP1 or SF3B1 genes. We did not find any isochromosome  in UM harboring 
EIF1AX mutations, confirming the hypothesis suggested by Yavuzyigitoglu of a 
different mechanism for chromosome aberration formation. 
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Sanger sequencing, BAP1 expression, and BAP1 MLPA 
• GNAQ, GNA11, PLCB4, CYSLTR2 and PTK2B sequencing
In UM, GNAQ and GNA11 mutations have been found both in benign nevi and 
in all stages of UM, leading to suppose that they are early and crucial events in 
UM pathogenesis. Altogether, we found GNAQ or GNA11 mutations in 71.4% of 
samples, a lower frequency compared to previous studies reporting about 
80-85% of GNAQ/11 mutated UM (Onken et al, 2008; van Raamsdonk et al,
2009; Harbour et al, 2010; Koopmans et al, 2013; Harbour et al, 2014; De 
Lange et al, 2015 ). The relatively small sample size could be at the basis of this 
difference. Recently, a very low GNAQ and GNA11 mutation rates have been 
observed in Greek patients (overall GNAQ/GNA11 mutation frequency 42%) 
and Chinese patients (overall GNAQ/GNA11 mutation frequency 38%) (Xy et al, 
2014; Psinakis et al, 2017). Until now, the difference in the reported frequencies 
of GNAQ or GNA11 mutations among the various studies did not allows 
conclusions on inter-ethnic differences. 
To further investigate the presence of other activating mutations able to induce 
MAPK pathway, we performed mutational analysis of PLCB4, CYSLTR2 and 
PTK2B genes in samples wild type for GNAQ or GNA11. Recently Johansson et 
al, and Moore et al identified novel mutations in PLCB4 and CYSLTR2 genes 
(Moore et al,2015; Johansson et al,2016). Another potential target of activating 
mutations is PTK2B, a. gene encoding a downstream protein of GPCr, whose 
expression level was evaluated in multiple myeloma and in glioblastoma cells 
(Lipinski et al, 2005; Zhang et al,2014).. Nevertheless, the putative oncogenic 
role of PTK2B in cancers has not been clarified yet. 
Altogether, only 3/13 UM with wild type GNAQ and GNA11, showed an 
activating mutation in PLCB4, CYSLTR2 or PTK2B. One of these mutation was 
found in hotspot ...and the other two were identified in PTK2B: R936Q occurring 
in the FAT region, and S542I occurring in the kinase domain, and in PLCB4 
1/13 UM sample harboring the mutation D630F. When we used PolyPhen-2 and 
SIFT to predict the possible impact of these  aminoacid substitutions to the 
structure and function of Plcb4 and Ptk2b proteins we observed is a 
discrepancy between the prediction provided by the two tools,  with a greater 
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tolerance of PolyPhen-2 than SIFT.
Considering that only 3 out of the 13 UM samples with GNAQ/GNA11 wild type 
harbored mutations in PTK2B or in PLCB4, it could be hypothesized that 
sporadic mutations could occur in other genes  of the same pathway activated 
by GNAQ/GNA11 mutations.
• SF3B1 and EIF1AX sequencing 
In our UM samples, SF3B1 mutations were identified in 10% of UM, a lower 
frequency compared to the mutation rate observed by Alsafadi et al (Alsafadi et 
al,2016). Recently, a mutational analysis performed in tumor DNA obtained from 
a large cohort of UM with a longer follow-up (20 years), showed an association 
between SF3B1 mutations and late metastases (Yavuzyigitoglu et al, 2016). As 
it could be expected, in our series Fisher’s exact test did not show any 
association between SF3B1 mutations and metastatic risk (P=0.08): to evaluate 
the prognostic value of SF3B1 mutations, time-to-event analyses (i.e. Kaplan-
Meier analyses), based on large cohort with a long follow-up, would be required 
(Yavuzyigitoglu et al, 2016).
EIF1AX mutations in UM were first described by Martin et al in tumors with 
disomy 3 (Martin et al,2013). Several authors (Martin et al,2013; Ewens et al, 
2014; Yavuzyigitoglu et al,2016) agree with the hypothesis of correlation 
between EIF1AX mutations and a good prognosis, although few cases with 
monosomy 3 and EIF1AX mutation were reported (Ewens et al, 2014). In our 
UM series, we identified EIF1AX mutations in 8,2% of sequenced samples. Two 
out of 5 UM with EIF1AX mutation, had monosomy 3, finding already reported in 
the literature (Martin et al,2013). In contrast with previous studies (Martin et al,
2013; Ewens et al,2014; Yavuzyigitoglu et al,2016) EIF1AX mutations were not 
associated to a good prognosis, possible due to the small samples size. Also in 
this case, when we used PolyPhen-2 and SIFT, we could notice a remarkable 
discrepancy between the two prediction tools, with a general greater tolerance 
of PolyPhen-2 compared to SIFT.
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• BAP1 sequencing and BAP1 IHC
The relationship between BAP1 loss and metastatic progression is reinforced by 
multiple independent studies (Harbour  et al,2010; Luchini et al,2016). BAP1 is 
a tumor suppressor gene, involved in maintaining genome integrity through 
multiple mechanisms (Lee et al,2014; Zarrizi et al,2014; Ismail et al,2014). Until 
recently, it was thought that nuclear localization was required for all BAP1 
functions. Recent experiments, however, showed a novel BAP1 cytoplasmic 
activity: wt BAP1 localizes at the endoplasmic reticulum, and has a role in 
promoting apoptosis via Ca2+ mitochondrial changes (Bononi et al, 2017). 
Moreover, it was shown that cells from individuals carrying heterozygous 
germline BAP1 mutations have a distinctive metabolic signature, consisting in 
impairment of mitochondrial respiration and increase of aerobic glycolysis 
leading to a Warburg effect (Bononi et al, 2017). Metastatic potential and 
prognosis in UM lacking BAP1 functions could be influenced also by these 
mechanisms, Warburg effect creating an environment that promotes tumor 
growth in hypoxia, and impaired apoptosis increasing the resistance to 
chemotherapy-induced apoptosis (Hsu et al, 2008; Cairns et al, 2011). BAP1 
protein activity depends on the deubiquitinating domain and, for its nuclear 
activities, on nuclear localization signals. Missense mutations, which are mainly 
found in the UCH domain, can impair the catalytic domain (Harbour et al, 2014; 
Ji et al, 2014; Pan H et al, 2015). Frameshift mutations can give rise to 
abnormal mRNAs, subjected to nonsense-mediated RNA decay (Lykke-
Andersen et al, 2015), or resulting in truncated proteins lacking the C-terminal 
nuclear localization signals or prone to rapid degradation (Ventii et al, 2008; 
Wang et al, 2016). Altogether, we found 31 BAP1 mutations in UM with 
monosomy/isodisomy 3. In 6 UM samples, Sanger sequencing identified 
heterozygous BAP1 mutations. All these samples were characterized by 
immune-cell infiltration, and in all of them BAP1 IHC clearly showed loss of 
nuclear immunosignal in UM cells, with infiltrating cells showing positive nuclear 
immunostaining. In these cases, a likely explanation for the observed BAP1 
mutation heterozygosity could be the presence of wt BAP1 alleles from 
infiltrating cells, even if we cannot definitely exclude heterogeneity of BAP1 
status in the tumor. Thirteen BAP1 mutations were in-frame mutations, 12 of 
those clustered in the region spanning exons 4 to 8 of the BAP1 gene, within 
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the UCH domain. In all but one case, the samples with BAP1 missense 
mutations were IHC negative: UM53, harboring in UCH domain the mutation 
H94R, predicted damaging by PolyPhen-2 and deleterious by SIFT, showed 
BAP1 nuclear signal. H94R could likely determine loss of UCH function while 
maintaining protein expression and nuclear localization. Polyphen-2 predicted 
as probably damaging/damaging all missense mutations. SIFT predicted as 
damaging all missense mutations with the exception of S697P, S63C and N78S, 
predicted as tolerated. We can observe a discrepancy between SIFT and 
Polyphen-2 prediction with a higher tolerance of SIFT.  
However, it has to notice that all the 11 in-frame mutations had as consequence 
the loss of BAP1 protein expression, independently from functionality prediction 
by Polyphen2 and SIFT. These data are in agreement with previous reports, 
showing that the effect of missense mutations on BAP1 expression and 
localization is the loss of BAP1 IHC nuclear staining, and at times cytoplasmic 
accumulation of inactive mutated BAP1 (Ventii et al, 2008; Bhattacharya et al,
2015; Yavuzyigitoglu et al, 2016; Luchini et al, 2016). Until now, there is no  a 
clear explanation for this phenomenon. Eighteen samples had truncating or 
read-through BAP1 mutations, and all showed the absence of BAP1 nuclear 
immunostaining. Previous studies showed that the consequence of out-of-frame 
mutations is the absence of BAP1 nuclear protein, with some exceptions: 
Koopmans (Koopmans et al, 2015) reported two hemizygous mutants harboring 
an out-of-frame deletion in exon 16 with a positive BAP1 staining, and 
Yavuzyigitoglu (Yavuzyigitoglu et al, 2016) described two UM cases (both with 
monosomy 3) expressing nuclear BAP1 protein despite the BAP1 nonsense 
mutations Q36*, and E406*, respectively. This latter finding is quite surprising, 
because both Q36* and E406* nonsense mutants are expected to have lost the 
epitope recognized by the antibody, and, in addition, they should have lost the 
nuclear localization signals. 
Fisher’s exact test showed statistically significant association between loss of 
BAP1 nuclear immunostaining and metastatic progression (P=0.005, Fisher’s 
test), in agreement to previous studies (Shahet al, 2013; Koopmans et al, 2014; 
Szalai et al, 2017). In the literature, data about BAP1 mutations, Bap1 
expression and/or Bap1 protein localization are not fully in agreement (Venti et 
al, 2008; Wiesner et al, 2012; Bhattacharya et al, 2015; Szalai et al, 2017). UM 
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cases lacking IHC BAP1 signal without BAP1 mutations were already reported 
(Harbour et al, 2010; Matatall et al, 2013; Yavuzyigitoglu et al, 2016; Koopmans 
et al, 2014), but until now no other mechanisms than mutations are known that 
could prevent BAP1 expression. DNA methylation, one of the key epigenetic 
mechanisms, was demonstrated not to be responsible for loss of BAP1 
expression in cells with apparent “wt” BAP1 by Sanger sequencing (Ibragimova 
et al, 2013), neither considering promoter methylation or BAP1 gene body 
methylation (Nasu et al, 2015).  
In our UM series, univariate analysis showed that chromosome 3 monosomy, 
8q gain, BAP1 mutations, and loss of BAP1 nuclear immunostaining were all 
significantly associated with metastatic progression, in agreement with previous 
studies (Damato et al, 2010; Ewens et al, 2014; Koopmans et al, 2014; van de 
Nes et al, 2016; Szalai et al, 2017). Also Associations between imbalances/
mutations and DPFS were in agreement with previous reports (Ventii et al,2008; 
Patel et al, 2001; van Essen et al, 2014; Koopmans et al, 2014), with the 
exclusion of BAP1 mutation, which did not reach a statistically significant 
association. Various factors could have influenced the latter result, e.g. 
heterogeneity in the length of follow-up, or the relatively low statistical power 
which is a common bias of rare disease studies. Most importantly, however, in 
11/43 (26%) UM with negative BAP1 IHC and no BAP1 mutations were found. 
Among the 11 cases with discrepancy between Sanger sequencing and IHC, 8 
had monosomy 3 and 3 partial monosomy 3, 6/11 were metastatic (follow-up 
6-39 months), 3/11 were non metastatic (follow-up 11-23 months), and 2 
patients were lost to follow-up.
•  Analysis of UM cases with BAP1 wt and negative BAP1 IHC
Van de Nes et al (van de Nes et al, 2016) showed hemizygous deletion of one 
or more BAP1 exons in a proportion of UM with monosomy 3, negative BAP1 
IHC and BAP1 wt by Sanger sequencing, and Yoshikawa et al (Yoshikawa et al, 
2016) demonstrated that the discrepancy between BAP1 IHC (negative) and 
BAP1 mutational status (wt) in malignant mesothelioma was due to BAP1 
deletions, which were too large to be detected by Sanger sequencing. As 
already pointed out in Result section, in 4/7 UM cases BAP1-MLPA analysis could 
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identify deletion of one or more BAP1 exons (UM50, UM23, UM02, and UM18 failed). 
Altogether in 7 UM samples,
Two of these samples (UM40 and UM54) did not show any BAP1 mRNA signal 
after hybridization with RNAscope BAP1 probe, whereas one sample (UM46) 
showed BAP1 mRNA signal. One UM sample (UM10) with no BAP1 exon 
deletion, showed positive BAP1 mRNA signal. In one out of the two samples 
failed for BAP1-MLPA, we observed mRNA signal. In 2 UM cases (UM23, 
UM02), both BAP1-MLPA and RNAscope assay failed. Considering together the 
results obtained from BAP1-MLPA and from RNAscope assay, in 7 UM samples 
(UM46, UM10, UM02, and UM23) we did not have clarified the discrepancy 
between BAP1 wild type and negative BAP1 IHC, than further studies are 
required to understand if post-transcriptional mechanisms that may inhibit Bap1 
protein expression in samples with BAP1 wild type  occur. 
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Germline BAP1 mutations
Germline BAP1 mutations were reported in less than 1% of UM patients in UK 
(Aoude et al, 2013; Soura et al, 2016) in association with a novel hereditary 
cancer syndrome, described as BAP1 -TPDS. 
Altogether, we found BAP1 germline mutations in 2/26 of examined samples
In UM58 case, we identified the missense mutation P338S, not detected in UM 
tumor tissue, where the mutation F168Sfs*19 has been observed. This 
evidence could be explained because during UM progression, the chromosome 
3 harboring the germline mutation P338S was lost and the remaining allele 
developed the somatic mutation F168Sfs*16. In UM37 case we identified the 
synonymous mutation L452L, also found in UM. In addition, in UM sample we 
identified the mutation p.A95P. We could suppose that during  tumor 
progression BAP1 wild type allele was lost and the remaining allele, already 
harboring the germline synonymous mutation L452L, developed the missense 
mutation A95P. In UM41 case we identified the frameshift mutation P110Sfs*4. 
The intronic variant c.1729+8 T>C in UM27 case was already reported in 
association with BAP1 tumor predisposition syndrome, and it has been 
described in ClinVar and refSNP with the ID rs150945583. This intronic variant 
has been described in ClinVar and Human Splicing Finder online software as 
benign, although ESEFinder, a tool of ALAMUT software, predicted  a possible 
effect at nearest splice site. 
There are some limitations of our mutational analysis. We have no personal and 
family history of the patients, therefore we cannot speculate if UM in patients 
harboring germline BAP1 mutation, was part of BAP1-TPDS or if it was a de 
novo event. This mutational analysis was performed in a limited number of 
samples  than previous reports (Abdel-Rahaman et al,2013; Betti et al, 2016; O 
Shea et al 2016), thus our result did not has statistic significance: is our purpose 
to expand the number of samples analyzed for BAP1 germline mutations.
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Conclusion 
In our UM samples, we did not found a prognostic factor combination in 
common to all metastatic cases. Indeed, 4 out of 63 (6%) samples (samples 
UM13, UM17, UM60 and UM62) resulted with disomy 3, BAP1 wild-type and 
IHC positive (evaluated as good prognosis), developed liver metastasis. Among 
these four samples, only UM17 showed high instability  with loss of four MLPA 
control probes. Among the metastatic UM, only one case (UM60) showed as 
unique imbalance the indicator of good prognosis 6p gain. It is known that rare 
UM with disomy 3 can develop metastases, but there is no evidence on possibly 
involved metastatic pathway(s). Damato et al, and Abdel-Rahman et al (Damato 
et al,2010; Abdel-Rahman et al 2011) reported metastatic disease occurring in 
UM with partial monosomy 3. Also Shields et al and Yonekawa et al reported 
unusual high frequency of metastasizing disomy 3 tumors (Shields et al, 2011; 
Yonekawa Y et al, 2014). A possible explanation given to justify this finding, was 
the use of different molecular techniques and different sampling methodologies. 
Indeed, the authors (Shields et al, 2011; Yonekawa Y et al, 2014) hypothesized 
that FNAB increase the chance to aspirate tissue with tumor heterogeneity.   
Although many studies have reported quite large numbers of UM cases, those 
that have given a detailed mutational and cytogenetic analysis are indisputably 
fewer. In this view, this study gives a contribution in defining the genetic UM 
landscape. 
Traditionally the various clinical and histopathologic tumor characteristics, are 
necessary for the assessment of prognosis for UM. The recently findings, 
established that for prognostication, loss of BAP1 protein expression, 
monosomy 3 and 8q gain represent the strongest, with important consequences 
for the implementation of a more intensive patient surveillance and adjuvant 
therapy. To date, no effective pharmacological therapies are available to treat 
UM and metastatic UM. Until recently, the possibility to use target cancer 
therapy has been hampered by the lack of known mutations, but now the 
knowledge is improving with the discovery of high frequency mutations in 
recurrent genes. Nonetheless, our work suggests that further studies are 
necessary to identify other driving mutations able to activate MAP kinase 
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pathways and to promote UM progression, important findings that could lead to 
better understand the UM pathogenesis.
The identification of mutations involved in UM pathogenesis could likely lead to 
better therapeutic strategies to treat UM and metastatic UM. The strong 
association between BAP1 mutations and metastatic risk, suggests that the 
pharmacological targeting of BAP1 mutations may be of therapeutic 
significance. In light of BAP1 role in histone modifications, HDAC inhibitors 
(histone deacetylases) were recently tested in UM cell lines but further studies 
to investigate the therapeutic potential of HDAC in tumors lacking BAP1 
expression are required. Several adjuvant trials targeting the driver mutations 
identified in UM are registered at the clinical trials service of the National 
Institute of Health (clinicaltrials.gov). In particular, ClinicalTrials.gov lists 69 trials 
for metastatic UM.  
In our study we assessed BAP1 status through sequencing analysis of 17 
exons and near splice sites, and we evaluate BAP1 protein expression through 
BAP1 IHC. Sanger direct sequencing is an expensive and long- lasting 
technique and a big amount of DNA is necessary, not always available. 
Conversely, BAP1 IHC is a rapid and cost-effective method to evaluate BAP1 
functional status. In our research we found a strong correlation between 
negative BAP1 IHC and metastatic disease risk, so in a future BAP1 
immunoistochemistry analysis should be implemented in the routine 
histopathological examination of UM. 
The validity of all these observations must be assessed in properly designed 
clinical trials. Further studies, concerning the identification and molecular 
characterization of mutations, involved in UM pathogenesis and tumor 
progression, could be helpful to define the more aggressive UM, taking 
advantages in patient care and clinical practice.
 115
REFERENCES
• Aalto Y, Eriksson L, Seregard S, et al. Concomitant loss of chromosome 3 and 
whole arm losses and gains of chromosome 1, 6, or 8 in metastasizing 
primary uveal melanoma. Invest Ophthalmol Vis Sci. 2001 Feb;42(2):313-7;
•  Abdel-Rahman MH, Christopher BN, Faramawi MF, et al. Frequency, 
molecular pathology and potential clinical significance of partial chromosome 
3 aberrations in uveal melanoma. Mod Pathol. 2011 Jul;24(7):954-62;
• Abdel-Rahman MH, Pilarski R, Cebulla CM, et al. Germline BAP1 mutation 
predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and 
other cancers. J Med Genet. 2011 Dec;48(12):856-9; 
• Albino AP, Fountain JW. Molecular genetics of human malignant melanoma. 
Cancer Trat 1 Res 993 65: 201-255;
•  Alsafadi S, Houy A, Battistella A, et al. Cancer-associated SF3B1 mutations 
affect alternative splicing by promoting alternative branchpoint usage. Nat 
Commun. 2016 Feb 4;7:10615;                                                                                  
• Amaro A, Gangemi R, Piaggio F, et al. The biology of  uveal melanoma. 
Cancer Metastasis Rev. 2017 Mar;36(1):109-140;
• Aoude LG, Wadt K, Bojesen A et al. A BAP1 mutation in a Danish family 
predisposes to uveal melanoma and other cancers. PLoS One. 2013 Aug 
19;8(8):e72144;
•  Aoyama T, Mastrangelo MJ, Berd D, et al. Protracted survival after resection 
of metastatic uveal melanoma.Cancer. 2000 Oct 19) 
• Atzpodien J, Terfloth K, Fluck M,et al. Cisplatin, gemcitabine and treosulfan is 
effective in chemotherapy-pretreated relapsed stage IV uveal melanoma 
patients. Cancer Chemother Pharmacol. 2008;62:685–688;
• Bastian BC, LeBoit PE, Hamm H, et al. Chromosomal gains and losses in 
primary cutaneous melanomas detected by comparative genomic 
hybridization. Cancer Res. 1998 May 15;58(10):2170-5;
• Battaglia A. The Importance of Multidisciplinary Approach in Early Detection of 
BAP1 Tumor Predisposition Syndrome: Clinical Management and Risk 
Assessment. Clin Med Insights Oncol.2014 Apr 28; 8:37-47;
•  Bauer J, Kilic E, Vaarwater J, et al. Oncogenic GNAQ mutations are not 
correlated with disease-free survival in uveal melanoma. Br J Cancer. 2009 
Sep 1;101(5):813-5.
 116
• Bhatia S, Moon J, Margolin KA, et al. Phase II trial of sorafenib in combination 
with carboplatin and paclitaxel in patients with metastatic uveal melanoma: 
SWOG S0512. PLoS One. 2012;7:e48787;
• Bhattacharya S, Hanpude P, Maiti TK. Cancer associated missense mutations 
in BAP1 catalytic domain induce amyloidogenic aggregation: A new insight in 
enzymatic inactivation. Sci Rep. 2015 Dec 18;
• Biankin AV, Waddell N, Kassahn KS, et al. Pancreatic cancer genomes reveal 
aberrations in axon guidance pathway genes. Nature. 2012 Nov 
15;491(7424):399-405;
• Bingham V, McIlreavey L, Greene C, et al. RNAscope in situ hybridization 
confirms mRNA integrity in formalin-fixed, paraffin-embedded cancer tissue 
samples. Oncotarget. 2017 Oct 16;8(55):93392-93403;
• Bishop KD, Olszewski AJ. Epidemiology and survival outcomes of ocular and 
mucosal melanomas: a population-based analysis. Int J Cancer. 2014 Jun 
15;134(12):2961-71.
• Bononi A, Yang H, Giorgi C et al. Germline BAP1 mutations induce a Warburg 
effect. Cell Death Differ. 2017 Oct;24(10):1694-1704. 
• Buder K, Gesierich A, Gelbrich G, et al. Systemic treatment of metastatic 
uveal melanoma: review of literature and future perspectives. Cancer Med.
2013;2:674–686;
• Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat Rev 
Cancer. 2011 Feb;11(2):85-95;
• Callender GR. Malignant melanotic tumors of the eye: a study of histologic 
types in 111 cases. Trans Am Acad Ophtalmol  Otolaryngol.1931; 36:131-142;
• Carbone M, Ferris LK, Baumann F, et al. BAP1 cancer syndrome: malignant 
mesothelioma, uveal and cutaneous melanoma, and MBAITs. J Transl Med. 
2012 Aug 30;10:179. doi:10.1186/1479-5876-10-179.
• Carbone M, Flores EG, Emi M et al. Combined Genetic and Genealogic 
Studies Uncover a Large BAP1 Cancer Syndrome Kindred Tracing Back Nine 
Generations to a Common Ancestor from the 1700s. PLoS Genet. 2015 Dec 
18;11(12):e1005633;
• Carbone M, Yang H, Pass HI, et al. BAP1 and cancer. Nat Rev Cancer. 2013 
Mar;13(3):153-9;
 117
• Carvajal RD, Sosman JA, Quevedo JF, et al. Effect of selumetinib vs 
chemotherapy on progression-free survival in uveal melanoma: a randomized 
clinical trial. JAMA. 2014;311:2397–2405;
• Cassoux N, Rodrigues MJ, Plancher C, et al.Genome-wide profiling is a 
clinically relevant and affordable prognostic test in posterior uveal melanoma. 
Br J Ophthalmol. 2014 Jun;98(6):769-741;
• Chang AE, Karnell LH, Menck HR. The National Cancer Data Base report on 
cutaneous and noncutaneous melanoma: a summary of 84,836 cases from 
the past decade. The American College of Surgeons Commission on Cancer 
and the American Cancer Society. Cancer. 1998 Oct 15;83(8):1664-78;
• Chattopadhyay C, Kim DW, Gombos DS, et al. Uveal melanoma: From 
diagnosis to treatment and the science in between. Cancer. 2016 Aug 1; 
1;122(15):2299-312;
• Clarke LE, Warf MB, Flake DD 2nd, et al. Clinical validation of a gene 
expression signature that differentiates benign nevi from malignant melanoma. 
J Cutan Pathol. 2015 Apr;42(4):244-52;
• Coupier I, Cousin PY, Hughes D, Legoix-Né P, Trehin A,et al. BAP1 and breast 
cancer risk. Fam Cancer. 2005;4(4):273-7;
•  Coupland SE, Lake SL, Zeschnigk M, et al. Molecular pathology of uveal 
melanoma. Eye (Lond). 2012 Feb;27(2):230-42;
• Cross NA, Ganesh A, Parpia M, et al. Multiple locations on  chromosome 3 
are the targets of specific deletions in uveal melanoma. Eye. 2006 Apr;
• Damato B, Dopierala J, Klaasen A, et al. Multiplex ligation-dependent probe 
amplification of uveal melanoma: correlation with metastatic death. Invest 
Ophthalmol Vis Sci 2009; 50(7): 3048–3055;
• Damato B, Catherine Duke, Sarah E, et al. Cytogenetics of uveal melanoma: 
a 7-year clinical experience. Ophthalmology. 2007 Oct;114(10):1925-31;
•  Damato B, Dopierala JA, Coupland SE. Genotypic profiling of 452 choroidal 
melanomas with multiplex ligation-dependent probe amplification. Clin Cancer 
Res 2010 Dec 15;16(24):6083-92;
• Damato B. Progress in the management of patients with uveal melanoma. The 
2012 Ashton Lecture. Eye. 2012; 26(9): 1157–1172;
• Daou S, Hammond-Martel I, Mashtalir N, et al. The BAP1/ASXL2 Histone H2A 
Deubiquitinase Complex Regulates Cell Proliferation and Is Disrupted in 
Cancer. The Journal of Biological Chemistry. 2015;290(48):28643-28663;
 118
• de la Cruz PO Jr, Specht CS, McLean IW: Lymphocitic infiltration in uveal 
malignant melanoma. Cancer 1990;65:112-115;
• De Lange MJ, van Pelt ST, Varsluis M, et al. Heterogeneity revealed by 
integrated genomic analysis uncovers a molecular switch in malignant uveal 
melanoma. Oncotarget. 2015 Nov 10; 6(35):37824-35;
• Diener-West M, Reynolds SM, Agugliaro DJ, et al Collaborative Ocular 
Melanoma Study Group. Development of metastatic disease after enrollment 
in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular 
Melanoma Study Group Report No. 26. Arch Ophthalmol. 2005 Dec;123(12):
1639-43;
•  Edge SE, Bryd DR, Compton CA, et al. Ophtalmic Oncology Task Force. 
Malignant Melanoma of the Uvea. AJCC Cancer Staging Manual, 7th ed 
Springer; 2010:547-559; 
• Ehlers JP, Worley L, Onken MD, et al. Integrative genomic analysis of 
aneuploid in uveal melanoma. Clinic Cancer Res. 2008 1;14(1):115-22;
• Epping MT, Bernards R. A causal role for the human tumor antigen 
preferentially expressed antigen of melanoma in cancer. Cancer Res. 2006 
Nov 15;66(22):10639-42;
• Epping MT, Wang L, Edel MJ, et al. The human tumor antigen PRAME is a 
dominant repressor of retinoic acid receptor signaling. Cell. 2005 Sep 23;122(6):
835-47;
• Ewens KG, Kanetsky PA, Richards-Yutz J, et al. Genomic profile of 320 uveal 
melanoma cases: chromosome 8p-loss and metastatic outcome. Invest 
Ophtalmol Vis Sci 2013; 54:5721-9;
• Ewens KG, Kanetsky PA, Richards-Yutz J,et al. Chromosome 3 status 
combined with BAP1 and EIF1AX mutation profile are associated with 
metastasis in uveal melanoma. Invest Ophthalmol Vis Sci. 2014 Jun 26;55(8):
5160-7;
• Feng X, Chen Q, Gutkind JS. Oncotargeting G proteins: The Hippo in the 
room. Oncotarget.2014 Nov 30;5(22):10997-9;
• Feng X, Degese MS, Iglesias-Bartolome R, et al. Hippo-independent 
activation of YAP by the GNAQ uveal melanoma oncogene through a trio-
regulated rho GTPase signaling circuitry. Cancer Cell. 2014 Jun 16;25(6):
831-45;
 119
• Field MG, Decatur CL, Kurtenbach S, et al. PRAME as an Independent 
Biomarker for Metastasis in Uveal Melanoma.  Clin Cancer Res. 2016 Mar 
1;22(5):1234-42;
• Field MG, Harbour JW. Recent developments in prognostic and predictive 
testing in uveal melanoma. Curr Opin Ophthalmol. 2014 May;25(3):234-9;
• Folberg R, Rummelt V, Parys-Van, et al. The prognostic value of tumor blood 
vessel morphology in primary uveal melanoma. Ophthalmology. 1993 Sep;
100(9):1389-98;
• Folberg R, Hendrix MJ, Maniotis AJ. Vasculogenic mimicry and tumor 
angiogenesis. Am J Pathol. 2000 Feb;156(2):361-81;
• Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other diseases. 
Nature Med  1995;1:27-31;
•  Fountain JW, Bale SJ, Housman DE, et al. Genetics of melanoma. Cancer 
Surv. 1990;9(4):645-71;
•  Fredericks AM, Cygan KJ, Brown BA,et al. RNA-Binding Proteins: Splicing 
Factors and Disease. Biomolecules. 2015 May 13;5(2):893-909;
• Furney SJ, Pedersen M, Gentien D, et al. SF3B1  mutations are associated 
with alternative splicing in uveal melanoma. Cancer Discov. 2013  Oct;3(10):
1122-1129;
•  Garinis GA, Paltrinos GP, Spanakis NE, et al. DNA Hypermethylation: When 
tumor  suppressor genes go silent. Hum Genet 2002; 111:115-127;
• Golas MM, Sander B, Will CL, et al. Molecular architecture of the multiprotein 
splicing factor SF3b.  Science. 2003 May 9; 300(5621):980-4;
• Griffin CA, Long PP, Schachat AP. Trisomy 6p in an ocular melanoma. Cancer 
Genet Cytogenet 1988; 32(1): 129–132;
• Guénard F, Labrie Y, Ouellette G, et al. INHERIT BRCAs. Genetic sequence 
variations of BRCA1-interacting genes AURKA, BAP1, BARD1 and DHX9 in 
French Canadian families with high risk of breast cancer. Journal of human 
genetics. 2009;54(3):152-161;
• Gupta MP, Lane AM, DeAngelis MM, et al. Clinical Characteristics of Uveal 
Melanoma in Patients With Germline BAP1 Mutations. JAMA Ophthalmol. 
2015 Aug;133(8):881-7;
• Hanahan D, Weiberg RA. Hallmarks of cancer. The next generation. Cell 
2011; 144(5):646-674;
• Hanahan D, Weiberg RA. The hallmarks of cancer. Cell 2000 ; 100(1): 5770;
 120
• Harbour JW, Chao DL. A molecular revolution in uveal melanoma: implications 
for patient care and targeted therapy. Ophthalmology. 2014 Jun;121(6):
1281-8;
• Harbour JW, Onken MD, Roberson ED, et al. Frequent mutation of BAP1 in 
metastasizing uveal melanomas. Science. 2010 Dec 3;330(6009):1410-3;
• Harbour JW, Roberson EDO, Anbunathan H, et al. Recurrent mutations at 
codon 625 of the splicing factor SF3B1 in uveal melanoma. Nature genetics 
2013;45(2):133-135;
• Harbour JW. A prognostic test to predict the risk of metastasis in uveal 
melanoma based on a 15-gene expression profile. Methods Mol Biol. 
2014;1102:427-40;
• Harbour JW. The genetics of uveal melanoma: an emerging framework for 
targeted therapy. Pigment Cell Melanoma Res. 2012 Mar;25(2):171-8;
•  Hausler T, Stang A, Anastassiou G, et al. Loss of heterozygosity of 1p in 
uveal melanomas with monosomy 3. Int J Cancer 2005; 116(6): 909–913;
• Helgadottir H, Höiom V. The genetics of uveal melanoma: current insights. 
The Application of Clinical Genetics. 2016;9:147-155;   
• Horsman DE, White VA. Cytogenetic analysis of uveal melanoma. Consistent 
occurrence of monosomy 3 and trisomy 8q. Cancer 1993; 71(3): 811–819;  
• Hsu PP, Sabatini DM. Cancer cell metabolism: Warburg and beyond. Cell. 
2008 Sep 5;134(5):703-7;
• Hughes S, Damato BE, Giddings I, et al. Microarray comparative genomic 
hybridisation analysis of intraocular uveal melanomas identifies distinctive           
imbalances associated with loss of chromosome 3. Br J Cancer 2005; 93(10): 
1191–1196;
• Ibragimova I, Maradeo ME, Dulaimi E, et al. Aberrant promoter 
hypermethylation of PBRM1, BAP1, SETD2, KDM6A and other chromatin-
modifying gene is absent or rare in clear cell RCC. Epigenetics. 2013 May;
8(5):486-93;
•  Inamdar GS, Madhunapantula SV, Robertson GP. Targeting the MAPK 
pathway in melanoma: why some approaches succeed and other fail. 
Biochem Pharmacol. 2010 Sep 1;80(5):624-37;
• Janssen CS, Sibbett R, Henriquez FL, et al. The T1799A point mutation is 
present in posterior uveal melanoma. Br J Cancer. 2008 N. 18;99(10):1673-7;
 121
• Johansson P, Aoude LG, Wadt K, et al. Deep sequencing of uveal melanoma 
identifies a recurrent mutation in PLCB4. Oncotarget. 2016 Jan 26;
• Johnson CP, Kim IK, Esmaeli B, et al. Systematic genomic  and translational 
efficiency studies of uveal melanoma. PLoS One. 2017 Jun 8;12(6):e0178189;
• Kadariya Y, Cheung M, Xu J, et al. Bap1 Is a Bona Fide Tumor Suppressor: 
Genetic Evidence from Mouse Models Carrying Heterozygous Germline Bap1 
Mutations. Cancer  Res. 2016 May 1;76(9):2836-44;
•  Kilic E, Naus NC, Van Gils W, et al. Concurrent loss of chromosome arm 1p 
and chromosome 3 predicts a decreased disease-free survival in uveal 
melanoma patients. Invest Ophthalmol Vis Sci 2005 46, 2253-7;
• Koopmans AE, Vaarwater J, Paridaens D, et al. Patient survival in uveal 
melanoma is not affected by oncogenic mutations in GNAQ and GNA11. BR J 
Cancer. 2013 Jul 23; 109(2): 493-6;
• Koopmans AE, Verdijk RM, Brouwer RW, et al. Clinical significance of 
immunohistochemistry for detection of BAP1 mutations in uveal melanoma. 
Mod Pathol. 2014 Oct;27(10):1321-30;
•  Ladanyi M, Zauderer MG, Krug LM, et al. New strategies in pleural 
mesothelioma: BAP1 and NF2 as novel targets for therapeutic development 
and risk assessment. Clin Cancer Res. 2012 Sep 1;18(17):4485-90;
• Landis CA, Masters SB, Spada A, et al. GTPase inhibiting mutations activate 
the ἀ chain of Gs and stimulate adenylyl cyclase in human pituitary tumors. 
Nature 1989; 340, 692-696;
• Lipinski CA, Tran NL, Menashi E, et al. The Tyrosine Kinase Pyk2 Promotes 
Migration and Invasion of Glioma Cells. Neoplasia 2005;7(5):435-445;
•  Luchini C, Veronese N, Yachida S, et al. Different prognostic roles of tumor 
suppressor gene BAP1 in cancer: A systematic review with meta-analysis. 
Genes Chromosomes Cancer. 2016 Oct;55(10):741-9;
•  Lyons J, Landis CA, Harsh G, et al. Two G protein oncogenes in human 
endocrine tumors. Science. 1990 Aug 10;249(4969):655-9;
• Lykke-Andersen S, Jensen TH. Nonsense-mediated mRNA decay: an intricate 
machinery that shapes transcriptomes. Nat Rev Mol Cell Biol. 2015 Nov; 16 
(11): 665-677
• Maat W, Kilic E, Luyten GP, et al. Pyrophosphorolysis detects B-RAF 
mutations in primary uveal melanoma. Invest Ophthalmol Vis Sci. 2008 Jan;
49(1):23-7;
 122
• Malcovati L., Papaemmanuil E, Bowen DT, et al. Clinical significance of 
SF3B1 mutations in myelodysplasic syndromes and myelodysplasic/
myeloproliferative  neoplasm. Blood 2011; 118:6239-46: Mar;89(3):285-94;
• Mariani P, Piperno-Neumann S, Servois V, et al. Surgical management of liver 
metastases from uveal melanoma: 16 years’ experience at the Institut Curie. 
Eur J Surg Oncol. 2009;35:1192–1197;
• Martin M, Maßhöfer L, Temming P, et al. Exome sequencing identifies 
recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with 
disomy 3. Nature genetics. 2013;45(8):933-936;
• Matatall KA, Agapova OA, Onken MD, et al. BAP1 deficiency  causes loss of 
melanocytic cell identity in uveal melanoma. BMC Cancer. 2013 Aug 5;13:371;
• McLaughlin CC, Wu XC, Jemal A, et al. Incidence of non cutaneous 
melanomas in the U.S. Cancer. 2005 Mar 1;103(5):1000-7;
• McLean IW, Foster WD, Zimmerman LE, et al. Modifications of Callender’s 
classification of uveal melanoma at the Armed Forces Institute of Pathology. 
Am J Ophthalmol. 1983 Oct;96(4):502-9;
• McLean. Tumors of the Eye and Ocular Adnexa .1995, AFIP Atlas of Tumor 
Pathology Third Series, Fascicle 12;
•  McNamara M, Felix C, Davison EV, et al. Assessment of chromosome 3          
copy number in ocular melanoma using fluorescence in situ hybridization.   
Cancer Genet Cytogenet 1997; 98(1): 4–8;
• Merbs SL, Sidransky D. Analysis of p16 (CDKN2/MTS-1/INK4A) alterations in 
primary sporadic uveal melanoma. Invest Ophthalmol Vis Sci. 1999 Mar; 
40(3):779-83;
•  Moore AR, Ceraudo E, Sher JJ, et al. Recurrent activating mutations of G-
protein-coupled receptor CYSLTR2 in uveal melanoma. Nat Genet. 2016 Jun;
48(6):675-80;
• The Collaborative Ocular Melanoma Study Group COMS report no. 4. 
Mortality in patients with small choroidal melanoma. 1997 Jul; Arch 
Ophthalmol 115(7):886-93;
•  Murali R, Wiesner T, Scolyer RA. Tumours associated with BAP1 mutations. 
Pathology. 2013 Feb; 45(2):116-26;
• Nasu M, Emi M, Pastorino S et al, High incidence of somatic BAP1 alterations 
in sporadic malignant mesothelioma. J Thorac Oncol. 2015 Apr;10(4):565-76;
 123
• Ness C, Garred O, Eide NA, et al. Multicellular tumor spheroids of human 
uveal melanoma induce genes associated whit anoikis resistance, 
lipogenesis, and SSXs. Mol Vis. 2017 Oct 3; 23:680-694;
• Nichols EE, Richmond A, Daniels AB. Disparities in Uveal Melanoma: Patient 
Characteristics. Semin Ophthalmol. 2016;31(4):296-303;
• Nichols EE, Richmond A, Daniels AB. Tumor Characteristics, Genetics, 
Management, and the Risk of Metastasis in Uveal Melanoma. Semin 
Ophthalmol. 2016;31(4):304-9;
• Njauw CN, Kim I, Piris A, et al. Germline BAP1 inactivation is preferentially 
associated with metastatic ocular melanoma and cutaneous-ocular melanoma 
families. PLoS One. 2012;7(4):e35295;
• O'Hayre M, Degese MS, Gutkind JS. Novel insights into G protein and G 
protein-coupled receptor signaling in cancer. Curr Opin Cell Biol. 2014 Apr;
27:126-35;
• Ohta M, Berd D, Shimizu M, et al. Deletion mapping of chromosome region 
9p21-p22 surrounding the CDKN2 locus in melanoma. Int J Cancer. 1996 Mar 
15;65(6):762-7;
• Olsen DS, Savner EM, Mathew A, Zhang F, Krishnamoorthy T, et al. Domains 
of eIF1A that mediate binding to eIF2, eIF3 and eIF5B and promote ternary 
complex recruitment in vivo. EMBO J. 2003 Jan 15;22(2):193-204:
• Onken MD, Ehlers JP, Worley LA,et al. Functional gene expression analysis 
uncovers phenotypic switch in aggressive uveal melanomas. Cancer Res. 
2006 May 1;66(9):4602-9;
• Onken MD, Worley LA, Char DH,et al. Collaborative Ocular Oncology Group 
report number 1: prospective validation of a multi-gene prognostic assay in 
uveal melanoma.Ophthalmology. 2012 Aug;119(8):1596-603; 
•  Onken MD, Worley LA, Dávila RM, et al. Prognostic testing in uveal 
melanoma by transcriptomic profiling of fine needle biopsy specimens. J Mol 
Diagn. 2006 Nov;8(5):567-73;
• Onken MD, Worley LA, Ehlers JP, et al. Gene expression profiling in uveal 
melanoma reveals two molecular classes and predicts metastatic death. 
Cancer Res.2005 Oct 15;64(20):7205-9;
•  Onken MD, Worley LA, Long MD, et al. Oncogenic mutations in GNAQ occur 
early in uveal melanoma. Invest Ophthalmol Vis  Sci. 2008 Dec;49(12):
5230-4; 
 124
• Onken MD, Worley LA, Person E, et al. Loss of heterozygosity of 
chromosome 3 detected with single nucleotide polymorphisms is superior to 
monosomy 3 for predicting metastasis in uveal melanoma. Clin Cancer Res. 
2007 May 15;13(10):2923-7;
• Ophthalmic Oncology Task Force. Local Recurrence Significantly Increases 
the Risk of Metastatic Uveal Melanoma. Ophthalmology. 2016 Jan;123(1):
86-91;
•  O'Shea SJ, Robles-Espinoza CD, McLellan L,et al. A population-based 
analysis of germline BAP1 mutations in melanoma. Hum Mol Genet. 2017 Feb 
15;26(4):717-728;
• Pan H, Jia R, Zhang L, et al. BAP1 regulates cell cycle progression through 
E2F1 target genes and mediates transcriptional silencing via H2A 
monoubiquitination in uveal melanoma cells. Int J Biochem Cell Biol. 2015 
Mar;60:176-84;
•  Papadopoulos S, Benter T, Anastassiou G, et al. Assessment of genomic 
instability in breast cancer and uveal melanoma by random amplified 
polymorphic DNA analysis. Int J Cancer 2002 99, 193-200;
• Parrella P, Fazio VM, Gallo AP, et al. Fine mapping of chromosome 3 in uveal 
melanoma: identification of a minimal region of deletion on chromosomal arm  
3p25.1-p25.2. Cancer Res. 2003 Dec 1;
• Parrella P, Sidransky D, Merbs SL. Allelotype of posterior uveal melanoma 
implications for a  bifurcated tumor progression pathway. Cancer Res. 1999;   
•  Parrella P, Caballero OL, Sidransky D, et al. Detection of c-myc amplification 
in uveal melanoma by fluorescent in situ Hybridaization. Invest Ophtalmol Vis 
Sci 2001; 42,1679-1684;
• Patel KA, Edmondson ND, Talbot F et al. Prediction of prognosis in patients 
with uveal melanoma using fluorescence in situ hybridisation. Br J 
Ophthalmol. 2001 Dec;85(12):1440-4;
• Peña-Llopis S, Vega-Rubín-de-Celis S, Liao A, et al. BAP1 loss defines  a 
new class of renal cell carcinoma. Nat Genet. 2012 Jun 10;44(7):751-9; 
• Pilarski R, Cebulla CM, Massengill JB,et al. Expanding the clinical phenotype 
of hereditary BAP1 cancer predisposition syndrome, reporting three new 
cases. Genes Chromosomes Cancer. 2014 Feb;53(2):177-82;
 125
• Pilarski R, Rai K, Cebulla C,et al. BAP1 Tumor Predisposition Syndrome. 
2016 Oct 13 In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, 
Stephens K, Amemiya A, editors. GeneReviews®;
• Popova T, Hebert L, Jacquemin V, et al. Germline BAP1 mutations predispose 
to renal cell carcinomas. Am J Hum Genet. 2013 Jun 6;92(6):974-80;
• Prescher G, Bornfeld N, Friedrichs W, et al. Cytogenetics of twelve cases of 
uveal melanoma and patterns of nonrandom anomalies and isochromosome 
formation. Cancer Genet Cytogenet. 1996 Mar;80(1):40-6;
•  Prescher G, Bornfeld N, Hirche H, et al. Prognostic implications of monosomy 
3 in uveal melanoma. Lancet. 1996 May 4;347(9010):1222-5;
• Prescher G, Bornfeld N, Horsthemke B, et al. Chromosomal aberrations 
defining uveal  melanoma of poor prognosis. Lancet 1992; 339(8794): 691–
692;
•  Psinakis F, Katseli A, Koutsandrea C, et al. Uveal Melanoma: GNAQ  and 
GNA111 Mutations in a Greek Population. Anticancer Res. 2017 oct; 37(10): 
5719-5726;
• Rai K, Pilarski R, Boru G, et al. Germline BAP1 alterations in familial uveal 
melanoma. Genes Chromosomes Cancer. 2017 Feb;56(2):168-174;
• Rai K, Pilarski R, Cebulla CM, et al. Comprehensive review of BAP1 tumor 
predisposition syndrome with report of two new cases. Clin Genet. 2016 Mar;
89(3):285-94;
• Romano E, Schwartz GK, Chapman PB,et al. Treatment implications of the 
emerging molecular classification system for melanoma. Lancet Oncol. 2011 
Sep;12(9):913-22;
• Rowley, D. A new consistent chromosomal abnormality in chronic myelogenus 
leukemia  identified by quinacrime fluorescence and Giemsa staining. Nature 
1973 243: 290-293;
• Scholes AG, Damato BE, Nunn J, et al. Monosomy 3 in uveal melanoma: 
correlation with clinical and histologic predictors of survival.Invest Ophthalmol 
Vis Sci. 2003 Mar;44(3):1008-1;
• Shah AA, Bourne TD, Murali R. BAP1 protein loss by immunohistochemistry: 
a potentially useful tool for prognostic prediction in patients with uveal 
melanoma. Pathology. 2013 Dec;45(7):651-6;
 126
• Shields CL, Ganguly A, Bianciotto CG, et al. Prognosis of uveal melanoma in 
500 cases using genetic testing of fine-needle aspiration biopsy specimens. 
Ophthalmology. 2011 Feb;118(2):396-401;
• Shields CL, Kaliki S, Furuta M, et al. American Joint Committee on Cancer 
Classification of Uveal Melanoma (Anatomic Stage) Predicts Prognosis in 
7,731 Patients: The 2013 Zimmerman Lecture. Ophthalmology. 2015 Jun;
122(6):1180-6;
• Shields CL, Kaliki S, Furuta M, Fulco E, Alarcon C, Shields JA. American Joint 
Committee on Cancer classification of posterior uveal melanoma (tumor size 
category) predicts prognosis in 7731 patients. Ophthalmology. 2013 Oct;
120(10):2066-71;
• Shields CL, Say EAT, Hasanreisoglu M, et al. Cytogenetic Abnormalities in 
Uveal Melanoma Based on Tumor Features and Size in 1059Patients: The 
2017 W. Richard Green Lecture. Ophthalmology.;
• Shoushtari AN, Carvajal RD. GNAQ and GNA11 mutations in uveal 
melanoma.Melanoma Res. 2014 Dec;24(6):525-34;
• Simpson ER, Gallie BL, Saakyan S, et al. AJCC Ophthalmic Oncology Task 
Force. International Validation of the American Joint Committee on Cancer's 
7th Edition Classification of Uveal Melanoma. JAMA Ophthalmol. 2015 Apr;
133(4):376-83;
• Singh, A.D., Croce, C.M., Wary,K.K., et al. Familial Uveal Melanoma: Absence 
of Germline mutations involving the Cyclin dependent Kinase-4 inhibitor gene. 
Ophtalmic genet. 17,39-40 1996;     
• Singh AD, Turell ME, Topham AK. Uveal melanoma: trends in incidence, 
treatment, and survival. Ophthalmology. 2011 Sep;118(9):1881-5;
• Singh AD. Uveal melanoma: implications of tumor doubling time. 
Ophthalmology. 2001 May;108(5):829-31.
• SinghAD, Borden EC. Metastatic Uveal Melanoma. Ophtalmol Clin North Am. 
2005;18:143-140;
• Sisley K, Rennie IG, Parsons MA, et al. Abnormalities of chromosome 3 and 8 in 
posterior uveal melanoma correlate with prognosis; Genes Chromosomes 
Cancer. 1997 May;19(1):22-8;
• Sisley K, Parsons MA, Garnham J, et al. Association of specific chromosome 
alterations with tumor phenotype in posterior uveal melanoma. Br J Cancer. 
2000 Jan;82(2):330-8;
 127
• Soufir N, Bressac-de Paillerets B, Desjardins L, et al. Individuals with 
presumably hereditary uveal melanoma do not harbour germline mutations in 
the coding regions of either the P16INK4A, P14ARF or cdk4 genes. Br J 
Cancer. 2000 Feb;82(4):818-22;
• Soura E, Eliades P, Shannon K, et al. Hereditary Melanoma: Update on 
Syndromes and Management - Emerging melanoma cancer complexes and 
genetic counseling. Journal of the American Academy of Dermatology. 
2016;74(3):411-420;
• Spencer W.H. Ophthalmic Pathology, an Atlas-Textbook. 4th Edition, 
Saunders;
Szalai E, Wells JR, Ward L, et al. Uveal Melanoma Nuclear BRCA1-Associated 
Protein-1 Immunoreactivity Is an Indicator of Metastasis. Ophthalmology. 2017 
Aug 17. pii: S0161-6420(17)31332-5;
• Tarlan B, Kıratlı H. Uveal Melanoma: Current Trends in Diagnosis and 
Management. Turkish Journal of Ophthalmology. 2016;46(3):123-137;
Te Raa GD, Derks IA, Navrkalova V, et al. The impact of SF3B1 mutations in 
CLL on the DNA-damage response. Leukemia. 2015 May;29(5):1133-42;
• Testa JR, Cheung M, Pei J, et al. Germline BAP1 mutations predispose to 
malignant mesothelioma. Nature genetics. 2011;43(10):1022-1025;
• The Cancer genome Atlas Network. Comprehensive molecular portraits of 
human breast  tumor. Nature 2012;490:61-70;
•  Thomson FH, Emerson J, Olson S, et al. Cytogeentics of 158 patients with 
regional or disseminated melanoma Subset analysis of near-diploid and 
simple karyotypes. Cancer Genet Cytogenet 1995 83:93-104;
• Trolet J, Hupé P, Huon I,et al. Genomic profiling and identification of high-risk 
uveal melanoma by array CGH analysis of primary tumors and liver 
metastases. Invest Ophthalmol Vis Sci. 2009 Jun;50(6):2572-80;
Tschentscher F, Hüsing J, Hölter T, Kruse E, Dresen IG, et al. Tumor 
classification based on gene expression profiling shows that uveal melanomas 
with and without monosomy 3 represent two distinct entities. Cancer Res. 2003 
May 15;63(10):2578-84;
•  Tschentscher F, Prescher G, Horsman DE, White VA, Rieder H,et al. Partial 
deletions of the long and short arm of chromosome 3 point to two tumor 
suppressor genes in uveal melanoma. Cancer Res. 2001 Apr 15;61(8):
3439-42. 
 128
• Tschentscher F, Prescher G, Zeschnigk M, et al. Identification of  
chromosomes 3, 6, and 8 aberrations in uveal melanoma by microsatellite 
analysis in comparison to comparative genomic hybridization. Cancer Genet 
Cytogenet 2000; 122(1): 13-17;
• Turunen JA, Markkinen S, Wilska R, et al. BAP1 Germline Mutations in 
Finnish Patients with Uveal Melanoma. Ophthalmology. 2016 May;123(5):
1112-7;
• Van Beek JG, Rooprnans AE, Vaarwater J, et al. The prognostic value of 
extraocular  extension in relation to monosomy 3 and gain of chromosome 8q 
in uveal melanoma. Invest Ophtalmol Vis Sci 2014; 55:1284-91;
• van de Nes JA, Nelles J, Kreis S, et al. Comparing the Prognostic Value of 
BAP1 Mutation Pattern, Chromosome 3 Status, and BAP1 
Immunohistochemistry in Uveal Melanoma. Am J Surg Pathol. 2016 Jun;40(6):
796-805;  
• van den Bosh T, Van Beek JG, Vaarwater J, et al. Higher percentage of FISH- 
determined monosomy 3 and 8q amplification in uveal melanoma cells relate 
to poor patient prognosis. Invest Ophtalmol Vis Sci 2012; 53:2668-74; 
• van Essen TH, van Pelt SI, Versluis M, et al. Prognostic parameters in uveal 
melanoma and their association with BAP1 expression. Br J Ophthalmol. 2014 
Dec;98(12):1738-43;
• van Raamsdonk CD, Bezrookove V, Green G, Bauer J, Gaugler L, et al. 
Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. 
Nature. 2009 Jan 29;457(7229):599-602; 
• Van Gils W, Lodder EM, Mensink HW, Kiliç E, Naus NC, et al. Gene 
expression profiling in uveal melanoma: two regions on 3p related to 
prognosis. Invest Ophthalmol Vis Sci. 2008 Oct;49(10):4254-62;
• Ventii KH, Devi NS, Friedrich KL, et al. BRCA1-associated protein-1 is a tumor 
suppressor that requires deubiquitinating activity and nuclear localization. 
Cancer Res. 2008 Sept 1;68(17):6953-62;
• Versluis M, de Lange MJ, van Pelt SI et al. Digital PCR validates 8q dosage 
as prognostic tool in uveal melanoma. PLoS One. 2015 Mar 
12;10(3):e0116371 
• Virgili G, Gatta G, Ciccolallo L, et al, EUROCARE Working Group. Incidence 
of uveal melanoma in Europe. Ophthalmology.  2007 Dec;114(12):2309-15;
 129
• Vit VV. Prognostic role of morphologic characteristics of the immune response 
in human melanomas of various cellular types. Arkh Pathol 1983;45:25-30;
• Wang F, Flanagan J, Su N, et al. RNAscope: A Novel In Situ RNA Analysis 
Platform for Formalin-fixed Paraffin-embedded Tissues.J of Mol Diagnostics 
2012; 14(1):22-29;
• Wang L, Lawrence MS, Wan Y, et al. SF3B1 and other novel cancer genes in 
chronic lymphocytic leukemia. N Engl J Med 2011 Dec 29;365(26):2497-506;
• Weis E, Shah CP, Lajous M, et al. The association between host susceptibility 
factors and uveal melanoma: a meta-analysis. Arch Ophthalmol.2006 Jan;
124(1):54-60;
• White VA, Chambers JD, Courtright PD et al. Correlation of cytogenetic 
abnormalities with the outcome of patients with uveal melanoma. Cancer. 
1998 Jul 15;83(2):354-9;
•  Wiesner T, Murali R, Fried I, et al. distinct subset of atypical Spitz tumors is 
characterized by BRAF mutation and loss of BAP1 expression. Am J Surg 
Pathol. 2012 Jun;36(6):818-30;
• Wiesner T, Obenauf AC, Murali R, et al. Germline  mutations in BAP1 
predispose to melanocytic tumors. Nat Genet. 2011 Aug 28;43(10):1018-21;
•  Xu X, Wei WB, Li B, Gao F, et al. Oncogenic and GNA11 mutations in uveal 
melanoma in Chinese. PloS One. 2014 Oct 3; 9(10):e109699.
• Yavuzyigitoglu S, Drabarek W, Smit KN et al. Rotterdam Ocular Melanoma 
Study Group. Correlation of Gene Mutation Status with Copy Number Profile 
in Uveal Melanoma. Ophthalmology. 2017 Apr;124(4):573-575;
•  Yavuzyigitoglu S, Koopmans AE, Verdijk RM, et al. Rotterdam Ocular 
Melanoma Study Group. Uveal Melanomas with SF3B1 Mutations: A Distinct 
Subclass Associated with Late-Onset Metastases. Ophthalmology. 2016 May;
123(5):1118-28;
• Yonekawa Y, Kim IK, Gragoudas ES, et al. Aggressive skull base metastasis 
from uveal melanoma: a clinicpathologic study.Eur J Ophthalmol. 2014 Sep-
Oct;24(5):811-3;
• Yoshida K, Sanada M, Shiraishi Y, et al. Frequent pathway mutations of 
splicing machinery in myelodysplasia. Nature. 2011 Sep 11;478(7367):64-9;
• Yoshikawa Y, Emi M, Hashimoto-Tamaoki T et al. High-density array-CGH with 
targeted NGS unmask multiple noncontiguous minute deletions on 
 130
chromosome 3p21 in mesothelioma. Proc Natl Acad Sci U S A. 2016 Nov 
22;113(47):13432-13437;
• Yu FX, Luo J, Mo JS, et al. Mutant Gq/11promote uveal melanoma 
tumorigenesis by activating YAP. Cancer Cell. 2014;
• Zaidi MR, Ksander BR, Merlino G, et al. Hippo-independent activation of YAP 
by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase 
signaling circuitry. Cancer Cell. 2014 Jun 16;25(6):831-45;
• Zhang Y, Moschetta M, Huynh D, et al. Pyk2 promotes tumor progression in 
multiple myeloma. Blood. 2014 Oct 23;
• Zloto O, Pe'er J, Frenkel S. Gender differences in clinical presentation and 
prognosis of uveal melanoma. Invest Ophthalmol Vis Sci. 2013 Jan 23;54(1):
652-6. 
